A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Phase: PHASE2
Conditions: Glioblastoma, Gliosarcoma
Sponsor: National Cancer Institute (NCI)

 
 
1
Protocol Update #09 
 
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY 
_________________________________________ 
 
PROTOCOL UPDATE TO ALLIANCE A071102 
_________________________________________ 
 
A PHASE II/III RANDOMIZED TRIAL OF VELIPARIB OR PLACEBO IN COMBINATION 
WITH ADJUVANT TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA WITH 
MGMT PROMOTER HYPERMETHYLATION 
Investigational Agent: veliparib (NSC #737664) will be supplied by NCI DCTD - CTEP IND 
Commercial agent(s): temozolomide 
Imaging site credentialing required for participation 
 
ClinicalTrials.gov Identifier: NCT02152982 
 
X Update: 
 
 
Status Change: 
 
 
 
 
 
 
Eligibility changes 
 
 
Activation 
 
 
 
 
 
 
Therapy / Dose Modifications / Study Calendar changes 
 
 
Closure 
 
 
 
 
 
 
Informed Consent changes 
 
 
Suspension / temporary closure 
 
 
 
 
 
X Scientific / Statistical Considerations changes 
 
 
Reactivation 
 
 
 
 
 
 
Data Submission / Forms changes 
 
 
 
 
 
 
 
 
X Editorial / Administrative changes 
 
 
 
 
 
 
 
 
 
Other :  
 
 
 
 
 
If your site utilizes the CIRB as your IRB of record 
No recommended IRB level of review is provided by the Alliance since the CIRB is the IRB of record 
for this trial. 
The site has 30 days after the posting of this amendment to implement it at their site. Please refer to the 
amendment application and CIRB guidelines for further instructions. 
  
If your site utilizes a local IRB as your IRB of record 
IRB approval (or disapproval) is required within 90 days. Please follow your local IRB guidelines. 
Expedited review is allowed. IRB approval (or disapproval) is required within 90 days. Please follow 
your IRB of record guidelines. 
 
 
 
UPDATES TO THE PROTOCOL 
 

 
 2
Cover Page 
Lilli Johnson has replaced Sakuni Taniya Silva as the Protocol Coordinator, and all contact information 
has been updated.  
 
Protocol Contacts (page 2) 
• 
Lori Cappello has replaced Wanda L. DeKrey as the A071102 Nursing Contact, and all contact 
information has been updated.  
• 
The IROC contact information has been updated 
 
Cancer Trials Support Unit Address and Contact Information (page 3) 
The CTSU Contact Information table has been updated with current CTSU logistical common language. 
 
Section 6.3 CT and MR Imaging Data Submission 
In the 4th paragraph after “3) Mail/CD Shipment”, the IROC contact information has been updated. 
 
Section 13.3.3 Analysis Plans for Primary, Secondary, and Exploratory Endpoints 
• 
Under the first bullet point, Overall Survival, the 5th sentence “To perform the test, 5000 
simulations will be performed…” has been changed to “To perform the test, 50,000 simulations 
will be performed…” 
• 
Under the first bullet point, Overall Survival, the 7th sentence “…same or more extreme than the 
observed tests statistic from the trial data divided by 5000.” has been changed to “…same or 
more extreme than the observed tests statistic from the trial data divided by 50,000” 
• 
The sentence “Note: 50,000 simulations will yield a standard deviation of 0.001 of the resulting 
p-value if the observed p-value is 0.05, and a standard deviation of 0.0007 if the observed 
standard deviation is 0.025.” has been added to the bottom of the first bullet point, Overall 
Survival.  
 
 
UPDATES TO THE SCREENING CONSENT 
 
No changes have been made to the screening consent form. 
 
UPDATES TO THE TREATMENT CONSENT 
 
No changes have been made to the treatment consent form. 
 
 
 
Replacement protocol and model consent documents have been issued. 
A071102 is closed to new patient accrual.  
____________________________________________________________ 
ATTACH TO THE FRONT OF EVERY COPY OF THIS PROTOCOL 
____________________________________________________________ 
 

A071102 
Version date: 01/22/2021 
1 
Update #09 
ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY 
 
ALLIANCE A071102 
 
A PHASE II/III RANDOMIZED TRIAL OF VELIPARIB OR PLACEBO IN COMBINATION 
WITH ADJUVANT TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA WITH 
MGMT PROMOTER HYPERMETHYLATION 
Investigational Agent: veliparib (NSC #737664 will be supplied by NCI DCTD – CTEP IND 
Commercial agent(s): temozolomide 
Imaging site credentialing required for participation 
ClinicalTrials.gov Identifier: NCT02152982 
Study Chair 
Jann N. Sarkaria, MD 
Mayo Clinic 
200 First St SW 
Rochester, MN 55905 
Tel: 507-284-8227  Fax: 507-284-0079 
Sarkaria.jann@mayo.edu 
 
Community Oncology Co-chair 
Medical Oncology Co-chair 
Correlative Study Co-chair 
Bret Friday, MD, PhD  
Sani Kizilbash, MBBS, MPH  
Erik Sulman, MD, PhD 
Essentia Health 
Mayo Clinic 
MD Anderson 
Tel: 218-786-3625 
Tel: 507-293-1732 
Tel: 713-563-2338 
Fax: 218-786-3762 
Fax: 507-284-1803 
Fax: 713-563-2331 
Bret.Friday@essentiahealth.org 
Kizilbash.Sani@mayo.edu 
epsulman@mdanderson.org 
 
Neuro-oncology Committee Chair 
Radiation Oncology Co-Chair 
Neuropathology Co-Chair 
Evanthia Galanis, MD 
Nadia Laack, MD 
Caterina Giannini, MD, PhD 
Mayo Clinic 
Mayo Clinic 
Mayo Clinic 
Tel: 507-284-7733 
Tel: 507-284-4561 
Tel: 507-538-1181 
Fax: 507-284-5280 
Fax: 507-284-5280 
Fax: 507-284-5280 
Galanis.evanthia@mayo.edu 
laack.nadia@mayo.edu 
giannini.caterina@mayo.edu 
 
Imaging Co-Chairs 
Imaging Co-Chair 
SWOG Co-Chair 
Leland Hu, MD 
Benjamin Ellingson, Ph.D., M.S. 
David E. Piccioni, MD, PhD 
Mayo Clinic 
UCLA 
UC San Diego Health 
Tel:480-301-7470 
Tel:310-481-7572 
Tel: 858-822-7778 
Fax:480-342-1606 
Fax:310-794-2796 
dpiccioni@ucsd.edu 
Hu.Leland@mayo.edu 
Bellingson@mednet.ucla.edu 
 
 
Primary Statistician  
Karla Ballman, PhD 
Tel: 646-962-8089 
kab2053@med.cornell.edu 
Secondary Statistician 
S. Keith Anderson, MS 
Tel: 507-284-8803 
Anderson.S@mayo.edu 
Protocol Coordinator  
Lilli Johnson Tel: 773-834-4091  
Fax: 312-345-0117 
lillij@bsd.uchicago.edu 
 
 
 
 
 
Participating Groups:  ALLIANCE / Alliance for Clinical Trials in Oncology (lead), ECOG-ACRIN / ECOG-ACRIN Medical 
Research Foundation, Inc., NRG / NRG Oncology Foundation Inc. and SWOG / SWOG

Alliance A071102 
Version date: 01/22/2021 
2 
Update #09 
Study Resources: 
CTEPAdverse Event Reporting System 
https://eapps-ctep.nci.nih.gov/ctepaers/ 
Medidata Rave iMedidata portal 
https://login.imedidata.com 
OPEN (Oncology Patient Enrollment Network) 
https://open.ctsu.org 
Biospecimen Management System 
http://bioms.allianceforclinicaltrialsinoncology.org 
 
Protocol Contacts: 
A071102 Nursing Contact 
Lori Cappello, MSN, APN-C, CCRP 
John Theurer Cancer Center at Hackensack        
Meridian Health 
Tel: 551-996-5098 
Email: Lori.Cappello@hmhn.org 
A071102 Pharmacy Contact 
Heidi D. Finnes, Pharm.D, BCOP 
Mayo Clinic 
Tel: 507-538-7066   
Email: finnes.heidi@mayo.edu 
Alliance Biorepository at Mayo Clinic 
Paraffin-embedded tissue: 
Helen Tollefson 
Pathology Coordinator 
Tel: 507-266-0724  Fax: 507-266-7240 
Email: Tollefson.Helen@mayo.edu 
 
Non-paraffin biospecimens: 
Roxann Neumann, RN, BSN, CCRP  
Biospecimens Accessioning and Processing (BAP)  
Tel: 502-538-0602  
Email:neumann.roxann@mayo.edu 
 
IROC 
The Ohio State University 
Wright Center of Innovation 
395 W. 12th Ave., RM #428 
Columbus, OH 43210 
Tel: 614-293-2929  Fax: 614-293-9275 
Alliance071102@irocohio.org 
 
A071102 Data Manager 
Meagan Odegaard 
Tel: 507-284-4124 
Email: odegaard.meagan@mayo.edu 
 
Protocol-related questions may be directed as follows: 
Questions 
Contact (via email) 
Questions regarding patient eligibility, treatment, and 
dose modification: 
Study Chair, Nursing Contact, Protocol Coordinator, 
and (where applicable) Data Manager 
Questions related to data submission, RAVE or patient 
follow-up: 
Data Manager  
Questions regarding the protocol document and model 
informed consent: 
Protocol Coordinator 
Questions related to IRB review:  
Alliance Regulatory Inbox 
regulatory@alliancenctn.org 
Questions regarding CTEP-AERS reporting: 
Pharmacovigilance Inbox  
pharmacovigilance@alliancenctn.org  
Questions regarding specimens/specimen submissions: 
Alliance Biorepository at Mayo Clinic  
Questions regarding drug supply 
NCI Pharmaceutical Management Branch (PMB) 
PMBAfterHours@mail.nih.gov 
Questions regarding drug administration 
Pharmacy Contact  
 

Alliance A071102 
Version date: 01/22/2021 
3 
Update #09 
CANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT INFORMATION 
For regulatory 
requirements: 
For patient enrollments:  
For study data submission:  
Regulatory documentation 
must be submitted to the 
CTSU via the Regulatory 
Submission Portal. 
Regulatory Submission 
Portal: (Sign in at 
www.ctsu.org,            and 
select the Regulatory 
Submission sub-tab under 
the Regulatory tab.)  
 
Institutions with patients 
waiting that are unable to 
use the Portal should alert 
the CTSU Regulatory Office 
immediately at 1-866-651-
2878 to receive further 
instruction and support. 
 
Contact  the CTSU 
Regulatory Help Desk at 1-
866-651-2878 for regulatory 
assistance. 
Please refer to the patient 
enrollment section for 
instructions on using the 
Oncology Patient Enrollment 
Network (OPEN) which can 
be accessed at 
https://www.ctsu.org/OPEN_
SYSTEM/ or 
https://OPEN.ctsu.org. 
 
Contact the CTSU Help Desk 
with any OPEN-related 
questions at 
ctsucontact@westat.com. 
 
 
Data collection for this study will be 
done exclusively through Medidata 
Rave.  Please see the data submission 
section of the protocol for further 
instructions. 
The most current version of the study protocol and all supporting documents must be downloaded 
from the protocol-specific Web page of the CTSU Member Web site located at https://www.ctsu.org.  
Access to the CTSU members’ website is managed through the Cancer Therapy and Evaluation 
Program - Identity and Access Management (CTEP-IAM) registration system and requires user log on 
with CTEP-IAM username and password. 
For clinical questions (i.e., patient eligibility or treatment-related) see the Protocol Contacts, Page 
2. 
For non-clinical questions (i.e., unrelated to patient eligibility, treatment, or clinical data 
submission) contact the CTSU Help Desk by phone or e-mail:  
CTSU General Information Line – 1-888-823-5923, or ctsucontact@westat.com. All calls and 
correspondence will be triaged to the appropriate CTSU representative.  
The CTSU website is located at https://www.ctsu.org. 
 
 
  Randomized trial of veliparib or placebo in combination with adjuvant temozolomide in newly 
diagnosed GBM with MGMT promoter hypermethylation 
 
Patient Eligibility for Pre-Registration 
Required Initial Laboratory Values 
(Within 14 days prior to study registration) 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
4 
Update #09 
Newly diagnosed Grade IV intracranial glioblastoma or 
gliosarcoma 
Absolute neutrophil count (ANC)        ≥ 1500 cells/mm3 
Sufficient tissue available for central pathology review and 
MGMT methylation status evaluation 
Platelets                                                 ≥ 100,000 cells/mm3 
Age ≥ 18 years 
Creatinine                                             ≤ 1.5x ULN  
 
Bilirubin 1                                                                   ≤ 1.5x ULN  
Patient Eligibility for Registration 
AST and ALT                                       ≤ 3 x ULN 
Tumor MGMT promoter hypermethylation 
 
Confirmation by central pathology review of WHO Grade IV 
glioblastoma or gliosarcoma 
 
Completion of concomitant radiation and TMZ with adequate 
recovery from toxicity  
1 Unless patient has Gilbert’s disease 
 
No prior allogeneic bone marrow transplant or double umbilical 
cord blood transplantation. 
 
Radiation dose and schedule conform to minimum standard 
defined in Appendix I. 
 
TMZ dosing schedule during radiation conforms to minimum 
standard defined in Appendix I. 
 
ECOG performance status of ≤ 2 
 
Non-pregnant/non-nursing 
 
Patients must sign an informed consent prior to analysis of 
MGMT promoter methylation and a second study-specific 
informed consent prior to study registration. 
 
Patients must have adequate organ and marrow function 
measured within 28 days prior to administration of ABT-888 
 
No Patients with treatment-related AML (t-AML)/MDS or with 
features suggestive of AML/MDS. 
 
Schema 
1 Cycle = 28 Days 
 
 
 
 
 
 
 
 
 
MGMT- 
 
 
RADIATION AND TEMOZOLOMIDE** 
 
Ineligible 
 
 
 
 
 
 
      + 
 
 
 
 
 
 
 
 
Pre-
Registration 
 
 MGMT 
TESTING * 
(Central 
Laboratory) 
AND central 
pathology 
review 
 
 
 
MGMT+ 
 
Registration/ 
Randomization 
 
TMZ (150 to 200mg/m2)  
PO qd days 1through 5 
+  
veliparib/placebo 40mg 
PO bid  
days 1 through 7 
Every 28 days x 6 cycles 
 
*Pre-registration and MGMT testing can be done at any time as long as the patient is randomized to 
treatment within 28-42 days after RT/TMZ completion. Please note that turnaround time of MGMT 
testing is 21 calendar days. 
 
**Must monitor CBC during RT + TMZ. 
 
Treatment is to continue for up to 6 months or until disease progression (confirmed progression) or 
unacceptable adverse event. Patients will be followed for progression for up to 5 years.  
Patients will be followed for survival for up to 10 years. 
 
Please refer to the full protocol text for a complete description of the eligibility criteria and 
treatment plan.

Alliance A071102 
Version date: 01/22/2021 
5 
Update #09 
  Randomized trial of veliparib or placebo in combination with adjuvant temozolomide in newly 
diagnosed GBM with MGMT promoter hypermethylation 
 
Schema page 2 of 2: Patient Enrollment Guide to A071102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Local diagnosis of GBM 
Pre-registration eligibility screening  
(See Section 3.2) 
& 
Patient Screening Consent 
Registration eligibility screening  
(See Section 3.3) 
Including post-RT/TMZ baseline MRI performed 
per Appendix II or III within 21-42 days after 
completion of RT/TMZ. 
 
Pre-registration (Step 0) 
Registration (Step 1) & Randomization 
OAOP for Drug Ordering 
Blinded drug will arrive at site within 7-10 days. 
(See Section 10.2) 
* Treatment with Optune cannot be 
initiated during protocol therapy. 
Treatment with Optune must be 
initiated by Day 1 of Cycle 1, but 
can begin any time prior to this as 
long as it is not started until after 
completion of radiation therapy. If 
patient did not declare intent to be 
treated with Optune prior to Day 1 
of Cycle 1, then treatment with 
Optune may ONLY be initiated after 
completion of protocol therapy (i.e. 
Cycle 6 Day 28). Patient diaries 
must be completed per Section 5.0. 
(See Sections 4.4, 4.7, 5.0, 8.1.11, 
and Appendix IX) 
Initiation of study treatment* 
within 14 days after registration 
(See Section 7.0) 
Specimen submission for MGMT & 
Central Pathology Review  
(See Section 6.2) 
Results will be returned to site within 21 days 
of receipt. 
IROC Credentialing approval prior to the 
registration of the first patient. 
(See Section 15.0) 
RT/TMZ treatment 
per Appendix I 
Treatment can be initiated at 
any time as long as 
registration occurs within 
28-42 days post last day of 
RT/TMZ. 

Alliance A071102 
Version date: 01/22/2021 
6 
Update #09 
TABLE OF CONTENTS 
Section 
Page 
1.0 
BACKGROUND ............................................................................................................................ 8 
1.1 
Rationale for selected approach and trial design ......................................................................... 8 
1.2 
Study Rationale ......................................................................................................................... 10 
1.3 
Relevant Data ............................................................................................................................ 11 
1.4 
Integration of NovoTTF-100A therapy within this trial ............................................................ 18 
2.0 
OBJECTIVES .............................................................................................................................. 19 
2.1 
Primary objective ....................................................................................................................... 19 
2.2 
Secondary objectives ................................................................................................................. 19 
2.3 
Correlative Science Objectives .................................................................................................. 19 
3.0 
PATIENT SELECTION ............................................................................................................. 19 
3.1 
On-Study Guidelines ................................................................................................................. 19 
3.2 
Pre-Registration Eligibility Criteria ........................................................................................... 20 
3.3 
Registration Eligibility Criteria ................................................................................................. 20 
4.0 
PATIENT REGISTRATION ...................................................................................................... 22 
4.1 
CTEP Registration Procedures .................................................................................................. 22 
4.2 
CTSU Registration Procedures .................................................................................................. 22 
4.3 
Patient Pre-registration Requirements ....................................................................................... 24 
4.4 
Patient Registration Requirements ............................................................................................ 25 
4.5 
Patient Registration/Randomization Procedures ....................................................................... 25 
4.6 
Registration to Correlative and Companion Studies ................................................................. 25 
4.7 
Stratification (or Grouping) Factors and Treatment Assignments ............................................. 26 
5.0 
STUDY CALENDAR .................................................................................................................. 27 
6.0 
DATA AND SPECIMEN SUBMISSION .................................................................................. 29 
6.1 
Data collection and submission ................................................................................................. 29 
6.2 
Specimen Collection and Submission ....................................................................................... 29 
6.3 
CT and MR Imaging Data Submission ...................................................................................... 33 
6.4 
Radiation Dosimetry Submission .............................................................................................. 35 
7.0 
TREATMENT PLAN/INTERVENTION.................................................................................. 36 
7.1 
Adjuvant therapy with temozolomide and either veliparib or placebo ...................................... 36 
8.0 
DOSE AND TREATMENT MODIFICATIONS, UNBLINDING .......................................... 37 
8.1 
Ancillary therapy, concomitant medications, and supportive care ............................................ 37 
8.2 
Dose Modifications ................................................................................................................... 39 
8.3 
Emergency Unblinding Procedures ........................................................................................... 41 
9.0 
ADVERSE EVENTS ................................................................................................................... 42 
9.1 
Routine adverse event reporting ................................................................................................ 42 
9.2 
CTCAE Routine Study Reporting Requirements ...................................................................... 42 
9.3 
CTEP Adverse Event Reporting System (CTEP-AERS) .......................................................... 43 
9.4 
Comprehensive Adverse Events and Potential Risks list (CAEPR) for ABT-888 (Veliparib, 
NSC 737664) .......................................................................................................................................... 46 
10.0 
DRUG INFORMATION ............................................................................................................. 49 
10.1 
General Considerations: ............................................................................................................ 49 
10.2 
Temozolomide for Oral Administration (Temodar®, TMZ) ..................................................... 49 
10.3 
Veliparib or Placebo (NSC 737664, ABT-888) ........................................................................ 51 
11.0 
MEASUREMENT OF EFFECT ................................................................................................ 55 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
7 
Update #09 
11.1 
Schedule of Evaluations: ........................................................................................................... 56 
11.2 
Definitions of Measurable and Non-Measurable Disease ......................................................... 56 
11.3 
Guidelines for Evaluation of Measurable Disease ..................................................................... 56 
11.4 
Measurement of Treatment/Intervention Effect ........................................................................ 57 
11.5 
Definitions of analysis variables ................................................................................................ 60 
12.0 
END OF TREATMENT/INTERVENTION ............................................................................. 60 
12.1 
Duration of Treatment ............................................................................................................... 60 
12.2 
Managing ineligible and canceled patients and major protocol violations ................................ 60 
12.3 
Extraordinary Medical Circumstances ...................................................................................... 61 
13.0 
STATISTICAL CONSIDERATIONS ....................................................................................... 61 
13.1 
Endpoints ................................................................................................................................... 61 
13.2 
Sample Size Derivation ............................................................................................................. 62 
13.3 
Analysis plans ............................................................................................................................ 62 
13.4 
Monitoring the Study ................................................................................................................. 65 
13.5 
Study Reporting ......................................................................................................................... 65 
13.6 
Descriptive Factors .................................................................................................................... 65 
13.7 
Inclusion of Women and Minorities .......................................................................................... 67 
14.0 
CORRELATIVE AND COMPANION STUDIES .................................................................... 68 
14.1 
DNA Extraction from Tissue (A071102-ST1) .......................................................................... 68 
14.2 
DNA Extraction from Blood (A071102-ST2) ........................................................................... 69 
14.3 
Analysis of advanced MR imaging (A071102-IM) ................................................................... 70 
15.0 
GENERAL REGULATORY CONSIDERATIONS AND CREDENTIALING .................... 73 
15.1 
Institutional credentialing .......................................................................................................... 73 
16.0 
REFERENCES ............................................................................................................................. 75 
APPENDIX I: DEFINITION OF STANDARD RT/TMZ .................................................................... 80 
APPENDIX II: REQUIRED CONSENSUS MRI ACQUISITION PARAMETERS ......................... 81 
APPENDIX III: REQUIRED CONSENSUS MRI ACQUISITION PARAMETERS INCLUDING 
ADVANCED MRI .................................................................................................................................... 85 
APPENDIX IV: FATIGUE/UNISCALE ASSESSMENTS ................................................................ 89 
APPENDIX V: PATIENT MEASUREMENT TOOLS ........................................................................ 90 
APPENDIX VI: PATIENT MEDICATION DIARIES ......................................................................... 94 
Appendix VI-A Temozolomide Medication Diary ................................................................................. 94 
Appendix VI-B Veliparib/Placebo Medication Diary ............................................................................ 96 
APPENDIX VII: MGMT ASSAY DESCRIPTION............................................................................... 98 
APPENDIX VIII: COLLABORATIVE AGREEMENTS LANGUAGE .......................................... 100 
APPENDIX IX: OPTUNE DIARY ....................................................................................................... 102 
 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
8 
Update #09 
1.0 
BACKGROUND 
Glioblastoma multiforme (GBM) is the most common primary adult brain tumor and is uniformly 
fatal. Recent studies have demonstrated a significant survival benefit for combining temozolomide 
(TMZ) chemotherapy with standard radiation therapy following optimal surgical debulking (1).  
Response to TMZ therapy is significantly influenced by promoter methylation of the DNA repair 
gene O6-methylguanine-methyltransferase (MGMT). For patients enrolled on the EORTC 22981 
trial and treated with radiation and TMZ, tumor MGMT promoter hypermethylation was associated 
with a 46% 2 year survival, while lack of promoter methylation was associated with a 14% 2 year 
survival (2). The extent of survival benefit with TMZ-based therapy in patients with MGMT-
methylated tumors is unparalleled by any other novel therapeutic in current clinical or pre-clinical 
studies, and this observation supports the general rationale for pursuing novel TMZ-sensitizing 
strategies in an attempt to obtain further survival gains with this efficacious therapy.  Aside from 
FDA approval of temozolomide, there has been little progress in developing more efficacious 
therapies for newly diagnosed GBM. Bevacizumab has shown promise in recurrent GBM, but two 
clinical trials of bevacizumab combined with conventional radiation and temozolomide failed to 
demonstrate a survival benefit for the combination compared to treatment with radiation and 
temozolomide alone. Thus, there is an urgent need to develop novel therapies for GBM patients. 
 
This clinical trial will evaluate the combination of a PARP inhibitor with adjuvant temozolomide 
after completion of concurrent radiation and temozolomide therapy. Based on extensive pre-clinical 
animal studies detailed below, we have made several observations that critically inform the design of 
this clinical trial. First, veliparib combined with TMZ alone can markedly enhance the efficacy of 
therapy. Second, the combination of veliparib with TMZ is ineffective in tumors with acquired TMZ 
resistance. Third, the combination of veliparib with TMZ is ineffective in TMZ-naïve GBM tumors 
that are inherently resistant to TMZ. Fourth, lack of MGMT expression is critical for the sensitizing 
effects of veliparib combined with TMZ. From these data, we hypothesize that tumor MGMT 
promoter hypermethylation can be used as an integral biomarker and key entry criteria for this 
randomized Phase II/III clinical trial to enrich for patients most likely to benefit from the combination 
of veliparib with adjuvant TMZ compared to adjuvant TMZ alone following completion of 
concurrent radiation/temozolomide therapy. Although the prognosis for MGMT hypermethylated 
tumors is better than for unmethylated tumors, the 5-year survival for MGMT promoter 
hypermethylated tumors is less than 5%. Thus, if successful, this clinical trial could significantly 
improve survival for this subset of patients. 
 
The rationale for the six months of temozolomide is the following; 
 
• 
The FDA label is for 6 cycles of TMZ 
• 
The RTOG0525 study indirectly addresses the question of the extent of benefit for greater TMZ 
exposure. In this trial, the patients receiving dose-dense TMZ (50% greater TMZ exposure) did 
not have a survival advantage. At a gross level, this suggests that more TMZ is not necessarily 
better. 
• 
The combination of veliparib and TMZ may be associated with higher toxicities, so extended 
dosing with the combination may not be as well tolerated as TMZ alone. 
 
1.1 
Rationale for selected approach and trial design 
Repair of TMZ-induced DNA methylation lesions 
TMZ leads to methylation of nucleotide bases in genomic DNA, and disruption of replication 
by un-repaired methylation damage is responsible for inducing cell death. The common 
methylation lesions N7-methylguanine and N3-methyladenine are efficiently repaired by base-

 
 
Alliance A071102 
 
Version date: 01/22/2021  
9 
Update #09 
excision repair (BER). In contrast, the highly mutagenic and cytotoxic lesion O6-methylguanine 
(O6MG) is repaired in a one-step process by MGMT. Both BER and MGMT are critical for cell 
survival, and either BER or MGMT repair inhibitors significantly enhance TMZ cytotoxicity 
(3-11). PARP1/2 functions as a scaffold for other BER-proteins, and disruption of BER function 
by PARP inhibition has been widely viewed as a key mechanism accounting for the TMZ-
sensitizing effects of PARP inhibitors (reviewed in (12)). However, at least one study 
demonstrated that the TMZ sensitizing effects of a PARP inhibitor are seen at inhibitor 
concentrations 10-fold lower than those associated with disruption of BER (13). Moreover, we 
have extensive in vivo preliminary data demonstrating that the PARP inhibitor veliparib 
preferentially sensitizes tumors that are inherently sensitive to TMZ. Since effective BER 
inhibition should increase TMZ sensitivity in essentially all tumors (14-16), our preliminary 
data suggest that PARP inhibitors may not sufficiently suppress BER when used in a clinically 
relevant dosing schedule in our highly clinically relevant orthotopic xenograft therapy 
evaluation model.  
Role of homologous recombination (HR) in tolerance of O6MG DNA lesions 
O6MG is the key cytotoxic lesion induced by TMZ, and we hypothesize that PARP inhibitor 
efficacy is linked to repair processing of this lesion. Persistent O6MG is mispaired with 
thymidine during replication and subsequently engaged by futile cycles of mismatch repair 
(MMR) that ultimately result in collapsed replication forks. Recovery from stalled replication 
requires HR-mediated DNA repair (17, 18). Core HR activity is modulated by Rad51 and 5 
paralogs (XRCC2, XRCC3, RAD51B, RAD51C and RAD51D), and disruption of any one of 
these family members results in chromosomal instability, hypersensitivity to crosslinking agents, 
defective RAD51 foci formation, and decreased HR activities (19-22). Consistent with the likely 
exclusive role for HR in mediating recovery following replication fork collapse, multiple models 
have demonstrated significant sensitivity of HR-defective cells to replication inhibitors (23, 24). 
Others have shown that HR-defective cells are hypersensitive to alkylating agents (25, 26). In 
one study, cells with combined defects in MGMT and HR (either XRCC2 or BRCA2 mutation) 
were highly sensitive to TMZ, and restoration of MGMT expression almost completely 
abolished the hypersensitivity observed in the HR-defective cells (27). These latter data 
demonstrate that the replication-arresting O6MG lesions induced by TMZ are specifically 
processed by HR and that deregulation of HR can have a significant impact on treatment efficacy.  
Poly(ADP-ribose) polymerase functionality in DNA repair 
PARP-1 and PARP-2 play key roles in the modulation of DNA repair. The proteins catalyze the 
poly-ADP-ribosylation of target proteins to form a branched nucleic acid-like polymer poly-
ADP-ribose (PAR). PAR modifications modulate protein functions and are dynamically 
regulated (reviewed in 12). At sites of DNA damage, PARP ribosylates itself and multiple target 
proteins and modulates activity of other proteins through direct interactions. Disruption of 
PARP activity leads to significant chemosensitizing effects in combination with alkylating 
agents, topoisomerase inhibitors, and DNA cross-linking agents (28-30). Thus, there is strong 
clinical interest in understanding how PARP inhibitors modulate recovery from DNA damage.  
PARP plays a key function in modulating HR, and this functionality is likely a key contributor 
to the clinical efficacy of PARP inhibitors. While PARP does not directly interact with Rad51, 
PARP inhibition results in a hyper-recombinogenic phenotype associated with elevated sister-
chromatid exchanges (SCE) and increased Rad51 foci formation (31, 32). PARP deficient cells 
are hypersensitive to hydroxyurea (HU)-induced replication arrest, and recovery following HU 
treatment in these cells is associated with elevated levels of sister chromatid exchanges, 
increased Rad51 foci formation and  delayed exit from S-phase (33). Consistent with these data, 
PARP inhibition can delay the initiation of HR-mediated repair of stalled replication forks (33). 
While the detailed mechanistic interactions of PARP with HR are not fully understood, several 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
10 
Update #09 
pre-clinical and clinical studies have demonstrated that tumors defective in HR are 
hypersensitive to PARP inhibitors, either alone or in combination with cytotoxic chemotherapies 
(34-39). Specifically relevant to this application, a recent study presented in 2010 at ASCO of 
veliparib combined with TMZ in metastatic breast cancer patients demonstrated efficacy only 
in the subset of patients harboring BRCA1 or 2 mutations (40). These data highlight the potential 
importance of HR integrity on the efficacy of PARP inhibitor combinations, and in some of the 
correlative studies proposed, we will evaluate whether molecular deficiencies within the HR 
pathway affect the TMZ-sensitizing effects of PARP inhibition in patient samples collected on 
this trial.  
 
1.2 
Study Rationale 
Clinical Significance 
There is intense interest in the development of PARP inhibitors as drugs for use in cancer 
therapy. At least 8 major pharmaceutical companies (Tesaro, AbbVie, Astra-Zeneca, BioMarin, 
Clovis, Eisai, Inotek, Teva) have PARP inhibitor programs with interest in developing 
indications in cancer therapy (41). Consistent with an important role for PARP in modulating 
HR, promising single agent activity has been observed in pre-clinical and early clinical trials 
with PARP inhibitors as monotherapy in BRCA1- or BRCA2-deficient tumors (35, 36, 42, 43). 
Our group has demonstrated that addition of veliparib to TMZ therapy can profoundly prolong 
survival in a subset of GBM xenograft lines when tested in an orthotopic therapy evaluation 
model (44). Collectively, these exciting results suggest that PARP inhibitors can be safely 
combined with cytotoxic agents, and in appropriately selected patients, the combination of 
PARP inhibitors with chemotherapy may provide significant clinical benefit. 
The combination of veliparib with TMZ has been evaluated in several clinical trials. In a Phase 
II clinical trial of heavily pre-treated colorectal cancer, the combination of TMZ (150 mg/m2 
days 1-5) and veliparib (40 mg bid days 1-7) was well tolerated with only 5 of 47 patients having 
adverse events (myelosuppression) (45). Similarly, in previously treated metastatic breast cancer, 
modest rates of thrombocytopenia were observed with TMZ (150 mg/m2 days 1-5) combined 
with veliparib at 40 mg bid, and very low rates when veliparib was reduced to 30 mg bid days 
1-7 (40). The ABTC 0801 trial evaluated the combination of veliparib with both concurrent 
radiation/TMZ and adjuvant TMZ in newly diagnosed GBM patients. In this study, the 
combination of veliparib given daily for 6 weeks with RT/TMZ or given daily for weeks 1, 3 
and 5 of RT/TMZ was poorly tolerated with significant myelosuppression (personal 
communication, M. Prados). The distinct difference between the ABTC experience in GBM 
patients and the former colorectal and breast cancer trials is the protracted dosing concomitant 
with TMZ during radiation in the GBM trial. As described below, we also have observed 
increased toxicity with protracted combination schedules of veliparib and TMZ in animal 
models. Therefore, we anticipate that limiting veliparib dosing to the adjuvant TMZ treatment 
phase in newly diagnosed GBM patients should be well tolerated based on the previously 
published trials with colon cancer and breast cancer. 
As described below, the extent of survival benefit observed in our preclinical data is 
unprecedented with the survival benefit of TMZ therapy nearly doubled when combined with 
ABT888 in a subset of xenograft models. Over half of the TMZ naïve xenograft lines harboring 
MGMT promoter hypermethylation had a significant survival extension with combined therapy, 
while none of the MGMT unmethylated tumors had a clinically relevant benefit. We believe 
these data provide a robust rationale for using MGMT hypermethylation as an enrollment 
criteria for the proposed trial and that the combination therapy has a strong likelihood of 
providing a clinically meaningful survival benefit in treated patients. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
11 
Update #09 
1.3 
Relevant Data  
Preliminary Data 
Mayo GBM xenograft model system 
 Pre-clinical novel therapeutic testing traditionally has been performed using tumor cell lines 
maintained in cell culture for many years that have significantly genetically diverged from the 
derivative patient tumor. In contrast, the Mayo GBM panel of 65 xenograft lines was established 
by implanting patient tumor specimens directly into the flank of nude mice and maintained by 
serial transplantation. Using this method, key genetic and molecular features of the original 
patient tumor are preserved, including EGFR amplification (46) and MGMT promoter 
methylation status (47). Our laboratory has extensive experience in testing traditional and novel 
therapies using this xenograft model (48-56). Specifically relevant to this application, a 
clinically relevant dosing schedule of TMZ was tested in 20 xenograft lines (47, 57, 58), and 
consistent with multiple clinical studies, MGMT promoter methylation in our GBM xenograft 
model was highly associated with TMZ sensitivity as compared to non-methylated tumors 
(p=0.008, rank-sum test). Moreover, for a subset of xenografts in which patients received TMZ 
at some point during their clinical care, there was a close correlation between the clinical 
response and xenograft sensitivity to TMZ (47). Collectively, these data highlight the high 
degree of clinical relevance of the Mayo GBM xenograft panel for evaluating novel TMZ-
sensitizing strategies.  
 
Initial Studies with veliparib in Combination with TMZ and RT 
PARP inhibitors are potent chemo-sensitizing agents, and in anticipation of developing a clinical 
trial in GBM, we obtained veliparib from CTEP as part of a pre-clinical LOI solicitation. The 
survival evaluation of combinations of veliparib with TMZ and/or RT was now been completed 
in 11 primary GBM xenograft lines. Ten xenograft lines were derived from TMZ-naïve GBM 
tumors, one from a recurrent GBM after failing TMZ therapy (GBM46R), and all have been 
passaged exclusively in nude mice prior to testing (46, 47). Of these primary lines, GBM6, 
GBM28, GBM43 and GBM79 are unmethylated within the MGMT promoter and express high 
levels of MGMT mRNA and protein. GBM5, GBM12, GBM22, GBM39, GBM46R, GBM59, 
and GBM63 are MGMT promoter hypermethylated and do not express appreciable MGMT 
levels. GBM28 has monosomy of Chromosome 10, and during serial passage the remaining 
allele of MGMT was deleted as demonstrated by PCR and western blotting such that later 
generation GBM28 tumors are deficient in MGMT. For clarity, the early passage GBM28 lines 
are denoted as GBM28A and late passage GBM28 (after MGMT deletion) are denoted as 
GBM28B. Because we have cryopreserved specimens from the pre- and post-deletion event, 
these paired tumor sub-lines are useful for examining the importance of MGMT expression. All 
of the pre-clinical studies shown below were performed using radiation and TMZ doses and 
schedules designed to closely mimic the typical clinical usage of TMZ, and all of the key studies 
were performed using an intracranial therapy evaluation model. Thus, the studies presented 
below provide a highly clinically relevant data set upon which the clinical trial design proposed 
is based.  
We initially published our results with the combination of veliparib, TMZ and radiation in 2009 
with specific focus on 2 MGMT methylated lines (GBM12 and GBM22) (44). To model clinical 
treatment paradigms, veliparib was combined both with RT/TMZ (2 Gy x 2 weeks and low-dose 
daily TMZ). Veliparib markedly enhanced the survival of mice with GBM12 orthotopic tumors 
treated with RT/TMZ with a 170 day increase in median survival. In an independent experiment 
with GBM12, the combination of veliparib with adjuvant dosing of TMZ (50 mpk/day, days 1-
5 every 28 days) for 3 cycles significantly extended median survival for the combination 
treatment compared to TMZ alone by 130 days (data not shown). In GBM22, the combination 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
12 
Update #09 
of RT and TMZ was highly efficacious, and the addition of veliparib did not further enhance the 
efficacy of combined therapy. However, veliparib combined with TMZ in GBM22-bearing mice 
resulted in a significant improvement in survival compared to TMZ alone. The extent of survival 
prolongation seen in these studies is profound in comparison to the efficacy of other novel 
therapeutic agents in our xenograft models (RAD001, erlotinib, enzastaurin) (50, 52), and we 
believe that the extent of benefit observed in these studies likely will translate into clinically 
meaningful survival benefits in at least a subset of GBM patients. Based on these results, we 
embarked on a series of studies, supported by an NIH RO1, designed to define the optimal 
schedule for combining TMZ and veliparib and to define a preliminary biomarker that could be 
used to enrich for a population of patients most likely to benefit from combination therapy.  
 
Optimal dose/schedule of TMZ and veliparib 
There is considerable interest in defining whether more dose-intensive TMZ dosing schedules 
might provide a clinical benefit in GBM patients. There are several clinical dosing regimens that 
have been explored including standard (TMZ 150-200 mg/m2 days 1-5 every 28 days), dose-
dense (TMZ 100 mg/m2 days 1-21 every 28 days) and metronomic (TMZ 75 mg/m2 
continuously). Although recent results from the RTOG 0525 clinical trial suggests that dose-
dense TMZ therapy does not provide a significant benefit as compared to standard TMZ therapy 
in GBM patients, the greater exposure to TMZ-induced lesions might provide a benefit when 
combined with continuous PARP inhibition. Therefore, we performed a study in GBM12 
orthotopic xenografts to compare the efficacy of standard and dose-dense TMZ dosing schedules 
alone and in combination with veliparib. In comparing the 2 TMZ dosing regimens without 
veliparib, dose-dense therapy was associated with longer survival as compared to standard 
dosing (data not shown). However, in combination regimens, veliparib significantly enhanced 
the efficacy of standard TMZ dosing (p<0.001) while the combination with dose-dense TMZ 
therapy was associated with a number of early toxicity-related deaths such that the combination 
was no better than dose-dense TMZ alone (p=0.58).  In comparing the 2 combination regimens, 
there was no difference in survival for the dose-dense TMZ/veliparib compared with standard 
TMZ/ABT (p=0.23). These data suggest that the combination of veliparib with either standard 
or dose-dense TMZ may be efficacious, but that veliparib combined with TMZ dose-dense 
therapy may be associated with increased toxicities in mice.  
The efficacy of dose-dense therapy was modeled in a second GBM tumor line that in retrospect 
was defined as MGMT deleted (GBM28B). In this experiment, dose-dense and standard TMZ 
dosing was compared alone and in combination with veliparib. In contrast to GBM12, there was 
no significant difference in the efficacy of standard or dose-dense TMZ monotherapy (data not 
shown). Veliparib combined with standard TMZ was associated with improved survival benefit 
as compared to monotherapy (p=0.04), while veliparib combined with dose-dense TMZ was no 
different than either standard or dose-dense TMZ monotherapy (p=0.73). In comparing survival 
on the 2 combination regimens, standard TMZ/veliparib was equivalent to dose-dense 
TMZ/ABT (p=0.34) dosing. Collectively, the GBM12 and GBM28B data suggest that veliparib 
combined with the standard TMZ dosing schedule (Days 1-5 every 28 days) is at least equally 
efficacious to a combination of veliparib with dose-dense TMZ.  
The optimal duration of veliparib therapy in combination of TMZ is unknown. Since veliparib 
has a relatively short half-life and should reach steady state quickly after initiation of therapy, 
we reasoned that pre-loading with veliparib prior to TMZ was not necessary. However, DNA 
damage incurred by TMZ can persist for several days following cessation of TMZ therapy, and 
therefore we tested whether extending veliparib therapy for 1 week following completion of a 5 
day course of TMZ would provide a significant survival benefit. Using GBM12 as a model, 
mice were randomized to 2 cycles of therapy.  

 
 
Alliance A071102 
 
Version date: 01/22/2021  
13 
Update #09 
There was no significant difference in survival for mice treated with TMZ (days 1-5 every 28 
days x 2 cycles) concurrent with veliparib (Days 1-5 x 2 cycles) or concurrent and extended 
veliparib (Days 1-12 x 2 cycles) (p=0.47). These data suggest no compelling rationale to 
significantly extend veliparib dosing beyond the completion of TMZ therapy during adjuvant 
cycles.  
The brain penetration of veliparib was evaluated in the same nude mouse model. Following 5 
days of treatment with veliparib, plasma and normal brain were harvested at for time points (0 
hr, 0.5 hr, 2 hr, 6 hr) after the last dose. Analysis of these data demonstrates an average 
concentration maximum of 1.2 µM in plasma and 0.27 µM in normal brain with a brain to 
plasma ratio of 0.23 µM. Area under the curve for plasma was 2.1 µM*hr and for brain was 0.86 
µM*hr  with a brain to plasma AUC ratio of 0.41. The half-life in plasma and brain are 2.7 hr 
and 3.4 hr respectively. These data demonstrate reasonable penetration of veliparib into the brain 
and are consistent with the observed efficacy in our orthotopic xenograft models 
To summarize, the data presented above demonstrate robust TMZ sensitizing potential for 
veliparib combined with TMZ in 3 GBM xenograft lines that are deficient for MGMT 
expression. With no compelling data supporting combinations with dose-dense TMZ, we plan 
to test the combination of veliparib with standard TMZ dosing in the adjuvant setting. 
 
Definition of an enrichment strategy 
The data presented above demonstrate excellent sensitizing potential for veliparib combined 
with TMZ in 3 distinct GBM tumor lines that are inherently TMZ sensitive and provide a 
rationale for testing the combination in GBM. Published data suggest that PARP inhibition 
should also sensitize tumors that are resistant to TMZ. To test this concept, we evaluated the 
efficacy of TMZ in 4 MGMT unmethylated tumor lines that express high levels of MGMT 
(GBM6, GBM28A, GBM43 and GBM79). The combination of veliparib with standard TMZ 
dosing did not provide a clinically meaningful increase in survival with the maximum benefit 
of a 7 day prolongation in median survival seen in GBM6. Of specific note, in contrast to the 
benefit seen with the same treatment regimen in the MGMT deficient GBM28B line, there was 
no benefit for the combination in GBM28A, which expresses MGMT.  
The efficacy of TMZ combined with veliparib was evaluated in a total of 8 xenograft lines that 
harbor MGMT promoter hypermethylation or lack MGMT expression. The data from all studies 
are summarized in Table 1. Overall, 4 of 8 tumor lines significantly benefited from combined 
veliparib + TMZ therapy as compared to TMZ alone, and in these 4 lines, combination therapy 
was associated with an approximate doubling in the median survival compared to TMZ therapy 
alone. Of interest, the inherently TMZ resistant GBM46R line, which was derived from a patient 
at the time of recurrence after progression on TMZ therapy, the combination of veliparib+TMZ 
was no better than TMZ alone. Collectively, these data suggest that MGMT promoter 
hypermethylation in previously untreated GBM may enrich for a population of tumors most 
likely to benefit from veliparib combined with TMZ.

Alliance A071102 
Version date: 01/22/2021 
14 
Update #09 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GBM12 and GBM28B do not express appreciable levels of MGMT, with MGMT expression 
suppressed by promoter hypermethylation in GBM12 and loss of both alleles of MGMT during 
routine heterotopic passage in GBM28. To evaluate the impact of MGMT expression on the 
sensitizing effects of veliparib, MGMT was ectopically overexpressed in both GBM12 and 
GBM28B via lentiviral transduction, and the efficacy of veliparib combined with TMZ was 
evaluated as described above. For GBM28, genomic PCR for MGMT in archived tumor samples 
defined the MGMT loss event happened by generation 13. While the initial study in GBM28B 
(MGMT deleted) was performed in a tumor from passage 28, the study in GBM28B was 
repeated with a passage 17 tumor (4 passages after loss of MGMT), and similar to the previous 
study with GBM28B, there was a clear TMZ-sensitizing effect of veliparib (p=0.05). To 
specifically address the importance of MGMT on the sensitizing effects of veliparib, this ‘early’ 
GBM28B line was transduced with a pSIN-MGMT lentiviral construct. As expected, over-
expression of MGMT rendered GBM28B resistant to TMZ and more strikingly, veliparib was 
no longer effective as a TMZ-sensitizing agent (p=0.19;). A similar effect was observed in 
GBM12 where TMZ alone or in combination with veliparib was completely ineffective in the 
setting of MGMT overexpression (Figures 1A and 1B). Collectively, these data demonstrate 
that in TMZ-naïve GBM tumors, lack of MGMT expression is critically important for effective 
sensitization by veliparib, and the mechanisms responsible for this effect are currently being 
investigated.
 
Table 1: Summary of veliparib/TMZ versus TMZ alone studies done in both 
MGMT unmethylated and MGMT hypermethylated tumors using an orthotopic 
therapy model and conventional TMZ dosing (50-66 mg/kg PO days 1-5 every 
28 days). The median survival for each treatment is reported in columns 2 through 
5. * p-values relate to the comparison of TMZ versus TMZ + ABT-888. 

Alliance A071102 
Version date: 01/22/2021 
15 
Update #09 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The combination of veliparib and TMZ also was studied in models of acquired TMZ resistance. 
For our initial studies, a single mouse with either GBM12 or GBM22 flank tumors were 
subjected to escalating doses of TMZ until the resulting tumors became highly resistant to TMZ 
therapy (the resulting tumors are denoted as GBM12TMZ and GBM22TMZ, respectively). 
GBM12TMZ is resistant due to MGMT over-expression while GBM22TMZ is resistant through 
non-MGMT dependent mechanisms. In contrast to the marked sensitizing effects observed in 
the parental GBM12 and 22 tumor lines, the combination of veliparib and TMZ was no better 
than TMZ alone in either GBM12TMZ and GBM22TMZ (Clarke et al.,2009). 
The heterogeneity of resistance emergence in GBM12 was studied in a second study in which 
mice implanted with GBM12 flank tumors were randomized to therapy with placebo, TMZ, and 
veliparib+TMZ. Tumor growth was monitored thrice weekly and tumors larger than their 
endpoint were cryopreserved and analyzed for mechanisms of resistance. Consistent with our 
studies in the intracranial therapy model, therapy with veliparib + TMZ was more effective at 
delaying tumor growth as compared to TMZ alone. In an analysis of resistance mechanisms 
from TMZ-treated tumors, 2 of 10 tumors had high-level mRNA MGMT expression. To test 
whether MGMT over-expression was linked to TMZ-resistance development in this model, one 
tumor without MGMT expression (animal #5920) and one tumor with high level MGMT 
expression (animal #3080) were grown as neurospheres and the efficacy of TMZ alone and in 
combination with the MGMT inhibitor O6BG was tested in a neurosphere formation assay. 
O6BG profoundly enhanced the efficacy of TMZ in the MGMT over-expressing line (#3080), 
but not in the MGMT low line (#5920). Since O6BG is a selective inhibitor for MGMT activity, 
these data confirm that TMZ resistance in the #3080 tumor is mechanistically lined to MGMT 
over-expression, while the mechanism of TMZ resistance in #5920 is currently unknown, but 
definitively not related to MGMT. 
The efficacy of TMZ and veliparib was evaluated in these 2 TMZ resistant GBM12 sub-lines in 
a flank tumor growth assay. Similar to the initial GBM12 flank study, mice implanted with 
tumor cells were randomized to therapy with placebo, veliparib, TMZ or TMZ + veliparib. Both 
the #3080 and #5920 tumor sub-lines were highly resistant to TMZ and TMZ + veliparib. In 
contrast to the GBM12 flank tumor study from which these tumor sub-lines were derived, these 
data support the idea that veliparib is ineffective in TMZ resistant tumor lines. 
A. GBM 12 
 
 
B. GBM 12 + MGMT 
 
 
Figure 1: Influence of MGMT expression on sensitizing effects of veliparib. The 
efficacy of TMZ alone and in combination with veliparib was tested in A) parental 
GBM12 and B) GBM12 transduced with pSIN-MGMT. * p-values relate to the 
comparison of TMZ versus TMZ + veliparib. 
 
Days
0
100
200
300
Survival
0.0
0.2
0.4
0.6
0.8
1.0
Placebo
TMZ
TMZ + ABT-888
Days
0
20
40
60
80
100
Survival
0.0
0.2
0.4
0.6
0.8
1.0
Placebo
ABT-888
TMZ
ABT-888 + TMZ

 
 
Alliance A071102 
 
Version date: 01/22/2021  
16 
Update #09 
In summary, we have tested veliparib combined with TMZ in 11 primary GBM xenograft lines. 
The combination was effective in 4 of 7 lines that are inherently sensitive to TMZ and are 
MGMT promoter hypermethylated with associated low MGMT expression. In contrast, the 
combination was ineffective in 4 inherently TMZ-resistant lines with MGMT promoter 
hypomethylation and high level MGMT expression. In one model (GBM28), loss of MGMT 
expression in a sub-line was associated with increased sensitivity to TMZ and effective 
sensitization with the addition of veliparib to TMZ therapy. Conversely, development of TMZ 
resistance, by either of 2 mechanisms in a tumor line (GBM12) originally sensitive to ABT/TMZ 
resulted in loss of efficacy for the combination. Collectively, we have tested 9 TMZ resistant 
xenograft models, and the combination of TMZ and veliparib was ineffective in all of them. In 
contrast, in 7 TMZ-sensitive xenograft models, 4 likely benefited from combination therapy. 
Moreover, in the MGMT non-expressing lines GBM28B and GBM12, in which the combination 
of TMZ and veliparib was effective, specific restoration of MGMT expression resulted in loss 
of the sensitizing effects of veliparib. On the basis of these in vivo data, we hypothesize that 
only TMZ sensitive tumors lacking MGMT expression will benefit from a combination strategy 
with veliparib and TMZ. 
Molecular studies have defined 2 major mechanisms of TMZ resistance: MGMT over-
expression and mutational inactivation of MMR. Promoter hypermethylation is a major 
mechanism of transcriptional repression of MGMT in GBM, and clinical data from RTOG 0525 
and EORTC 22981 both have demonstrated that MGMT promoter hypermethylation is 
associated with superior survival for newly diagnosed GBM patients treated with radiation and 
temozolomide. While there are undoubtedly other mechanisms that modulate MGMT 
expression and inherent TMZ sensitivity, we hypothesize that MGMT promoter 
hypermethylation can be used to highly enrich for a population of patients most likely to benefit 
from PARP inhibitor therapy combined with TMZ. While MMR mutation is a major mechanism 
of TMZ resistance in colon cancer and likely in a subset of recurrent GBM, genome-wide 
mutational analyses performed by the TCGA in TMZ-naïve GBM samples suggest a low rate 
of MMR mutation in newly diagnosed GBM. Thus, based on the known mechanisms of inherent 
TMZ resistance in GBM, we propose to use only MGMT promoter hypermethylation to enrich 
for patients most likely to respond to combination therapy. 
Two potential strategies for patient selection were entertained for this randomized Phase II/III 
clinical trial. In one design, all patients would be enrolled on the trial and the MGMT 
methylation status could be used as a stratification factor or simply in the analysis of patient 
outcomes. With careful attention to the anticipated accrual of MGMT promoter hypermethylated 
tumors, the trial could be powered specifically to test the hypothesis that MGMT promoter 
hypermethylation will select for a subset of patients most likely to respond to veliparib in 
combination with TMZ. A second design would limit enrollment only to patients with MGMT 
promoter hypermethylation (approximately 30% of newly diagnosed GBM patients based on 
results from RTOG 0525). On the basis of our preliminary animal data demonstrating a lack of 
benefit for inherently TMZ resistant tumors and those tumors with MGMT expression, this 
design will maximize potential clinical benefit while limiting the number of patients exposed to 
the risk of adverse events related to veliparib therapy. With the goal of maximizing patient 
benefit in the current trial design, we have elected to pursue the latter trial design, and only 
patients with tumor MGMT promoter hypermethylation will be enrolled on this Phase II/III 
clinical trial. 
The RTOG is currently testing veliparib combined with metronomic TMZ therapy in recurrent 
GBM that have failed TMZ therapy in a randomized Phase II study (RTOG 0929). Based on our 
preclinical data discussed above, we would argue that a negative result on RTOG 0929 would 
not negate the rationale for our currently planned study in TMZ-naïve patients with MGMT 
promoter hypermethylation. In fact, if RTOG 0929 is negative, this would further support the 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
17 
Update #09 
translational relevance of the pre-clinical studies presented herein. Thus, we do not believe that 
a go/no-go decision for the current trial proposal should be linked to the future results from 
RTOG 0929.  
The pharmacokinetics (PK), safety and tolerability of veliparib alone and combined with 
temozolomide have been studied in multiple clinical trials. Initial PK studies demonstrated no 
significant interactions between veliparib and temozolomide, and no effect of food on the 
bioavailability of veliparib. In an initial Phase I clinical trial, dose escalation of veliparib was 
well tolerated up to 40 mg PO BID in combination with TMZ at 200 mg/m2. In a subsequent 
expansion cohort, thrombocytopenia or neutropenia was minimized in the first cycle by starting 
TMZ at 150 mg/m2 and then escalating to 200 mg/m2 if well tolerated. In combination with a 
second Phase I trial, the recommended dosing regimen for Phase II testing is veliparib 40 mg 
BID given on Days 1-7 in combination with TMZ 150 mg/m2 Days 1-5 in cycle 1 and if no 
significant hematologic toxicity is encountered, to escalate TMZ dosing to 200 mg/m2 in cycle 
2 through cycle 6. With this dosing regimen, a randomized Phase II clinical trial in melanoma 
patients compared TMZ alone to combinations with 20 or 40 mg veliparib BID. In comparison 
to TMZ therapy alone, the incidence of Grade 3/4 thrombocytopenia and neutropenia were 
significantly increased with TMZ in combination with veliparib. Other common effects, that 
were similar in incidence to TMZ alone, included nausea, vomiting, constipation, anorexia and 
fatigue. The combination regimen also has been tested in a randomized trial compared to 
pegylated doxorubicin in recurrent ovarian cancer and now is accruing patients for an open label 
Phase II clinical trial and a randomized phase II trial in BRCA 1/2 mutant metastatic breast 
cancer patients. While cyclical dosing of veliparib and TMZ in these Phase II studies is well 
tolerated, a Phase I study of daily veliparib combined with radiation and daily temozolomide for 
6 weeks in newly diagnosed GBM was poorly tolerated even when veliparib was dosed at 10 
mg BID. Based on this latter experience, the current trial will test the combination of veliparib 
40 mg BID and TMZ (150 to 200 mg/m2) only during adjuvant therapy following completion 
of conventional daily radiation combined with daily TMZ.  
There is limited data on the efficacy of veliparib combined with TMZ. In a Phase I study of 42 
patients with solid malignancies, there were 2 confirmed partial responses and 3 unconfirmed 
partial responses. In a Phase IB study of the combination in castration refractory metastatic 
prostate cancer, 2 of 25 patients had a biochemical partial response with a reduction in PSA. In 
the randomized Phase II melanoma study, there was no statistically significant difference for 
overall response rate, progression-free survival or overall survival between those patients treated 
with TMZ only, TMZ + veliparib 20 mg BID or TMZ + veliparib 40 mg BID. Similarly, in a 
preliminary analysis of a Phase II ovarian cancer trial, there was no difference in overall 
response rate for patients treated with TMZ + veliparib compared to pegylated liposomal 
doxorubicin. While the data for the latter trial is not mature and several other Phase II trials have 
not reached maturity, the limited efficacy observed in these studies using an unselected 
population of patients underscores the potential importance of enriching for a population of 
patients that are most likely to benefit from combination therapy. Based on extensive pre-clinical 
data used to develop the current trial, only newly diagnosed GBM patients with tumor MGMT 
promoter hypermethylation will be eligible to enroll on this trial. Using this enrichment strategy, 
we believe the current trial has a much greater chance for success in defining an efficacious 
regimen for a subset of patients with GBM. 
Pseudoprogression (PsP) is a radiographic finding of apparent worsening of a tumor on MRI 
following radiation and temozolomide therapy in the setting of a patient that is clinically stable 
and on stable doses of steroids. Although the pathophysiology of PsP has not been clearly 
delineated, the effect likely is a manifestation of tumor cytotoxicity following therapy. 
Consistent with this idea, there may be an increased frequency of PsP in patients with MGMT 
promoter hypermethylation, and the survival for patients with PsP appears to be superior to those 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
18 
Update #09 
without PsP (71). The RANO criteria have defined PsP as occurring within the first 12 weeks 
following completion of radiation therapy (59). However, there are isolated reports of PsP or 
treatment-related necrosis happening beyond this 12 week window (68; 69, 70) and in a 
preliminary report of patients treated with a dose-intensive CCNU/TMZ adjuvant chemotherapy 
regimen, 3 of 8 patients with MGMT promoter hypermethylation experienced PsP at times 
substantially later than the 12 week window (67). Since the current trial is enrolling only MGMT 
methylated patients, we anticipate a higher than typical rate of PsP, and patients suspected of 
having PsP are eligible for enrollment on this trial. The testing of a TMZ-sensitizing strategy 
with veliparib may lead to an even higher rate of PsP, and these events may occur later than the 
typical 12 week window. Because the incidence of PsP indicates a favorable therapeutic 
response, continued therapy with veliparib/placebo combined with TMZ is critical in this setting. 
Thus, for the purposes of this trial, patients with typical radiographic and clinical findings 
consistent with pseudoprogression should remain on study even if the initial indication of PsP 
occurs beyond the RANO-defined cut-off of 12 weeks.  
1.4 
Integration of NovoTTF-100A therapy within this trial 
The EORTC recently completed accrual on a randomized clinical trial evaluating the use of the 
NovoTTF-100A (Optune) device in conjunction with adjuvant TMZ in patients with newly 
diagnosed GBM who have completed concurrent RT/TMZ. The interim analysis from this trial 
demonstrated the median progression free survival was 7.1 months for TTF therapy vs. 4.0 
months for control patients treated with adjuvant TMZ alone (p=0.001). Similarly, the median 
overall survival was 20.5 months versus 15.6 months, respectively (p=0.004) (Stupp et al., 
JAMA 2015). In conjunction with these data, the U.S. Food and Drug Administration (FDA) 
approved the Optune device for use in combination with adjuvant TMZ in newly diagnosed 
GBM patients on October 5, 2015. While the mechanisms of action of Optune therapy remains 
under investigation, there is no expectation that integrating Optune therapy with adjuvant 
TMZ/veliparib will result in undue risk to the patient associated with veliparib treatment. 
Therefore, with Update #3 of this clinical trial, patients will be allowed to use the Optune device 
as part of routine clinical care for GBM. To ensure statistical rigor, patients will be stratified 
based on use of Optune therapy. Patients only will be allowed to use Optune on this trial if they 
initiate Optune therapy with the start of Cycle 1, or wait to initiate after completion of protocol 
therapy.     
 
 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
19 
Update #09 
2.0 
OBJECTIVES  
2.1 
Primary objective  
Test whether the experimental combination of ABT-888 (veliparib) combined with TMZ, 
compared to the control of placebo combined with TMZ, significantly extends overall survival 
in newly diagnosed GBM patients with tumor MGMT promoter hypermethylation. 
2.2 
Secondary objectives 
2.2.1 
Test whether the experimental treatment significantly extends progression-free 
survival. 
2.2.2 
Test whether the experimental treatment improves objective tumor response. 
 
2.2.3 
Test whether the experimental treatment is associated with significantly greater 
rates of grade 3 or higher adverse events. 
2.3 
Correlative Science Objectives 
2.3.1 
Evaluate the utility of dynamic susceptibility contrast (DSC) and diffusion 
weighted imaging (DWI) MRI techniques in defining time to progression in the 
setting of a large multi-institutional clinical trial. 
2.3.2 
Test the concordance between site-determined MGMT methylation status and 
central laboratory determination of MGMT status in cases with local testing. 
2.3.3 
Evaluate whether genetic or epigenetic alterations in DNA repair or replication 
genes are associated with overall survival, progression-free survival, and objective 
tumor response. 
2.3.4 
Test whether polymorphisms in MGMT, PARP1, or other DNA repair proteins, 
are associated with overall survival, progression-free survival, objective tumor 
response, or rates of grade 3 or higher adverse events. 
3.0 
PATIENT SELECTION 
For questions regarding eligibility criteria, see the Contact Information page. Please note that the 
Study Chair cannot grant waivers to eligibility requirements.  
3.1 
On-Study Guidelines 
This clinical trial can fulfill its objectives only if patients appropriate for this trial are enrolled. 
All relevant medical and other considerations should be taken into account when deciding 
whether this protocol is appropriate for a particular patient. Physicians should consider the risks 
and benefits of any therapy, and therefore only enroll patients for whom this treatment is 
appropriate.  
Although they will not be considered formal eligibility (exclusion) criteria, physicians should 
recognize that the following may seriously increase the risk to the patient entering this protocol: 
• 
Psychiatric illness which would prevent the patient from giving informed consent. 
• 
Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes 
mellitus or cardiac disease which, in the opinion of the treating physician, would make this 
protocol unreasonably hazardous for the patient. 
• Patients with a “currently active” second malignancy other than non-melanoma skin cancers. 
Patients are not considered to have a “currently active” malignancy if they have completed 
therapy and are free of disease for ≥ 3 years. Patients treated for prior brain tumor, 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
20 
Update #09 
nasopharynx or sinus cancer with a previous course of radiation in which significant dose 
to the brain was delivered may not participate in this trial. 
• 
Patients who cannot swallow oral formulations of the agent(s). 
In addition: 
• 
Women and men of reproductive potential should agree to use an appropriate method of 
birth control throughout their participation in this study due to the teratogenic potential of 
the therapy utilized in this trial. Appropriate methods of birth control include abstinence, 
oral contraceptives, implantable hormonal contraceptives or double barrier method 
(diaphragm plus condom). 
3.2 
Pre-Registration Eligibility Criteria  
3.2.1 Histologic documentation: Newly diagnosed WHO Grade IV intracranial glioblastoma or 
gliosarcoma. GBM with oligodendroglial features are NOT PERMITTED in this study if 
they are 1p19q codeleted. Sites submitting GBM with oligodendroglial features will be 
asked to provide results of 1p/19q codeletion status. 
3.2.2 Sufficient tissue available for central pathology review and MGMT methylation status 
evaluation. 
3.2.3 Age ≥ 18 years of age 
3.2.4 Patients who have had a local MGMT testing that is unmethylated are not allowed to 
participate. 
3.3 
Registration Eligibility Criteria  
3.3.1 Tumor MGMT promoter hypermethylation determined by central testing at MD Anderson. 
3.3.2 Confirmation by central pathology review of WHO Grade IV glioblastoma or gliosarcoma. 
3.3.3 Required Lab Values: 
Required Initial Laboratory Values: 
(Within 14 days prior to study registration) 
 
 
 
Absolute neutrophil count (ANC)  
≥ 1500 cells/mm3 
Platelets  
≥ 100,000 cells/mm3 
Creatinine  
≤ 1.5x ULN  
Bilirubin 1  
≤ 1.5x ULN 
ALT  
≤ 3 x ULN 
AST  
≤ 3 x ULN 
 
 
1 Unless patient has Gilbert’s disease 
3.3.4 ECOG Performance Status ≤ 2 
3.3.5 Measurable disease or non-measurable disease as defined in Section 11.0. 
Extent of resection: Patients with complete resection, partial resection, or biopsy are 
eligible. 
3.3.6  Progression: Patients deemed to have progressive disease based on clinical deterioration 
after chemoradiation or radiographic progression outside of the radiation field are not 
eligible. (See Section 11.4.3.2 for definition of clinical deterioration). Patients deemed to 
have pseudoprogression (as defined in Section 11.4.3.2) are eligible. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
21 
Update #09 
3.3.7 Prior Treatment  
• 
Must have completed standard radiotherapy and concomitant TMZ therapy as 
defined in Appendix I and determined by the study oncologist. 
• 
Besides concomitant TMZ with radiation, no other therapy (neo-adjuvant or 
adjuvant) can be given prior to study registration, including chemotherapy (also 
including Gliadel/BCNU wafers), biologics, immunotherapy, or radiation therapy. 
The only exception is the Optune device (NovoTTF-100A), which may be started 
any time after end of radiation therapy up through the initiation of Cycle 1. Intent 
to use Optune must be declared at registration for stratification (see Sections 4.4 and 
4.7). See Sections 5.0 and 8.1.11 for additional requirements. 
• 
No prior allogeneic bone marrow transplant or double umbilical cord blood 
transplantation. 
3.3.8 Not pregnant and not nursing, because this study involves an agent that has known 
genotoxic, mutagenic and teratogenic effects. Females of childbearing potential must have 
negative urine or serum pregnancy test within 7 days of registration but before start of 
treatment. A female of childbearing potential is a sexually mature female who: 1) has not 
undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally 
postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the 
preceding 12 consecutive months). 
 
3.3.9 
Concomitant Medications:  
• 
Patients receiving anticoagulation should be on stable dose 2 weeks prior to 
registration. 
3.3.10 Comorbid Conditions: Patients are unable to participate due to the following: 
• 
Generalized or partial seizure disorder that is uncontrolled at the time of registration. 
The definition of controlled generalized seizures is patients must be on a stable dose 
of anti-seizure medication and without generalized seizures for at least 10 days prior 
to registration.  The definition of controlled partial seizures is patients must be on a 
stable dose of anti-seizure medication for at least 10 days prior to registration. 
Patients with occasional breakthrough partial seizures are allowed at treating 
physician’s discretion. 
• 
Grade 3 or 4 thromboembolic disease within 6mo of registration 
• 
Known history of prolonged QT syndrome 
3.3.11 No history of major surgery ≤ 14 days prior to registration 
3.3.12 Patients must have adequate organ and marrow function measured within 28 days prior to 
administration of ABT-888 as defined below: 
≥10.0 g/dL Hb with no blood transfusion in the past 28 days 
3.3.13 No Patients with treatment-related AML (t-AML)/MDS or with features suggestive of 
AML/MDS. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
22 
Update #09 
4.0 
PATIENT REGISTRATION 
4.1 
CTEP Registration Procedures 
Food and Drug Administration (FDA) regulations and National Cancer Institute (NCI) policy 
require all individuals contributing to NCI-sponsored trials to register and to renew their 
registration annually.  To register, all individuals must obtain a Cancer Therapy Evaluation 
Program 
(CTEP) 
Identity 
and 
Access 
Management 
(IAM) 
account 
(https://ctepcore.nci.nih.gov/iam).  In addition, persons with a registration type of Investigator 
(IVR), Non-Physician Investigator (NPIVR), or Associate Plus (AP) (i.e., clinical site staff 
requiring write access to OPEN, RAVE, or TRIAD or acting as a primary site contact) must 
complete their annual registration using CTEP’s web-based Registration and Credential 
Repository (RCR) (https://ctepcore.nci.nih.gov/rcr).  Documentation requirements per 
registration type are outlined in the table below. 
Documentation Required 
IVR 
NPIVR 
AP 
A 
FDA Form 1572 
 
 
Financial Disclosure Form 
 
 
 
NCI Biosketch (education, training, employment, 
license, and certification) 
 
 
 
HSP/GCP training 
 
 
 
Agent Shipment Form (if applicable) 
 
CV (optional) 
 
 
 
 
An active CTEP-IAM user account and appropriate RCR registration is required to access all 
CTEP and CTSU (Cancer Trials Support Unit) websites and applications.  In addition, IVRs and 
NPIVRs must list all clinical practice sites and IRBs covering their practice sites on the FDA 
Form 1572 in RCR to allow the following: 
• 
Added to a site roster 
• 
Assigned the treating, credit, consenting, or drug shipment (IVR only) tasks in 
OPEN 
• 
Act as the site-protocol PI on the IRB approval 
Additional 
information 
can 
be 
found 
on 
the 
CTEP 
website 
at 
< 
https://ctep.cancer.gov/investigatorResources/default.htm >.  For questions, please contact the 
RCR Help Desk by email at < RCRHelpDesk@nih.gov >. 
4.2 
CTSU Registration Procedures 
This study is supported by the NCI Cancer Trials Support Unit (CTSU). 
IRB Approval:   

 
 
Alliance A071102 
 
Version date: 01/22/2021  
23 
Update #09 
Each investigator or group of investigators at a clinical site must obtain IRB approval for this 
protocol and submit IRB approval and supporting documentation to the CTSU Regulatory 
Office before they can be approved to enroll patients.  Assignment of site registration status in 
the CTSU Regulatory Support System (RSS) uses extensive data to make a determination of 
whether a site has fulfilled all regulatory criteria including but not limited to the following: 
• 
An active Federal Wide Assurance (FWA) number 
• 
An active roster affiliation with the Lead Network or a participating organization 
• 
A valid IRB approval 
• 
Compliance with all protocol specific requirements. 
In addition, the site-protocol Principal Investigator (PI) must meet the following criteria: 
• 
Active registration status 
• 
The IRB number of the site IRB of record listed on their Form FDA 1572 
• 
An active status on a participating roster at the registering site. 
Sites participating on the NCI CIRB initiative that are approved by the CIRB for this study are 
not required to submit IRB approval documentation to the CTSU Regulatory Office. For sites 
using the CIRB, IRB approval information is received from the CIRB and applied to the RSS in 
an automated process. Signatory Institutions must submit a Study Specific Worksheet for Local 
Context (SSW) to the CIRB via IRB Manager to indicate their intent to open the study locally.  
The CIRB’s approval of the SSW is then communicated to the CTSU Regulatory Office.  In 
order for the SSW approval to be processed, the Signatory Institution must inform the CTSU 
which CIRB-approved institutions aligned with the Signatory Institution are participating in the 
study. 
4.2.1 Downloading Site Registration Documents 
Site registration forms may be downloaded from the A071401 protocol page located on the CTSU 
members’ website. Permission to view and download this protocol and its supporting documents is 
restricted and is based on person and site roster assignment housed in the CTSU RSS. 
• 
Go to https://www.ctsu.org and log in to the members’ area using your CTEP-
IAM username and password. 
• 
Click on the Protocols tab in the upper left of your screen 
• 
Either enter the protocol # in the search field at the top of the protocol tree, or 
• 
Click on the By Lead Organization folder to expand 
• 
Click on the Alliance link to expand, then select trial protocol # A071102 
• 
Click on LPO Documents, select the Site Registration documents link, and 
download and complete the forms provided. 
4.2.2 Requirements for A071102 Site Registration 
• 
IRB approval (For sites not participating via the NCI CIRB; local IRB 
documentation, an IRB-signed CTSU IRB Certification Form, Protocol of Human 
Subjects Assurance Identification/IRB Certification/Declaration of Exemption 
Form, or combination is accepted) 
• 
The enrolling site must be aligned to a RTI provider.  To manage provider 
associations access the Provider Association tab on the CTSU website at 
https://www.ctsu.org/RSS/RTFProviderAssociation, to add or remove associated 
providers.  Sites must be linked to at least one IROC credentialed provider to 
participate on trials with an RT component. Enrolling sites are responsible for 
ensuring that the appropriate agreements are in place with their RTI provider, and 
that appropriate IRB approvals are in place.   

 
 
Alliance A071102 
 
Version date: 01/22/2021  
24 
Update #09 
• 
IROC Credentialing Status Inquiry (CSI) Form - this form is submitted to IROC to 
begin the modality credentialing process.  
• 
Alliance Imaging Core Lab at IROC Ohio Credentialing (see Section 15.0). 
4.2.3 Submitting Regulatory Requirements 
Submit required forms and documents to the CTSU Regulatory Office via the Regulatory 
Submission Portal, where they will be entered and tracked in the CTSU RSS.  
Regulatory Submission Portal: www.ctsu.org  (members’ area) → Regulatory Tab 
→Regulatory Submission  
When applicable, original documents should be mailed to: 
CTSU Regulatory Office 
1818 Market Street, Suite 3000 
Philadelphia, PA 19103 
Institutions with patients waiting that are unable to use the Portal should alert the CTSU 
Regulatory Office immediately at 1-866-651-2878 in order to receive further instruction and 
support. 
4.2.4 Checking Your Site’s Registration Status 
You can verify your site registration status on the members’ section of the CTSU website.   
• 
Go to https://www.ctsu.org and log in to the members’ area using your CTEP-IAM 
username and password 
• 
Click on the Regulatory tab 
• 
Click on the Site Registration tab 
• 
Enter your 5-character CTEP Institution Code and click on Go 
Note: The status given only reflects compliance with IRB documentation and institutional 
compliance with protocol-specific requirement outlined by the Lead Network. It does not 
reflect compliance with protocol requirements for individuals participating on the protocol 
or the enrolling investigator’s status with the NCI or their affiliated networks. 
4.2.5 Credentialing 
See Section 15.0 for credentialing requirements   
4.3 
Patient Pre-registration Requirements 
• 
Screening Informed consent: the patient must be aware of the neoplastic nature of his/her 
disease and willingly consent after being informed of the procedure to be followed, the 
experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and 
discomforts. Current human protection committee approval of this protocol and a consent 
form is required prior to patient consent and registration. 
• 
Central pathology review and MGMT analysis submission: Patients may be pre-
registered to this study on the basis of the diagnosis of glioblastoma or gliosarcoma made at 
the original institutions. All patients must submit ALL diagnostic H&E’s and one tissue 
block. (See Section 6.2). Submission of these samples for MGMT promoter methylation 
assessment is MANDATORY for all patients pre-registered to this study. 
If a prior analysis of MGMT status at the treating institution revealed an unmethylated tumor 
status, these patients will not be eligible and MUST not be pre-registered. See Section 3.2.4. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
25 
Update #09 
4.4 
Patient Registration Requirements 
• 
Treatment Informed consent: the patient must be aware of the neoplastic nature of his/her 
disease and willingly consent after being informed of the procedure to be followed, the 
experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and 
discomforts. Current human protection committee approval of this protocol and a consent 
form is required prior to patient consent and registration. 
• 
Confirmation of eligibility and MGMT status: Sites will be notified within 21 calendar 
days of specimen receipt whether or not the patient is eligible based on central pathology 
review and MGMT testing. 
• 
Novo TTF-100a (Optune): at the time of study registration (Step 1) the intention of 
patient’s use of Optune device must be declared for stratification (see Section 4.7). See 
Sections 5.0 and 8.1.11 for administration requirements and guidelines.  
4.5 
Patient Registration/Randomization Procedures 
Patient enrollment will be facilitated using the Oncology Patient Enrollment Network (OPEN).  
OPEN is a web-based registration system available on a 24/7 basis.  To access OPEN, the site 
user must have an active CTEP-IAM account (check at < https://ctepcore.nci.nih.gov/iam >) 
and a 'Registrar' role on either the LPO or participating organization roster. Registrars must hold 
a minimum of an AP registration type.   
All site staff will use OPEN to enroll patients to this study.  It is integrated with the CTSU 
Enterprise System for regulatory and roster data and, upon enrollment, initializes the patient in 
the Rave database. OPEN can be accessed at https://open.ctsu.org or from the OPEN tab on the 
CTSU members’ side of the website at https://www.ctsu.org. To assign an IVR or NPIVR as the 
treating, crediting, consenting, drug shipment (IVR only), or investigator receiving a transfer in 
OPEN, the IVR or NPIVR must list on their Form FDA 1572 in RCR the IRB number used on 
the site’s IRB approval.   
Prior to accessing OPEN, site staff should verify the following: 
• 
All eligibility criteria have been met within the protocol stated timeframes.  
• 
All patients have signed an appropriate consent form and HIPAA authorization form 
(if applicable). 
Note: The OPEN system will provide the site with a printable confirmation of registration and 
treatment information. Please print this confirmation for your records. 
To receive site reimbursement for specific tests and/or bio-specimen submissions, completion 
dates must be entered in the OPEN Funding screen post registration. Please refer to the protocol-
specific funding page on the CTSU members’ website for additional information. Timely entry 
of completion dates is recommended as this will trigger site reimbursement. 
Further instructional information is provided on the OPEN tab of the CTSU members’ side of 
the CTSU website at https://www.ctsu.org or at https://open.ctsu.org.  For any additional 
questions contact the CTSU Help Desk at 1-888-823-5923 or ctsucontact@westat.com. 
4.6 
Registration to Correlative and Companion Studies 
4.6.1 Registration to Substudies described in Section 14.0 
There are three substudies within Alliance A071102. These correlative science studies must 
be offered to all patients enrolled on Alliance A071102. These substudies do not require 
separate IRB approval. The substudies included within Alliance A071102 are: 
• 
DNA Extraction from Tissue, Alliance A071102-ST1 (Section 14.1)  

 
 
Alliance A071102 
 
Version date: 01/22/2021  
26 
Update #09 
 
Extracted DNA from the tumor block in excess of that required for MGMT analysis, 
and recurrent tissue samples will be used for future correlative studies and is an optional 
portions of this sub-study. 
• 
DNA Extraction from Blood, Alliance A071102-ST2 (Section 14.2)  
Extracted DNA from a blood sample for germ-line DNA will be used in conjunction 
with the tumor DNA for future correlative studies and are optional portions of this sub-
study. 
For patients who consent to participate in the germline DNA analysis, a blood sample 
must be submitted. 
• 
Analysis of advanced MR imaging, Alliance A071102-IM (Section 14.3)   
 
Institutions MUST select one of the two categories under the section entitled “Optional 
Imaging Study” in the treatment model consent to indicate whether your site has elected 
to participate in the advanced imaging sub-study. Patients at institutions that are not able 
to do advanced images should answer “no” to the imaging question in the treatment 
model consent as the imaging sub-study is not applicable. 
4.7 
Stratification (or Grouping) Factors and Treatment Assignments 
• 
Patients will be stratified by age group: <70 vs. ≥70 years 
• 
ECOG performance status 0-1 vs. 2  
• 
Extent of resection gross total resection vs. subtotal resection or biopsy 
• 
Planned concomitant use of Optune device (yes versus no) 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
27 
Update #09 
5.0 
STUDY CALENDAR   
Laboratory and clinical parameters during treatment are to be followed using individual institutional 
guidelines and the best clinical judgment of the responsible physician. It is expected that patients on 
this study will be cared for by physicians experienced in the treatment and supportive care of patients 
on this trial. 
Pre-Study Testing Intervals  
• 
To be completed ≤ 14 DAYS before registration: All laboratory studies, history and physical. 
 
 
Prior to 
Registration 
Days 1 of 
each cycle (10) 
Post treatment 
follow up 
Tests & Observations 
 
 
 
History and physical, weight, PS 
X 
X(1) 
X(11)** 
Height 
X 
 
 
Pulse, Blood Pressure 
X 
X(1) 
 
Adverse Event Assessment 
 
X(1) 
X** 
Patient Medication Diary (See Appendix VI) 
 
X(2) 
 
Patient Optune Diary (See Appendix IX) 
 
X(14) 
 
Fatigue/Uniscale Assessment (See Appendix IV) 
X(3) 
X(1) 
X** 
Mini Mental State Examination (See Appendix V) 
X(13) 
 
 
Laboratory Studies 
 
 
 
Complete Blood Count, Differential, Platelets 
X 
X(4) 
X** 
Serum Creatinine,  
X 
X(5) 
 
Albumin, glucose 
X 
X(5) 
 
AST, ALT, Alk. Phos., Bili 
X 
X(5) 
X** 
Serum or Urine HCG 
X(6) 
 
 
Staging 
 
 
 
Central Pathology review  
and MGMT testing for 
eligibility 
X(7) 
 
 
Brain Imaging (MRI or CT)(8) See Section 6.3 
X(9) 
X(12) 
X(11) 
Correlative studies: For patients who consent to participate 
Blood samples (A071102-ST2) 
(See Section 6.0 and 14.2) 
Baseline (Before start of treatment)*** 
Tissue samples (A071102-ST1) 
(See Section 6.0 and 14.1) 
Recurrence (within 3 months if surgery was 
performed) 
Banking of Residual Tissue 
(See Section 6.0 and 14.1) 
Prior to registration: MD Anderson will forward 
residual to the Alliance Biorepository at Mayo 
Clinic. 
Advanced MR Imaging(8)  (See Section 6.3 and 
Appendix III) 
X(9) 
X(12) 
X(11) 
 
** 
Visit to be performed 21-35 days after the last day of drug therapy (i.e. Cycle 6 Day 7). 
*** It is strongly preferred that the research blood sample is drawn prior to start of study therapy, 
however, it is acceptable to submit within 60 days after registration to the treatment trial. 
1 
To be completed once every 28 days +/- 7 days. 
2 
The diary must begin the day the patient starts taking the medication and must be completed and 
returned to the treating institution with each cycle. Medication reconciliation should be 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
28 
Update #09 
performed on each day 1 visit: Patients should return remaining pills from the last cycle and this 
should be reconciled. 
3 
To be completed ≤ 21 days prior to treatment, see Appendix IV. 
4 
CBC to be completed +/- 5 days of Day 1 for each cycle and on day 14 +/- 5 days for each cycle. 
5 
To be completed +/- 7 days of each cycle start. 
6 
For women of childbearing potential (see Section 3.3.9). Must be done ≤ 7 days prior to 
registration and prior to starting treatment. 
7 
Central Pathology Review and MGMT testing can be done at any time as long as the patient is 
randomized to treatment within 28 to 42 days after completion of RT/TMZ 
8 
All imaging must be submitted to the Imaging and Radiation Oncology Core within 2 weeks of 
registration (for baseline scans) or acquisition (for all other scans). Images must be submitted 
from all timepoints outlined in footnotes 9, 11 and 12. For patients who have progressive disease, 
submit one scan after confirmed progression and no further scans. Any scans performed as part 
of the clinical care for glioblastoma should be submitted to IROC. For patients who go off study 
for reasons other than progression (i.e., toxicity) please continue to submit images until 
progression. The Appendix II/III guidelines MUST be followed for the post-RT/TMZ and 
restaging scans. Pre-radiation baselines that do not reflect the parameters in Appendix II 
are acceptable. 
9 
Must be done both prior to radiation (pre-RT/TMZ baseline scan) and 21-42 days after 
completion of radiation and temozolomide (post-RT/TMZ baseline scan).  
10 
For patients who develop progressive disease (defined in Section 11) while on treatment, they 
will be followed every 6 months as per the survival and disease follow up. For patients who go 
off-study treatment for reasons other than progressive disease, please see Section 12.1.3.  
11 
Once patient completes protocol treatment (i.e. Cycle 6 Day 28), physical exams and MR are 
required every 10 weeks (+/- 4 weeks) from last MR during treatment for the first 3 years (from 
end of treatment, i.e., Cycle 6 Day 28 for those patients who complete all treatment), then every 
6 months (+/- 28 days) in years 4 and 5, or until confirmed progression. For this protocol, 
confirmed progression means that after an ‘initial scan’ with suspected imaging progression, a 
confirmatory scan should be performed 4 weeks (+/- 2 weeks) after the ‘initial’ MR showing 
suspected imaging progression. If the confirmatory scan confirms progression (confirmed 
progression), then the date of progression should be noted as that of the ‘initial scan.’ After  
confirmed progression, survival calls every 6 months only are required. Ideally, patients should 
be scanned on the same physical scanner during follow up. See Section 11.4.3.1. 
12 
MR is required every 2 months (+/-14 days) during treatment (i.e., Cycle 6 Day 28) with 
temozolomide plus veliparib/placebo. The timing of scans is not based on cycles; it is based on 
the baseline scan that is performed after RT/TMZ but prior to study registration. The post-
RT/TMZ baseline scan should be performed in accordance with Appendix II or III as 
appropriate. In cases where the post-RT/TMZ scan imaging parameters do not match 
Appendix II/III, subsequent follow-up scans should conform to the imaging parameters 
defined in Appendix II/III as appropriate. If a patient discontinues protocol therapy for 
reasons other than progression, then they should follow the post-treatment follow-up schedule. 
13 
Report score only in Rave.  
14 
Only required for patients wearing Optune. See Section 8.1.11 for administration guidelines. 
The Optune diary must be used during protocol treatment beginning on Day 1 of Cycle 1. See 
Appendix IX. All diaries must be completed by the patient and returned to the treating institution 
with each cycle. Usage reports provided by Novocure may be used in lieu of patient diaries. If 
a patient begins treatment with Optune after completion of protocol therapy, then the diary is 
not required to be used. However, treatment with Optune must be reported in Rave via the 
Patient Status Clinical Follow-Up Form.” 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
29 
Update #09 
6.0 
DATA AND SPECIMEN SUBMISSION  
6.1 
Data collection and submission 
Data collection for this study will be done exclusively through the Medidata Rave clinical data 
management system. Access to the trial in Rave is granted through the iMedidata application to 
all persons with the appropriate roles assigned in Regulatory Support System (RSS). To access 
Rave via iMedidata, the site user must have an active CTEP-IAM account (check at 
https://eapps-ctep.nci.nih.gov/iam/index.jsp) and the appropriate Rave role (Rave CRA, Read-
Only, Site Investigator) on either the LPO or participating organization roster at the enrolling 
site. To the hold Rave CRA role or CRA Lab Admin role, the user must hold a minimum of an 
AP registration type.  To hold the Rave Site Investigator role, the individual must be registered 
as an NPIVR or IVR.  Associates can hold read-only roles in Rave.   
Upon initial site registration approval for the study in RSS, all persons with Rave roles assigned 
on the appropriate roster will be sent a study invitation e-mail from iMedidata. To accept the 
invitation, site users must log into the Select Login (https://login.imedidata.com/selectlogin) 
using their CTEP-IAM user name and password, and click on the “accept” link in the upper 
right-corner of the iMedidata page. Please note, site users will not be able to access the study in 
Rave until all required Medidata and study specific trainings are completed. Trainings will be 
in the form of electronic learnings (eLearnings), and can be accessed by clicking on the link in 
the upper right pane of the iMedidata screen. 
Users who have not previously activated their iMedidata/Rave account at the time of initial site 
registration approval for the study in RSS will also receive a separate invitation from iMedidata 
to activate their account. Account activation instructions are located on the CTSU website, Rave 
tab under the Rave resource materials (Medidata Account Activation and Study Invitation 
Acceptance). Additional information on iMedidata/Rave is available on the CTSU members’ 
website under the Rave tab at www.ctsu.org/RAVE/ or by contacting the CTSU Help Desk at 
1-888-823-5923 or by e-mail at ctsucontact@westat.com.   
A Schedule of Forms is available on the Alliance study webpage, within the Case Report Forms 
section. The Schedule of Forms is also available on the CTSU site within the study-specific 
Education and Promotion folder, and is named Time & Events. 
6.1.1 Supporting documentation 
This study requires supporting documentation for diagnosis and progression. Supporting 
documentation will include: 
• 
Pre-registration operative note, pathology report, local MGMT testing (if performed), 
and radiation summary (if complete during the pre-registration timeframe) 
• 
Baseline initial consult note, post radiation visit note, imaging report, and radiation 
summary (if not already submitted at pre-registration) 
• 
Progression pathology report (as applicable), operative report (as applicable), imaging 
report, clinic note 
6.2 
Specimen Collection and Submission  
For all patients pre-registered to Alliance A071102:  
Real time pre-registration histopathology review will be conducted on the diagnostic tissue 
(biopsy and/or surgery) to confirm the diagnosis of Glioblastoma or Gliosarcoma (WHO grade 
IV). Glioblastoma with oligodendroglial features are NOT PERMITTED in this study if they 
are 1p19q codeleted. Sites submitting GBM with oligodendroglial features will be asked to 
provide results of 1p/19q codeletion status. ALL original diagnostic H&E slides used to make 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
30 
Update #09 
the diagnosis should be clearly labeled and forwarded along with at least 1 FFPE block 
containing tumor as soon as possible after surgery for pre-registration. The submission of 
these samples for histopathology review is required for all patients pre-registered to this 
study. 
MGMT promoter hypermethylation will be used as an integral biomarker and key entry criteria 
for enrollment on this trial. The central reading pathologist will select the block suitable for 
analysis, have sections cut, and then ship the sections to the Alliance Biorepository at Mayo 
Clinic for processing, where they will be forwarded to MD Anderson to Dr. Sulman’s lab for 
testing. The MGMT results will be returned to the treating site in real-time so that those patients 
can be registered for the study if they are MGMT methylated.  Typical turnaround time for 
Central Pathology Review and MGMT testing is within 21 calendar days of receipt of tissue at 
the Alliance Biorepository at Mayo Clinic.  
For those patients in whom MGMT status is known and methylated, from the treating site 
(assessed by a CLIA-certified lab using either MGMT qMS-PCR or pyrosequencing), but 
central review is negative, patients are not eligible to participate. A detailed description of 
the assay is provided in Appendix VII. Submission of these samples for MGMT promoter 
methylation assessment is required for all patients pre-registered to this study.  
For patients registered to substudy A071102-ST1 and/or A071102-ST2:  All participating 
institutions must ask patients for their consent to participate in the correlative substudies planned 
for Alliance A071102-ST1 and A071102-ST2, although patient participation is optional.  DNA 
extraction will be performed for future studies as outlined in Sections 14.1 and 14.2.  
 
 
Pre-
registration 
≤ 60 days after 
registration 
At 
recurrence 
Storage/ 
Shipping 
conditions  
Submit to: 
Mandatory for all patients registered to A071102: (parent study) 
ALL diagnostic H&E slides 
from original Diagnosis(See 
§6.2.2) 
X1 
 
 
 
Mayo FFPE 
One paraffin block 
containing at least 1 cm2 of 
viable tumor or acceptable 
alternatives (See §6.2.2)* 
X1 
 
 
 
Mayo FFPE 
For patients registered to A071102-ST1**, submit the following: 
ALL diagnostic H&E slides 
from recurrent  tumor 
(§6.2.4) 
 
 
X2 
 
Mayo FFPE 
One paraffin block (or 
acceptable alternatives) 
from recurrent  tumor 
(§6.2.4) 
 
 
X2 
 
Mayo FFPE 
For patients registered to A071102-ST2***, submit the following: 
Whole blood 
EDTA/lavender top tube 
(See §6.2.5) 
 
1 x 10 mL**** 
 
Cool 
pack/ship 
over night 
Mayo BAP 
 
1 
Submit as soon as possible after surgery at pre-registration. Pre-registration requirement, 
confirmation of diagnosis through central review.  

 
 
Alliance A071102 
 
Version date: 01/22/2021  
31 
Update #09 
2 
Submit at the time of recurrence if new surgery is performed. Samples may be collected and 
submitted up to 3 months after recurrence/progression. 
* 
Residual tissue from MGMT testing will be banked if patients opt in. Patients opt in by 
circling “yes” on screening consent for question “My samples and related information may 
be kept at the Alliance biorepository at Mayo Clinic for use in future health research.” 
** 
Patients opt in by answering “yes” on screening consent for question “I agree to have my 
specimen collected and I agree that my specimen and related information may be used.” 
*** Patients opt in by answering “yes” on treatment consent for question “I agree to have my 
blood collected and I agree that my blood sample and related information may be used for 
the laboratory stud(ies) described above.” 
**** It is strongly encouraged that whole blood samples are collected prior to the initiation of study 
treatment. However, sample collection and submission may take place within 60 days after 
registration to the treatment trial. 
6.2.1 Specimen submission using the Alliance Biospecimen Management System  
USE OF THE ALLIANCE BIOSPECIMEN MANAGEMENT SYSTEM (BioMS) IS 
MANDATORY AND ALL SPECIMENS MUST BE LOGGED AND SHIPPED VIA THIS 
SYSTEM.  
BioMS is a web-based system for logging and tracking all biospecimens collected on 
Alliance trials.  Authorized individuals may access BioMS at the following URL:  
http://bioms.allianceforclinicaltrialsinoncology.org using most standard web browsers 
(Safari, Firefox, Internet Explorer).  For information on using the BioMS system, please 
refer to the ‘Help’ links on the BioMS web page to access the on-line user manual, FAQs, 
and training videos.  To report technical problems, such as login issues or application errors, 
please contact: 1-855-55-BIOMS or Bioms@alliancenctn.org.  For assistance in using the 
application or questions or problems related to specific specimen logging, please contact: 1-
855-55-BIOMS or Bioms@alliancenctn.org. 
After logging collected specimens in BioMS, the system will create a shipping manifest.  
This shipping manifest must be printed and placed in the shipment container with the 
specimens. 
All submitted specimens must be labeled according to sections 6.2.2, 6.2.3, 6.2.4 and 6.2.5.  
A copy of the Shipment Packing Slip produced by BioMS must be printed and placed in the 
shipment with the specimens. 
Instructions for the collection of samples are included below. Please be sure to use a method 
of shipping that is secure and traceable. Extreme heat precautions should be taken when 
necessary.  
Shipment on Monday through Friday by overnight service to assure receipt is encouraged. 
If shipping on Friday, FedEx or UPS must be used and the air bill must be marked “For 
Saturday delivery.” Do not ship specimens on Saturdays. 
6.2.2 Tissue collection and processing for histopathology review (mandatory for all patients) 
Consistent and accurate histologic grading is important for this study. Submission of ALL 
diagnostic H&E slides and at least 1 paraffin block from the original diagnosis is required 
for all patients enrolled to this study.  
A de-identified surgical pathology report should be sent with tissue. Usually, this is 
generated by obscuring all PHI (names and dates) with white-out or a black magic marker, 
labeling each page of the report with the Alliance patient ID, and photocopying the report. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
32 
Update #09 
If your patient has had a central pathology review previously performed by Dr. Caterina 
Giannini from Mayo Clinic Rochester, please obtain patient release for the report and submit 
to the pathology coordinator for review. 
Tissue submission for central pathology review is required prior to registration. 
ALL original diagnostic H&E slides used to make the diagnosis of glioblastoma or 
gliosarcoma should be clearly labeled (as outlined below), and forwarded as soon as 
possible after surgery for pre-registration. If the original slides cannot be released, recut 
slides from ALL tumor blocks used to make the diagnosis are acceptable.   
At least 1 paraffin block containing 1 cm2 of viable tumor must also be submitted. The 1 
cm2 of viable tumor can be present in a single paraffin block or be the composite of multiple 
blocks in cases with small tumor content in each block. 
If an institution is unable to provide a tissue block, cut 13 five-micron sections and mount 
on charged glass slides. H&E stain the first slide. Slides need to be cut with a new blade and 
using a fresh water bath to avoid contamination. Please make sure each slide is labeled 
with the specimen surgical pathology number, block number and order of sections cut 
either via your institution’s standard method for labeling clinical slides or using a 
permanent marker. Please DO NOT use sticky labels. The labeling of study number, 
patient ID, patient initials, sample type, and collection time is not required on 
unstained slides. These H&E slides will be reviewed centrally under the research base’s 
protocol for assessing tissue quality before being forwarded to MD Anderson Sulman’s lab 
for MGMT promoter methylation testing.  For samples containing less than 1 square cm of 
tumor tissue, multiple sections could be mounted onto each slide or additional slides can be 
provided to ensure that the appropriate amount of tumor tissue is available. Do not bake or 
place covers slips on the slides. 
The diagnostic slide(s) and block(s) must be appropriately packed to prevent damage (e.g., 
slides should be placed in appropriate slide container) and placed in an individual plastic 
bag.  Label the bag with the protocol number, patient initials, and study patient ID number. 
In order to assure prompt handling, please call the Alliance Pathology Coordinator at 
(507) 266-0724 to alert of the time/date sent and courier contracted. 
Ship tissue specimens, de-identified pathology report and BioMS Shipping Manifest to the 
Alliance Biorepository at Mayo Clinic FFPE: 
Alliance Biorepository at Mayo Clinic FFPE 
Attn: PC Office (Study A071102) 
RO-FF-03-24-CC/NW Clinic 
200 First Street SW 
Rochester, MN 55905 
The Alliance Operations Office will forward the unstained slides for MGMT promoter 
methylation assessment to: Dr. Sulman’s laboratory. 
6.2.3 Banking of residual tissue after mandatory eligibility tests have been completed 
With the patient’s consent, residual paraffin blocks of primary and, when available, 
recurrent tissue obtained from tumor specimens may be sent to the Alliance Biorepository 
at Mayo Clinic.  
The Alliance has instituted special considerations for the small percentage of hospitals 
whose policy prohibits long-term storage of blocks, and the smaller percentage of hospitals 
whose policies prohibit release of any block.  

 
 
Alliance A071102 
 
Version date: 01/22/2021  
33 
Update #09 
Please contact the Alliance Biorepository at Mayo Clinic if additional assurances with your 
hospital pathology department are required. 
The MGMT methylation assay requires DNA extraction from the tumor block, and DNA in 
excess of that required for the methylation assay will be sent from the Sulman laboratory to 
the Alliance Biorepository at Mayo Clinic. 
6.2.4 Tissue submission (A071102-ST1) 
Submission of diagnostic H&E slides and at least 1 paraffin block at time of recurrence is 
required (if surgery was performed) from patients who consent to optional substudy and 
experience tumor recurrence. If an institution is unable to provide a tissue block, cut 13 five-
micron sections and mount on charged glass slides. H&E stain the first slide. Please see 
Section 6.2.1 and 6.2.2 for specimen labeling and submission instructions. 
6.2.5 Blood Submission (A071102-ST2)  
For patients who consent to participate, collect 10 mL of venous blood in lavender top 
(EDTA anticoagulant) vacutainer tube(s). The tubes should be inverted approximately 8-
10 times to mix the EDTA.  Refrigerate sample until shipping. The sample should be 
placed in a biohazard bag and shipped according to IATA guidelines the same day as the 
blood is drawn on a cold pack by overnight courier service to the Alliance Biorepository at 
Mayo BAP.  
Note: It is strongly encouraged that whole blood samples are collected prior to the initiation 
of study treatment. However, sample collection and submission may take place within 60 
days after registration to the treatment trial. 
Specimens must be labelled with the protocol number (A071102-ST2), patient ID, 
patient initials, sample type (whole blood) and collection date & time.  
 
Ship blood specimens to the Alliance Biorepository at Mayo Clinic BAP freezer at following 
address: 
Alliance Biorepository at Mayo Clinic 
BAP Freezer 
Stabile SL-16  
150 Third Street SW 
Rochester, MN 55902 
507-293-0065 
 
Contacts  
Roxann Neumann 
507- 538-0602 
 
Ann Thorson 
507-284-0163 
6.3 
CT and MR Imaging Data Submission 
Acquisition of MR imaging in a uniform manner for all patients across the study and for an 
individual patient on serial imaging is critical information for this trial. We have defined the 
standard imaging parameters that are required for imaging on 1.5 T and 3 T MRI scanners and 
sites should follow these parameters for all patients irrespective of whether or not they enroll in 
the optional advanced imaging substudy.  

 
 
Alliance A071102 
 
Version date: 01/22/2021  
34 
Update #09 
A071102 IM1is a secondary objective of this study, and will evaluate whether advanced MR 
imaging can be used to more clearly differentiate pseudoprogression from true progression. 
Recognizing that not all institutions can perform this advanced MR imaging readily, institutions 
may elect to participate or to not participate in the advanced MR imaging portion of this study. 
We have defined a set of imaging parameters and contrast administration for dynamic 
susceptibility contrast (DSC) and diffusion weighted imaging (DWI) that are inclusive of the 
standard imaging parameters and the advanced imaging parameters. For those institutions that 
elect to participate, Appendix III must be used. The standard and advanced imaging 
parameters are captured on this appendix. For those institutions that elect not to 
participate in this portion of the study, the patients should not be registered to the imaging 
sub-study and the model consent should indicate “no” and Appendix II must be used. The 
parameters in Appendix II and Appendix III do not apply to the baseline prior to initiation of 
RT/TMZ. The parameters defined in Appendices II or III must be used for the scans after 
completion of RT/TMZ therapy and any future scans. 
Complete digital data sets in DICOM format, along with Alliance Adjunctive Data Form (if 
applicable) and Alliance Image Measurement Form (if applicable), must be submitted to the 
Imaging and Radiation Oncology Core (IROC Ohio). Images must be submitted for the 
following time points: baseline prior to initiation of radiation therapy, baseline after completion 
of radiation therapy, while on treatment and during follow-up until progression. For patients 
who have progressive disease, submit one scan after confirmed progression and no further scans. 
For patients who go off study for reasons other than progression (i.e., toxicity) please continue 
to collect images until progression. All scans performed after approval of Update #04 must 
be submitted to IROC Ohio within two weeks of acquisition. BMP files, JPG files, or hard 
copies (films) are not acceptable.  The raw data of the entire study should be saved until the scan 
is accepted by IROC Ohio. De-identify the patient data using institutional procedures to remove 
patient name and medical record number while preserving the Alliance patient ID number and 
protocol number. The de-identified digital images may be temporarily burned to a CD or 
transferred to a PC based system. 
 
Data should be transferred electronically to IROC Ohio via Web Transfer, FTP Transfer or 
Mail/CD Shipment: as follows: 
1) Web Transfer (http://upload.imagingcorelab.com) 
Any PCs with internet access and web browser (e.g., Internet Explorer, Mozilla Firefox) can be 
used to web transfer DICOM images and other required files to IROC Ohio. The standard Web 
Transfer information will be provided separately through the specific trial e-mail, per the request 
by participating sites before their first data submission. 
2) FTP Transfer 
Any FTP software can be used to initiate access to the secure FTP Server of the Imaging and 
Radiation Oncology Core. The standard FTP access information will be provided separately 
through the specific trial e-mail, per the request by participating sites before their first data 
submission. 
3) Mail/CD Shipment 
Only if electronic data transfer approaches cannot be achieved, the de-identified images in 
digital DICOM format can be burned to a CD and mailed to IROC Ohio. Submit only one 
patient’s images per CD, with the patient’s Alliance ID number, study type, date of scans, and 
name of submitting institution. 
Submit these data to: 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
35 
Update #09 
IROC Ohio 
Attn: Alliance Trial A071102 
The Ohio State University 
395 W. 12th Avenue, Suite #428 
Columbus, Ohio, 43210 
Tel: 614-293-2929 
Fax: 614/293-9275 
Once the imaging data submission is done, send an e-mail to IROC Ohio at the specific trial 
email Alliance071102@irocohio.org to inform that the study has been submitted from the 
institution. Please include the basic information of submitted data sets as follows: 
1)          Alliance patient ID number 
2)          Scan time point (i.e., baseline) 
3)          Date of scans 
4)          Institution name 
IROC Ohio will acknowledge receipt of the imaging data via email confirmation to the 
institution within 1 business day of receipt, and will notify the institution and Alliance imaging 
committee of the quality check report within 3 business days.  
6.4 
Radiation Dosimetry Submission 
SUBMISSION OF RADIATION DOSIMETRY TO IROC Rhode Island IS MANDATORY.  
RT data MUST be de-identified. Please include the protocol and Alliance patient ID number. 
Digital Submission: 
Submission of treatment plan in digital format as DICOM RT is required. Digital data must 
include CT scans, structures, plan, and dose files. Submission may be by either sFTP or CD. 
Instructions for data submission are on the IROC Rhode Island (formerly QARC) web site at 
http://irocri.qarc.org/ under "Digital Data."  
Items to be submitted: 
RT treatment plans including CT, structures, dose, and plan files.  These items are included in 
the digital plan. 
Radiotherapy record (treatment chart) including prescription and daily and cumulative doses to all 
required areas 
Note: In rare cases where a treatment planning system does not have the capability for DICOM 
RT export, screen captures of the planning data may be submitted. Screen capture submissions 
should include isodose distributions in the axial, sagittal and coronal planes through the center 
of the PTV as well as dose volume histograms (DVH’s) for the GTVs, CTVs, PTVs, and Organs 
at Risk. 
It is preferred that the radiotherapy record be submitted as a PDF or other digital format. The 
radiotherapy record and any other screen capture data may be submitted by sFTP, e-mailed to: 
DataSubmission@QARC.org, or mailed to: 
IROC Rhode Island QA Center 
640 George Washington Highway, Building B, Suite 201 
Lincoln, Rhode Island 02865-4207 
Phone: (401) 753-7600 
Fax: 
(401) 753-7601 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
36 
Update #09 
7.0 
TREATMENT PLAN/INTERVENTION 
Protocol treatment is to begin ≤ 14 days of registration. For questions regarding treatment, please see 
the study contacts page.  
It is acceptable for individual chemotherapy doses to be delivered ≤ a 24-hour (business day) window 
before and after the protocol-defined date for Day 1 of a new cycle. For example, if the treatment due 
date is a Friday, the window for treatment includes the preceding Thursday through the following 
Monday. In addition, patients are permitted to have a new cycle of chemotherapy delayed up to 7 
days for major life events (e.g., serious illness in a family member, major holiday, vacation that 
cannot be rescheduled) without this being considered a protocol violation. Documentation to justify 
this delay should be provided. 
This is a randomized, double-blind trial. Blinded, patient-specific clinical supplies of 
veliparib/placebo will be requested by the Alliance Statistical and Data Center at the time of 
randomization and should arrive at the clinical site ≤ approximately 7-10 days of randomization (see 
Section 10). 
Protocol therapy will consist of 6 cycles administered on days 1-7 of each 28 day cycle. Treatment 
will continue until disease progression (confirmed progression) or unacceptable adverse event or 
maximizing the dose reductions, for a maximum period of 6 cycles.  
Treatment with TMZ after completion of the 6 cycles of therapy is discouraged. There are several 
reasons for this. First, the FDA labelling for TMZ is for 6 months. Second, the combination of 
veliparib + TMZ is associated with an increased risk of thrombocytopenia, so the study team felt that 
the duration of combination therapy should be limited to the FDA labelling for TMZ. Finally, there 
is no good evidence that extending TMZ to 12 cycles vs. 6 cycles provides a survival or progression-
free survival benefit. Specifically, the RTOG0525 study was a large phase III that randomized 
patients to dose dense TMZ vs. standard TMZ. Despite the dose dense TMZ getting 50% for drug, 
there was no advantage in OS or PFS. Although not a direct answer to the question of 6 vs. 12 cycles 
of TMZ, the data from this trial demonstrate that ‘more is not better’. The upshot of this, is that the 
study team believes the data support the idea that limiting TMZ to 6 cycles will not be detrimental. 
See Section 12.1.4 for follow up instructions for patients who receive non-protocol therapy.  
 
Agent 
Dose 
Route 
Day 
ReRx 
temozolomide 
150-200 mg/m2 
PO 
Day 1-5 
every 28 days 
veliparib 
or placebo* 
40 mg bid 
PO 
Day 1-7 
every 28 days 
*Patients may begin the veliparib/placebo in AM or PM on day 1. If begun in PM on day 1, then 
patients must take AM dose on day 8 so that 14 doses are taken per cycle. 
 
Patients will be treated with a combination of temozolomide and either veliparib or placebo. 
Temozolomide will be dosed at 150 mg/m2 PO once daily Days 1-5 for the first cycle of therapy. If 
this dose level is well tolerated (refer to Section 7.1.2 for details), then the dose of temozolomide 
should be increased in subsequent cycles to 200 mg/m2. If the dose is not escalated in cycle 2, then 
the dose of TMZ should remain at 150 mg/m2 for all 6 cycle. The dose of veliparib is fixed at 40 mg 
bid PO days 1-7 unless dose-reductions are required for toxicity. Because veliparib may accentuate 
the bone marrow suppression associated with temozolomide, pneumocystis pneumonia (PCP) 
prophylaxis is strongly recommended (see Section 8). 
7.1 
Adjuvant therapy with temozolomide and either veliparib or placebo 
7.1.1 Patients will be treated with 6 cycles of oral temozolomide (days 1-5) and oral veliparib 
(twice daily on days 1-7). Cycles of treatment will be 28 days in length. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
37 
Update #09 
7.1.2 For cycle 1 of adjuvant therapy, temozolomide will be dosed at 150 mg/m2/day. If no grade 
3 or higher adverse events attributable to temozolomide occur in cycle 1, the nadir of the 
absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, the nadir of the platelet count is ≥ 100 x 
109/L, and a delay for recovery of hematologic toxicities is no longer than 7 days, then the 
dose of temozolomide should be escalated to 200 mg/m2/day for cycles 2 to 6. If the dose 
was not escalated at cycle 2, dose should not be escalated in subsequent cycles. 
7.1.3 Temozolomide dosing should be based on actual body weight. The smallest temozolomide 
capsules are 5 mg. Therefore, patient doses of temozolomide will be rounded to the nearest 
interval of 5 mg. Temozolomide capsules should be taken with up to 200 mL of water on an 
empty stomach one hour before or two hours after food. 
7.1.4 Veliparib should be administered at 40 mg/dose (irrespective of body weight) and should be 
taken twice a day (approximately 12 hours apart, irrespective of meals). If a dose is missed, 
it may be made up if taken within 4 hours of the scheduled dose (either morning or evening 
dose). If it is outside of this 4 hour window, the patient should not make up the missed dose 
of veliparib. 
7.1.5 Patients with pseudoprogression can remain on study. See Section 11.4.3.2. 
8.0 
DOSE AND TREATMENT MODIFICATIONS, UNBLINDING  
8.1 
Ancillary therapy, concomitant medications, and supportive care 
8.1.1 Patients should not receive any other anti-cancer agent which would be considered 
treatment for the primary neoplasm or impact the primary endpoint. 
8.1.2 No other investigational therapy should be given to patients. 
8.1.3 Patients should receive full supportive care while on this study. This includes blood 
product support, antibiotic treatment, and treatment of other newly diagnosed or concurrent 
medical conditions.  All blood products and concomitant medications such as steroids, 
antidiarrheals, analgesics, antiemetics and/or antiepileptics received from the first day of 
study treatment administration until 30 days after the final dose will be recorded in the 
medical records.  
8.1.4 Treatment with hormones or other chemotherapeutic agents may not be administered 
except for steroids given for serious medical condition or given in relationship to the disease 
as needed, and hormones administered for non-disease-related conditions (e.g., insulin for 
diabetes). 
8.1.5 Antiemetics: Since temozolomide may cause nausea, an appropriate anti-emetic per 
institutional standard may be given in conjunction with temozolomide. 
Additional symptoms should be managed as per standard antiemetic guidelines. 
8.1.6 Diarrhea: This can be managed conservatively with loperamide. The recommended dose 
of loperamide is 4 mg at first onset, followed by 2 mg every 2-4 hours until diarrhea free 
(maximum 16 mg/day). 
In the event of grade 3 or 4 diarrhea, the following supportive measures are allowed:  
hydration, octreotide, and other antidiarrheals.   
If diarrhea is severe (requiring intravenous rehydration) and/or associated with fever or 
severe neutropenia (grade 3 or 4), broad-spectrum antibiotics should be considered.  Patients 
with severe diarrhea or any diarrhea associated with severe nausea or vomiting should be 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
38 
Update #09 
evaluated and considered for intravenous hydration and correction of electrolyte 
imbalances. 
8.1.7 Blood products should be utilized as clinically warranted and following institutional 
policies and recommendations. 
8.1.8 Alliance Policy Concerning the Use of Growth Factors 
Blood products and growth factors should be utilized as clinically warranted and following 
institutional policies and recommendations.  The use of growth factors should follow 
published guidelines of the American Society of Clinical Oncology 2006 Update of 
Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based, 
Clinical Practice Guideline.  J Clin Oncol 24(19): 3187-3205, 2006. 
Darbopoietin or Epoetin (EPO): Use of darbopoietin or epoetin in this protocol is NOT 
permitted in this protocol. 
Filgrastim (G-CSF) and sargramostim (GM-CSF) 
 
Filgrastim/pegfilgrastim and sargramostim may not be used: 
a. 
To avoid dose reductions or delays. 
b. 
For the treatment of febrile neutropenia the use of CSFs should not be routinely 
instituted as an adjunct to appropriate antibiotic therapy. However, the use of CSFs 
may be indicated in patients who have prognostic factors that are predictive of 
clinical deterioration such as pneumonia, hypotension, multi-organ dysfunction 
(sepsis syndrome) or fungal infection, as per the ASCO guidelines.  Investigators 
should therefore use their own discretion in using the CSFs in this setting.  The use 
of CSF (filgrastim/pegfilgrastim or sargramostim) must be documented and 
reported.  
c. 
If filgrastim/pegfilgrastim or sargramostim are used, they must be obtained from 
commercial sources. 
8.1.9 Palliative radiation therapy:  Patients who require radiation therapy during protocol 
treatment will be removed from protocol therapy due to disease progression. 
8.1.10 PCP Prophylaxis: Temozolomide with or without steroids can result in significant 
immunosuppression and places patients at increased risk for opportunistic infections such 
as Pneumocystis carinii pneumonia (PCP) and gram-negative organisms. Combined therapy 
with temozolomide and veliparib may increase this risk. Therefore, antibiotic prophylaxis 
is strongly recommended for patients treated on this protocol. Prophylaxis should start with 
the first day of cycle 1 (± 5 days) and should continue for at least 1 month following 
discontinuation of all drug therapy. The decision to continue PCP prophylaxis beyond this 
time point is left to the discretion of the treating physician. Patients who continue to 
demonstrate lymphopenia, 1 month after completion of the final cycle of TMZ therapy 
should be considered for ongoing prophylaxis. 
Recommended prophylaxis regimens are listed below: 
 
Trimethoprim/sulfamethoxazole (Bactrim): This is the preferred method. Initial therapy 
should 
be 
trimethoprim/sulfamethoxazole 
SS 
orally, 
1 
tablet 
daily; 
or 
trimethoprim/sulfamethoxazole DS orally 1 tablet, 3 times per week.  
  
Dapsone may be given as 100 mg orally each day. Patients with prior history of G6PD 
deficiency are not appropriate candidates for dapsone and should be treated with an 
alternative regimen. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
39 
Update #09 
 
Pentamidine can be administered via inhalation (300 mg via aerosol) once per month. 
Atovaquone may be administered at 1500 mg orally each day. 
8.1.11 Concomitant treatment with Optune device 
Patients electing to use the Optune device must declare this at the time of registration to 
allow for stratification (see Sections 4.4 and 4.7). Initiation of Optune therapy after day 
1 cycle 1 is not allowed. Should the patient choose to begin Optune therapy after completion 
of protocol treatment with TMZ and veliparib/placebo, then this is acceptable. The site 
should NOT modify the stratification factor, but should report this via Rave. The 
administration of the Optune device is per institutional standard. The Optune diary 
(Appendix IX) should be completed by the patient per Section 5.0 if it is worn during 
protocol therapy. Usage reports provided by Novocure may also be used in lieu of patient 
diaries. Modifications of the use of Optune are per institutional standard. 
8.2 
Dose Modifications 
• 
The descriptions and grading scales found in the revised NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for dose modifications 
and AE reporting through Rave. However, CTCAE version 5.0 must be utilized for serious 
adverse event reporting through CTEP-AERS.  
• 
If multiple adverse events are seen, administer dose based on greatest reduction required for 
any single adverse event observed.  Reductions or increases apply to treatment given in the 
preceding cycle and are based on adverse events observed since the prior dose. 
• 
If the patient experiences a significant adverse event requiring a dose reduction at the start 
of the cycle, the dose will remain lowered for the entire subsequent cycle.  
• 
Veliparib and temozolomide will not be re-escalated once reduced  
• 
If dose reductions beyond lowest dose level is required OR either veliparib is held for 3 
weeks or temozolomide is held for 4 weeks, veliparib or temozolomide will be discontinued. 
If veliparib is discontinued, the patient may remain on temozolomide by itself to complete 
all 6 cycles. However, if temozolomide is discontinued, patient is off the treatment portion 
of the study.  
• 
Please note that dose modifications do not apply to cycle 1. These are for cycle 2 forward. 
CTEP-AERS reporting may be required for some adverse events (See Section 9.0). 
8.2.1 Dose Levels 
Dose 
Level 
veliparib/placebo 
(Twice daily on Days 1 
through 7) 
Temozolomide Cycle 1 dose 
(dose reduction for cycle 2 on)** 
(Daily on Days 1 through 5) 
Temozolomide Cycle 2-6 dose 
 (dose reduction for cycle 3 on) 
(Daily on Days 1 through 5) 
 0* 
 
40 mg PO twice daily 
150mg/m2/day 
200mg/m2/day 
-1 
 
40 mg PO in AM,  
20mg PO in PM OR 
20 mg PO in AM,  
40 mg PO in PM 
100mg/m2/day 
150mg/m2/day 
-2 
 
20 mg PO twice daily 
75 mg/m2/day 
100mg/m2/day 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
40 
Update #09 
Dose 
Level 
veliparib/placebo 
(Twice daily on Days 1 
through 7) 
Temozolomide Cycle 1 dose 
(dose reduction for cycle 2 on)** 
(Daily on Days 1 through 5) 
Temozolomide Cycle 2-6 dose 
 (dose reduction for cycle 3 on) 
(Daily on Days 1 through 5) 
-3 
Discontinue 
Discontinue 
75mg/m2/day 
 
*Dose level 0 refers to the starting dose. 
**For patients who were unable to escalate to 200mg/m2 at cycle 2, please use this column for 
any subsequent dose modifications 
8.2.2 Hematological toxicity 
• 
For grade 2 neutrophil count decreased on day 1, delay TMZ and veliparib until grade 
≤ 1, then resume TMZ and veliparib at same dose. For grade 2 neutrophil count 
decreased on days 2-28, continue therapy with no change.  
• 
For grade 3 or 4 neutrophil count decreased delay TMZ and veliparib until grade ≤ 
1, then resume TMZ and veliparib at 1 dose level decreased.  
• 
For febrile neutropenia at any time, delay TMZ and veliparib until resolved, then 
resume TMZ and veliparib at 1 dose level decreased. 
• 
For grade 1 platelet count below 100 x 109L or any grade 2 platelet count decreased 
on day 1, delay TMZ and veliparib until platelets recover to >100,000, then resume 
TMZ and veliparib at same dose. For grade 1 platelet count below 100 x 109L or any 
grade 2 platelet count decreased on days 2-28, continue therapy with no change. 
• 
For grade 3 or 4 platelet count decreased, delay TMZ and veliparib until platelets 
recover to >100,000, then resume TMZ and veliparib at one dose level decreased. 
8.2.3 Gastrointestinal toxicity 
• 
For grade 3 nausea or grade 3 or 4 vomiting while on optimal antiemetic therapy, 
delay TMZ and veliparib until grade ≤ 1, then resume TMZ and veliparib at 1 dose level 
decreased. 
• 
For grade 3 diarrhea, delay TMZ and veliparib until grade ≤ 2, then resume TMZ at 1 
dose level decreased and veliparib at same dose.  
• 
For grade 4 diarrhea, delay TMZ and veliparib until grade ≤ 2, then resume TMZ and 
veliparib at 1 dose level decreased.  
8.2.4 Neurotoxicity: 
• 
For grade 3 or 4 seizure in patients with seizures at pre-registration, and 
currently on optimal antiepileptic therapy, delay veliparib until grade of seizures 
returns to baseline grade (grade at pre-registration), then resume veliparib at 1 dose 
level decreased. 
• 
For grade 3 or 4 seizure in patients with seizures at pre-registration, and 
currently not on optimal antiepileptic therapy, delay veliparib until grade ≤ 1, then 
resume veliparib at 1 dose level decreased. 
• 
For grade 3 or 4 seizure in patients without prior incidence of seizures, delay 
veliparib until grade ≤ 1, then resume veliparib at 1 dose level decreased. 
8.2.5 Vascular disorders: 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
41 
Update #09 
• 
For grade 2 or 3 thromboembolic event, delay TMZ and veliparib until medical 
intervention is initiated and patient deemed stable, then resume TMZ and veliparib at 
same dose. 
• 
For grade 4 thromboembolic event, delay TMZ until patient deemed stable, then 
resume TMZ at same dose. Discontinue veliparib.  
8.2.6 Other toxicity 
• 
For other clinically significant grade 3 or 4 non-hematologic toxicities likely related 
to TMZ or veliparib, delay TMZ and veliparib. Resume drug at 1 dose level reduced 
when the toxicity resolves to grade 2 or less. 
8.2.7 Dose Modifications for Obese Patients 
There is no clearly documented adverse impact of treatment of obese patients when dosing 
is performed according to actual body weight. Therefore, all dosing is to be determined 
solely by actual weight without any modification. This will eliminate the risk of calculation 
error and the possible introduction of variability in dose administration. Failure to use actual 
body weight in the calculation of drug dosages will be considered a major protocol 
deviation. Physicians who are uncomfortable with calculating doses based on actual body 
weight should recognize that doing otherwise would be a protocol violation. Physicians may 
consult the published guidelines of the American Society of Clinical Oncology Appropriate 
Chemotherapy Dosing for Obese Adult Patients with Cancer: American Society of Clinical 
Oncology Clinical Practice Guideline.  J Clin Oncol 30(13): 1553-1561, 2012. 
8.3 
Emergency Unblinding Procedures  
Emergency unblinding will be available 24 hours a day, every day, according to the criteria 
below.  
Unblinding can be done only in cases of an emergency. Follow the directions below to unblind 
patient treatment. Please note that if a treatment assignment is unblinded, the patient must 
discontinue protocol therapy. 
Emergency Unblinding Procedures: 
Examples of emergencies include 1) a life-threatening unexpected adverse event that is at least 
possibly related to the investigational agent and for which unblinding would influence treatment 
decisions; or 2) medication error, such as accidental overdose. Expected adverse events are listed 
in the “Toxicities” section below.  
Contact the Alliance Executive Officer on call by calling 773-702-6800, pressing 1 to speak 
with an operator, and then asking for pager ID 8625 to return the call.  
The institution must provide the following information to the Alliance Executive Officer:   
• 
Study ID (A071102) 
• 
Patient ID number 
• 
Patient initials (e.g., “L, F, M”) 
• 
Institution name 
• 
Name and telephone number of treating physician 
• 
Name and contact information of person requesting the unblinding procedure 
• 
Name and contact information of person to inform of treatment assignment 
• 
Reason for unblinding request 
 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
42 
Update #09 
Please remember that emergency unblinding request may be authorized only by an Alliance 
Executive Officer, and emergency unblinding applies only if unblinding would influence 
management of the medical situation.  
After the Executive Officer deems unblinding is warranted, the treatment assignment will be 
provided to the contact person at the treating site.  
9.0 
ADVERSE EVENTS  
The prompt reporting of adverse events is the responsibility of each investigator engaged in clinical 
research, as required by Federal Regulations. Adverse events must be described and graded using the 
terminology and grading categories defined in the NCI’s Common Terminology Criteria for Adverse 
Events (CTCAE), Version 4.0 for dose modifications and adverse event reporting through Rave. 
However, CTCAE v5.0 must be used for serious AE reporting through CTEP-AERS as of April 1, 
2018. The CTCAE is available at http://ctep.cancer.gov/ reporting/ctc.html. Attribution to protocol 
treatment for each adverse event must be determined by the investigator and reported on the required 
forms, using the codes provided. 
Please refer the NCI Guidelines: Adverse Event Reporting Requirements for further details on 
procedures to follow with AE reporting. 
9.1 
Routine adverse event reporting 
Adverse event data collection and reporting, which are required as part of every clinical trial are 
done to ensure the safety of patients enrolled in the studies as well as those who will enroll in 
future studies using similar agents. Adverse events are reported in a routine manner at scheduled 
times according to the study calendar in Section 5.0. For this trial, RAVE is used for routine AE 
reporting. 
 
Solicited Adverse Events: The following adverse events are considered "expected" and their 
presence/absence should be solicited, and severity graded, at baseline and for each cycle of 
treatment. 
CTCAE v4.0 Term 
CTCAE v4.0 System Organ Class (SOC) 
Nausea 
Gastrointestinal 
Fatigue 
General Disorders 
Constipation 
Gastrointestinal 
Platelet Count decrease 
Investigations 
Anorexia 
Metabolism and Nutrition Disorders 
Neutrophil count decreased 
Investigations 
Diarrhea 
Gastrointestinal 
Headache 
Nervous System Disorder 
Seizures 
Nervous System Disorder 
 
9.2 
CTCAE Routine Study Reporting Requirements 
In addition to the solicited adverse events listed in Section 9.1, the following table outlines the 
combinations of time points, grades and attributions of AEs that require routine reporting to the 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
43 
Update #09 
Alliance Statistics and Data Center. Questions about routine reporting should be directed to the 
Data Manager. 
*Combinations of CTCAE Grade & Attribution Required for Routine AE Data 
Submission on Case Report Forms (CRFs) 
 
Attribution 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Grade 5 
Unrelated 
 
 
a 
a 
a 
Unlikely 
 
 
a 
a 
a 
Possible 
 
a 
a, b 
a, b 
a, b 
Probable 
 
a 
a, b 
a, b 
a, b 
Definite 
 
a 
a, b 
a, b 
a, b 
a. 
Adverse Events: Other CRF - Applies to AEs occurring between registration and within 30 
days of the patient’s last treatment date, or as part of the Clinical Follow-Up Phase. 
b.  
Adverse Events: Late CRF - Applies to AEs occurring greater than 30 days after the 
patient’s last treatment date. 
9.3 
CTEP Adverse Event Reporting System (CTEP-AERS) 
Investigators are required by Federal Regulations to report serious adverse events as defined in 
the table below.  CTCAE term (AE description) and grade: The descriptions and grading scales 
found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 
4.0 will be utilized until March 31, 2018 for expedited AE reporting. CTCAE version 5.0 will 
be utilized for AE reporting via CTEP-AERS beginning April 1, 2018. All appropriate treatment 
areas should have access to a copy of the CTCAE version 5.0 and CTCAE version 4.0. A copy 
of the 
CTCAE 
version 
5.0 
can 
be 
downloaded 
from 
the 
CTEP 
web site 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. 
In the rare occurrence when Internet connectivity is lost, a 24-hour notification is to be made to 
CTEP by telephone at 301-897-7497. Once Internet connectivity is restored, the 24-hour 
notification phoned in must be entered electronically into CTEP-AERS by the original submitter 
at the site.  
Be sure to read this entire protocol section, as requirements are described in both table and bullet 
points following the table. In case of a conflict between the table and the bullet points, the bullet 
points (additional instructions or exclusions) supersede the table. 
9.3.1 Late Phase 2 and Phase 3 Studies:  Expedited Reporting Requirements for Adverse 
Events that Occur on Studies under an IND ≤ 30 Days of the Last Treatment 1 
FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312) 
NOTE:  Investigators MUST immediately report to the sponsor (NCI) ANY Serious Adverse Events, 
whether or not they are considered related to the investigational agent(s)/intervention (21 CFR 
312.64) 
 An adverse event is considered serious if it results in ANY of the following outcomes:   
1) Death 
2) A life-threatening adverse event  
3) An adverse event that results in inpatient hospitalization or prolongation of existing hospitalization 
for ≥ 24 hours  
4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
functions  
5) A congenital anomaly/birth defect.  

 
 
Alliance A071102 
 
Version date: 01/22/2021  
44 
Update #09 
6) Important Medical Events (IME) that may not result in death, be life threatening, or require 
hospitalization may be considered serious when, based upon medical judgment, they may jeopardize 
the patient or subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH E2A and ICH E6). 
ALL SERIOUS adverse events that meet the above criteria MUST be immediately reported to the 
NCI via CTEP-AERS within the timeframes detailed in the table below. 
Hospitalization 
Grade 1 
Timeframes 
Grade 2 
Timeframes 
Grade 3 
Timeframes 
Grade 4 & 5 
Timeframes 
Resulting in 
Hospitalization ≥ 24 hrs 
10 Calendar Days 
24-Hour; 
5 Calendar Days 
Not resulting in 
Hospitalization ≥ 24 hrs 
Not required 
10 Calendar 
Days 
Expedited AE reporting timelines are defined as: 
o “24-Hour; 5 Calendar Days” - The AE must initially be reported via CTEP-AERS ≤ 24 hours 
of learning of the AE, followed by a complete expedited report ≤ 5 calendar days of the 
initial 24-hour report. 
o “10 Calendar Days” - A complete expedited report on the AE must be submitted ≤ 10 
calendar days of learning of the AE. 
1 Serious adverse events that occur more than 30 days after the last treatment require reporting as 
follows:  
Expedited 24-hour notification followed by complete report ≤ 5 calendar days for: 
• 
All Grade 4, and Grade 5 AEs that are at least possibly related to treatment 
Expedited 10 calendar day reports for: 
• 
Grade 2 adverse events resulting in hospitalization or prolongation of hospitalization, and 
that are at least possibly related to treatment  
• 
Grade 3 adverse events that are at least possibly related to treatment 
Additional Instructions or Exclusions to CTEP-AERS Adverse Event Reporting System for 
Phase 2 and 3 Trials Utilizing an Agent Under a CTEP IND or non-CTEP IND: 
• 
All adverse events reported via CTEP-AERS (i.e., serious adverse events) should also be 
forwarded to your local IRB, according to local IRB policies. 
• 
Alliance A071102 uses a drug under a CTEP IND. These reporting requirements should be 
followed for all agents (any arm) in this trial. 
• 
Grade 3/4 hematosuppression and hospitalization resulting from such do not require CTEP-
AERS, but should be submitted as part of study results.  
• 
Treatment expected adverse events include those listed in Section 10.0, in the package insert for 
temozolomide, in the CAEPR and the IB for ABT-888. The SPEER column of the ABT-888 
CAEPR includes “expected” severity grades in addition to event terms. 
• 
Death due to progressive disease should be reported as Grade 5 “Disease progression” in the 
system organ class (SOC) “General disorders and administration site conditions.” Evidence that 
the death was a manifestation of underlying disease (e.g., radiological changes suggesting tumor 
growth or progression: clinical deterioration associated with a disease process) should be 
submitted. 
• 
Secondary Malignancy:  

 
 
Alliance A071102 
 
Version date: 01/22/2021  
45 
Update #09 
A secondary malignancy is a cancer caused by treatment for a previous malignancy (e.g., 
treatment with investigational agent/intervention, radiation or chemotherapy). A secondary 
malignancy is not considered a metastasis of the initial neoplasm.  
CTEP requires all secondary malignancies that occur following treatment with an agent under 
an NCI IND/IDE be reported via CTEP-AERS. Three options are available to describe the 
event:  
1. Leukemia secondary to oncology chemotherapy (e.g., acute myelocytic leukemia [AML])  
2. Myelodysplastic syndrome (MDS)  
3. Treatment-related secondary malignancy  
Any malignancy possibly related to cancer treatment (including AML/MDS) should also be 
reported via the routine reporting mechanisms outlined in each protocol.  
• 
Second Malignancy:  
A second malignancy is one unrelated to the treatment of a prior malignancy (and is NOT a 
metastasis from the initial malignancy).  Second malignancies require ONLY routine reporting 
via CDUS unless otherwise specified. 
• All pregnancies and suspected pregnancies occurring in female patients or in the partner of a male 
patient during therapy or within 28 days after completion of treatment on A071102 must be 
reporting via CTEP-AERS. In CTCAE version 5.0, use the event term, “pregnancy, puerperium, 
and perinatal condition-other, fetal exposure (grade 4)”.  
a. CTEP-AERS reports should be amended upon completion of the pregnancy to 
report pregnancy outcome (e.g. normal, spontaneous abortion, therapeutic abortion, 
congenital abnormalities). 
b. Any Pregnancy loss should be reported expeditiously, as Grade 4 “Pregnancy loss” 
under the Pregnancy, puerperium and perinatal conditions SOC. A Pregnancy loss 
should NOT be reported as a Grade 5 event under the Pregnancy, puerperium and 
perinatal conditions SOC, as currently CTEPAERS recognizes this event as a 
patient death.  
c. The CTEP-AERS report should be amended for any neonatal deaths or 
complications occurring within 28 days of birth independent of attribution. Infant 
deaths occurring after 28 days considered to be related to in utero exposure to the 
agents used in this trial should be reported via CTEP AERS. A neonatal death 
should be reported expeditiously as Grade 4, “Death neonatal” under the General 
disorders and administration SOC. 
• 
The reporting of adverse events described in the table above is in addition to and does 
not supplant the reporting of adverse events as part of the report of the results of the 
clinical trial, e.g. cooperative group data reporting. 

Alliance A071102 
Version date: 01/22/2021 
46 
Update #09 
9.4 
Comprehensive Adverse Events and Potential Risks list (CAEPR) for ABT-888 
(Veliparib, NSC 737664) 
The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a single list of 
reported and/or potential adverse events (AE) associated with an agent using a uniform 
presentation of events by body system. In addition to the comprehensive list, a subset, the 
Specific Protocol Exceptions to Expedited Reporting (SPEER), appears in a separate column 
and is identified with bold and italicized text. This subset of AEs (SPEER) is a list of events that 
are protocol specific exceptions to expedited reporting to NCI via CTEP-AERS (except as noted 
below).  Refer to the 'CTEP, NCI Guidelines: Adverse Event Reporting Requirements' 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf for 
further clarification.  Frequency is provided based on 2310 patients. Below is the CAEPR for 
ABT-888 (veliparib). 
NOTE: Report AEs on the SPEER ONLY IF they exceed the grade noted in parentheses next 
to the AE in the SPEER.  If this CAEPR is part of a combination protocol using multiple 
investigational agents and has an AE listed on different SPEERs, use the lower of the grades to 
determine if expedited reporting is required. 
 
Version 2.4, May 13, 20181 
 
 Adverse Events with Possible  
 Relationship to ABT-888 (Veliparib) 
 (CTCAE 5.0 Term) 
[n= 2310] 
 
 
 Specific Protocol Exceptions 
to Expedited Reporting 
(SPEER) 
 
Likely (>20%) 
Less Likely (<=20%) 
Rare but Serious (<3%)  
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS 
  
 
Anemia 
 
 Anemia (Gr 3) 
 
Febrile neutropenia 
 
 Febrile neutropenia (Gr 3) 
GASTROINTESTINAL DISORDERS 
  
 
Abdominal pain 
 
  
 
Constipation 
 
 Constipation (Gr 2) 
 
Diarrhea 
 
 Diarrhea (Gr 3) 
Nausea 
 
 
 Nausea (Gr 3) 
 
Vomiting 
 
 Vomiting (Gr 3) 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS 
  
Fatigue 
 
 
 Fatigue (Gr 3) 
INVESTIGATIONS 
  
 
Lymphocyte count decreased  
 Lymphocyte count decreased  
(Gr 4) 
 
Neutrophil count decreased 
 
 Neutrophil count decreased (Gr 4) 
Platelet count decreased 
 
 
 Platelet count decreased (Gr 4) 
 
Weight loss 
 
 Weight loss (Gr 2) 
 
White blood cell decreased 
 
 White blood cell decreased (Gr 4) 
METABOLISM AND NUTRITION DISORDERS 
  
 
Anorexia 
 
 Anorexia (Gr 2) 
 
Dehydration 
 
 Dehydration (Gr 3) 
 
Hypophosphatemia 
 
 Hypophosphatemia (Gr 3) 
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND 
POLYPS) 
  
 
 
Leukemia secondary to 
oncology chemotherapy 
  
 
 
Myelodysplastic syndrome 
  

 
 
Alliance A071102 
 
Version date: 01/22/2021  
47 
Update #09 
 
 Adverse Events with Possible  
 Relationship to ABT-888 (Veliparib) 
 (CTCAE 5.0 Term) 
[n= 2310] 
 
 
 Specific Protocol Exceptions 
to Expedited Reporting 
(SPEER) 
 
Likely (>20%) 
Less Likely (<=20%) 
Rare but Serious (<3%)  
 
 
 
Treatment related secondary 
malignancy 
  
NERVOUS SYSTEM DISORDERS 
  
 
Dizziness 
 
  
 
Dysgeusia 
 
 Dysgeusia (Gr 2) 
 
Headache 
 
 Headache (Gr 3) 
 
 
Seizure 
  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS 
  
 
Rash maculo-papular 
 
  
VASCULAR DISORDERS 
  
 
 
Thromboembolic event2 
  
 
1This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all Principal 
Investigators at the time of revision.  The current version can be obtained by contacting 
PIO@CTEP.NCI.NIH.GOV.  Your name, the name of the investigator, the protocol and the agent should be 
included in the e-mail. 
 
2Thromboembolic events, including deep vein thrombosis and pulmonary embolism, have been observed at a higher 
frequency compared to control arm when administered in combination with temozolomide. 
 
Adverse events reported on ABT-888 (Veliparib) trials, but for which there is insufficient evidence to suggest 
that there was a reasonable possibility that ABT-888 (Veliparib) caused the adverse event: 
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS - Bone marrow hypocellular; Blood and lymphatic system 
disorders - Other (pancytopenia) 
CARDIAC DISORDERS - Cardiac disorders - Other (Takotsubo cardiomyopathy); Heart failure; Left ventricular 
systolic dysfunction; Palpitations; Sinus bradycardia; Sinus tachycardia 
EAR AND LABYRINTH DISORDERS - Vertigo 
EYE DISORDERS - Blurred vision 
GASTROINTESTINAL DISORDERS - Abdominal distension; Ascites; Colitis; Colonic obstruction; Dental 
caries; Dry mouth; Duodenal ulcer; Dyspepsia; Dysphagia; Enterocolitis; Esophagitis; Flatulence; Gastritis; 
Gastroesophageal reflux disease; Lower gastrointestinal hemorrhage; Mucositis oral; Obstruction gastric; Rectal 
hemorrhage; Rectal pain; Small intestinal obstruction 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS - Chills; Edema limbs; Fever; Flu 
like symptoms; Malaise; Non-cardiac chest pain; Pain 
HEPATOBILIARY DISORDERS - Hepatic failure; Hepatobiliary disorders - Other (cirrhosis) 
INFECTIONS AND INFESTATIONS - Appendicitis; Catheter related infection; Infections and infestations - 
Other (peritonsillar abscess); Lung infection; Lymph gland infection; Mucosal infection; Sepsis; Shingles; Skin 
infection; Upper respiratory infection; Urinary tract infection 
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - Bruising; Dermatitis radiation; Radiation 
recall reaction (dermatologic) 
INVESTIGATIONS - Alanine aminotransferase increased; Alkaline phosphatase increased; Aspartate 
aminotransferase increased; Blood bilirubin increased; Cardiac troponin I increased; Creatinine increased; 
Electrocardiogram QT corrected interval prolonged; Lipase increased 
METABOLISM AND NUTRITION DISORDERS - Hyperglycemia; Hypernatremia; Hypoalbuminemia; 
Hypocalcemia; Hypokalemia; Hypomagnesemia; Hyponatremia 
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - Arthralgia; Arthritis; Back pain; Bone 
pain; Generalized muscle weakness; Muscle cramp; Myalgia; Neck pain; Pain in extremity 
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) -Tumor pain 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
48 
Update #09 
NERVOUS SYSTEM DISORDERS - Ataxia; Cognitive disturbance; Depressed level of consciousness; 
Dysarthria; Extrapyramidal disorder; Intracranial hemorrhage; Lethargy; Memory impairment; Movements 
involuntary; Paresthesia; Peripheral motor neuropathy; Peripheral sensory neuropathy; Presyncope; Reversible 
posterior leukoencephalopathy syndrome; Stroke; Syncope; Tremor 
PSYCHIATRIC DISORDERS - Agitation; Anxiety; Confusion; Depression; Insomnia; Psychiatric disorders - 
Other (emotional instability); Psychosis; Restlessness 
RENAL AND URINARY DISORDERS - Dysuria; Hematuria; Proteinuria  
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - Cough; Dyspnea; Epistaxis; Hypoxia; 
Nasal congestion; Pharyngolaryngeal pain; Pleural effusion; Pneumonitis; Respiratory failure 
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - Alopecia; Dry skin; Hyperhidrosis; Nail changes; 
Palmar-plantar erythrodysesthesia syndrome; Pruritus; Purpura; Rash acneiform 
VASCULAR DISORDERS - Flushing; Hot flashes; Hypertension; Hypotension; Vascular disorders - Other 
(brainstem infarction)  
 
Note: ABT-888 (Veliparib) in combination with other agents could cause an exacerbation of any adverse event 
currently known to be caused by the other agent, or the combination may result in events never previously 
associated with either agent. 
 

Alliance A071102 
Version date: 01/22/2021 
49 
Update #09 
10.0 DRUG INFORMATION 
10.1 
General Considerations:  
• 
Temozolomide dosing will be based on actual body weight. The smallest temozolomide 
capsules are 5 mg. Therefore, patient doses of temozolomide will be rounded to the nearest 
interval of 5 mg. 
• 
It is not necessary to change the doses of temozolomide due to changes in weight unless the 
calculated dose changes by ≥10%. 
• 
Veliparib/placebo and temozolomide should start together on Day 1 of each cycle. If TMZ 
is unavailable, initiation of veliparib/placebo should be delayed until TMZ can be started. 
Conversely, if veliparib/placebo is unavailable, TMZ initiation should not be delayed more 
than 7 days.   
10.2 
Temozolomide for Oral Administration (Temodar®, TMZ)  
PROCUREMENT 
Commercial supplies.  
 
FORMULATION 
Commercially available for oral administration as:  Capsules:  5 mg, 20 mg, 100 mg, 140 mg, 
180 mg, 250 mg 
 
PREPARATION, STORAGE AND STABILITY 
Refer to package insert for complete dispensing instructions. Store capsules at room temperature 
of 15ºC to 30ºC.  
 
ADMINISTRATION 
Refer to the treatment section for specific administration instructions. Capsules should not be 
opened or chewed but swallowed whole with a glass of water. Temozolomide may be 
administered on an empty stomach to reduce nausea and vomiting. Bedtime administration may 
be advised. Do not repeat if vomiting occurs after dose is administered, wait until the next 
scheduled dose. 
 
DRUG INTERACTIONS 
Ethanol/Nutrition/Herb Interactions: Food reduces rate and extent of absorption. 
 
PHARMACOKINETICS 
Absorption: Rapid and complete 
Distribution: Vd: Parent drug: 0.4 L/kg; penetrates blood brain barrier; CSF levels are ~35% to 
39% of plasma levels 
Protein binding: 15% 
Bioavailability: 100% 
Time to peak, serum: Empty stomach: 1 hour; with food (high-fat meal): 2.25 hours 
Metabolism: Prodrug, hydrolyzed to the active form, MTIC; MTIC is eventually eliminated as 
CO2 and 5-aminoimidazole-4-carboxamide (AID), a natural constituent of urine 
Half-life elimination: Mean: Parent drug: 1.8 hours 
Excretion: Urine (~38%; parent drug 6%); feces <1% 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
50 
Update #09 
Clearance:  1.45 L/hour 
 
ADVERSE EVENTS 
Consult the package insert for the most current and complete information. With CNS 
malignancies, it is difficult to distinguish between CNS adverse events caused by 
temozolomide versus the effects of progressive disease. 
 
Common known potential toxicities, > 10%:   
Cardiovascular: Peripheral edema (11%) 
Central nervous system: Fatigue (34% to 61%), headache (23% to 41%), seizure (6% to 23%), 
hemiparesis (18%), fever (13%), dizziness (5% to 12%), coordination abnormality (11%) 
Dermatologic: Alopecia (55%), rash (8% to 13%) 
Gastrointestinal: Nausea (49% to 53%; grades 3/4: 1% to 10%), vomiting (29% to 42%; grades 
3/4: 2% to 6%), constipation (22% to 33%), anorexia (9% to 27%), diarrhea (10% to 16%) 
Hematologic: Lymphopenia (grades 3/4: 55%), thrombocytopenia (grades 3/4: adults: 4% to 
19%), neutropenia (grades 3/4: adults: 8% to 14%), leukopenia (grades 3/4: 11%) 
Miscellaneous: Viral infection (11%) 
 
Less common known potential toxicities, 1% - 10%:  
Central nervous system: Amnesia (10%), insomnia (4% to 10%), somnolence (9%), ataxia (8%), 
paresis (8%), anxiety (7%), memory impairment (7%), depression (6%), confusion (5%) 
Dermatologic: Pruritus (5% to 8%), dry skin (5%), radiation injury (2% maintenance phase after 
radiotherapy), erythema (1%) 
Endocrine & metabolic: Hypercorticism (8%), breast pain (females 6%) 
Gastrointestinal: Stomatitis (9%), abdominal pain (5% to 9%), dysphagia (7%), taste perversion 
(5%), weight gain (5%) 
Genitourinary: Incontinence 98%), urinary tract infection (8%), urinary frequency (6%) 
Hematologic: Anemia (grades 3/4: 4%) 
Neuromuscular & skeletal: Paresthesia (9%), back pain (8%), abnormal gait (6%), arthralgia 
(6%), myalgia (5%) 
Ocular: Blurred vision (5% to 8%), diplopia (5%), vision abnormality (visual deficit/vision 
changes 5%) 
Respiratory: Pharyngitis (8%), upper respiratory tract infection (8%), cough (5% to 8%), 
sinusitis (6%), dyspnea (5%) 
Miscellaneous: Allergic reaction (up to 3%) 
 
Rare toxicities <1%:  
Alkaline phosphatase increased, alveolitis, anaphylaxis, aplastic anemia, emotional lability, 
erythema multiforme, febrile neutropenia, flu-like syndrome, hallucination, hematoma, 
hemorrhage, herpes simplex, herpes zoster, hyperglycemia, hypokalemia, interstitial 
pneumonia/pneumonitis, myelodysplastic syndrome, opportunistic infection (e.g., PCP), oral 
candidiasis, pancytopenia, peripheral neuropathy, petechiae, pneumonitis, pulmonary fibrosis, 
secondary malignancies (including myeloid leukemia), Stevens-Johnson syndrome, toxic 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
51 
Update #09 
epidermal necrolysis and liver damage which may cause yellowing of eyes and skin, swelling 
and may result in liver failure. 
 
NURSING GUIDELINES 
• 
Myelosuppression has been found to be the dose-limiting toxicity.  Gr 3 
thrombocytopenia occurred in 6% of patients and Gr 4 in 1%.  Gr 3 and Gr 4 
lymphopenia occurred in 55% of patients. Leukopenia, lymphopenia, 
thrombocytopenia and anemia usually occur 2-8 weeks after initiation of treatment. 
Monitor CBC carefully and report any significant changes to MD. Instruct patient 
to report signs/symptoms of infection, unusual bruising and bleeding to health care 
team. 
• 
In previous studies, patients have developed pneumocystis carinii pneumonia (PCP) 
when taking concomitant temozolomide and steroids.  Instruct patient to report any 
fever, cough, chest pain, of other signs of infection to the health care team.  Counsel 
patients on the importance of taking PCP prophylaxis as prescribed if ordered. 
• 
Advise patient that a mild-moderate rash may be experienced.  
• 
Fatigue may be experienced.  Work with patient in energy conserving lifestyle. 
• 
Remind patient that drug needs to be taken on an empty stomach with a full glass 
of water.  Drug should not be crushed, chewed, opened, or dissolved. 
• 
Nausea and vomiting are common. Teach patient to self-medicate with anti-emetics 
as directed by their healthcare provider. Assess for effectiveness. If vomiting occurs, 
do not repeat dose. Wait until next scheduled dose. 
• 
Constipation can occur. Encourage patient to increase fluid intake. Administer stool 
softeners or laxatives if ordered and monitor for their effectiveness. 
• 
Headache may be seen. Assess for more serious condition (i.e. cerebral bleed, 
disease progression) first and then treat symptomatically and monitor for 
effectiveness. 
10.3 
Veliparib or Placebo (NSC 737664, ABT-888)  
DESCRIPTION 
Chemical Name: 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide 
Other Names: A-861695.0, ABT-888 
Classification: Poly (ADP-ribosome) polymerase (PARP) Inhibitor 
Molecular Formula: C13H16N4O  
Molecular Weight: 244.29 
Description: light orange opaque capsule with two black bands 
 
PHARMACOLOGY 
Storage:  Store intact bottles between 15 and 25C (59 – 77F). 
Stability:  Shelf-life stability studies for veliparib/placebo capsules are ongoing. 
Route(s) of Administration: Oral.  Veliparib and matching placebo capsules may be administered 
without regard to meals. 
 
SUPPLIER 
 
Clinical Supplies:  Veliparib (NSC 737664) and matching Placebo will be provided free of 
charge by AbbVie Inc. and distributed by the Pharmaceutical Management Branch (PMB), 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
52 
Update #09 
Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis 
(DCTD), National Cancer Institute (NCI). 
 
 
Veliparib 20 mg and 0 mg matching placebo will be supplied as immediate release capsules.  The 
veliparib capsule contains veliparib, microcrystalline cellulose, colloidal silicon dioxide, 
magnesium stearate, gelatin, sodium lauryl sulfate, and titanium dioxide. May contain FD&C 
blue #1, FD&C yellow #6, or FD&C yellow #5.  The matching placebo capsule contains 
microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, gelatin, sodium lauryl 
sulfate, and titanium dioxide. May contain FD&C blue #1, FD&C yellow #6, or FD&C yellow 
#5. 
 
 
Veliparib and matching Placebo will be supplied in bottles containing 64 capsules with a child-
resistant cap and a tamper-evident seal.   
 
 
Each blinded, patient-specific bottle will be labeled with … 
 
• the protocol number (i.e., “A071102”) 
• the bottle number (i.e., “Bottle 1 of 1”  
• the number of capsules (i.e., “64 capsules”) 
• the patient ID number (e.g.,"XXXXXXXXX", which represents the unique patient 
identifier assigned at registration) 
• the patient initials (i.e., Last initial, First initial, Middle initial [e.g., "LFM"]) 
• the agent identification (i.e., “Veliparib 20 mg or Placebo”  
•  a blank line for the pharmacist to enter the patient’s name  
• administration instructions (i.e., “Take __ capsules two times daily for 7 days as 
directed.”) 
• storage instructions (i.e., “Store at room temperature (15ºC to 25ºC; 59ºF to 77ºF).” 
• emergency contact instructions 
• a Julian date 
 
 
The Julian date indicates the day the bottle was labeled and shipped and is composed of the last 
two digits of the calendar year (e.g., 2014 = 14, 2015 = 15) and a day count (e.g., January 1 = 
001, December 31 = 365).  For example, a bottle labeled and shipped on January 1, 2014 would 
have a Julian date of ‘14001’ and a bottle labeled and shipped on December 31, 2014 would 
have a Julian date of ‘14365’.  The Julian date will be used by PMB for recalls.  When a lot 
expires, PMB will determine the last date the expired lot was shipped and will recall all bottles 
(i.e., both veliparib and Placebo) shipped on or before that date thus eliminating any chance of 
breaking the blind. 
 
 
Questions about drug orders, transfers, returns, or accountability should be addressed to the 
PMB by calling (240) 276-6575 Monday through Friday between 8:30am and 4:30pm Eastern 
Time. You may also contact the PMB via e-mail at PMBAfterHours@mail.nih.gov. 
 
Agent Orders:  
No blinded starter supplies will be available for this study.  Blinded, patient specific clinical 
supplies will be sent to the registering investigator at the time of randomization and should arrive 
within approximately 7 to 10 days. This randomization will be performed by the Alliance 
Statistical Center. The assigned Alliance patient ID number must be recorded by the registering 
institution for proper bottle dispersion.  Once a patient has been registered, the Alliance 
Statistical Center will electronically transmit a clinical drug request for that patient to the PMB. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
53 
Update #09 
This request will be entered and transmitted by the Alliance Statistical Center the day the patient 
is registered and will be processed by the PMB the next business day and shipped the following 
business day. Shipments within the United States will be sent by FedEx Ground (up to 5 business 
days for delivery) and shipments to Canada will be sent by FedEx (generally one to two day 
delivery).  Shipments to United States sites can be expedited by the provision of an express 
courier account name and number to the Alliance Statistical Center at the time the patient is 
randomized.  Please note that additional processing time is required for QA/QC checks on 
patient-specific/blinded orders and next day delivery is not available.   
The initial request will be for 1 bottle [a 2 cycle (8 week) supply] of 20 mg capsules of veliparib 
or matching placebo at the recommended starting dose of 40 mg BID for 7 days of a 28 day 
cycle.  After 6 weeks (two weeks before needed), sites may reorder an additional 1 bottle [a 2 
cycle (8 week)] supply using the PMB On-line Agent Order Processing (OAOP) program.  The 
assigned patient ID number (e.g., "XXXXXXX") and the patient initials (e.g., "LFM") should 
be entered in the "Patient or Special Code" field.  A separate order is required for each patient 
ID number (e.g., "XXXXXXX") being ordered. All drug orders should be shipped directly to 
the physician responsible for treating the patient.  
NCI-supplied agents may be requested by eligible participating Investigators (or their authorized 
designee) at each participating institution.  The CTEP-assigned protocol number must be used 
for ordering all CTEP-supplied investigational agents.  The eligible participating investigators 
at each participating institution must be registered with CTEP, DCTD through an annual 
submission of FDA Form 1572 (Statement of Investigator), NCI Biosketch, Agent Shipment 
Form, and Financial Disclosure Form (FDF).  If there are several participating investigators at 
one institution, CTEP-supplied investigational agents for the study should be ordered under the 
name of one lead participating investigator at that institution. 
Submit agent requests through the PMB Online Agent Order Processing (OAOP) application.  
Access to OAOP requires the establishment of a CTEP Identity and Access Management (IAM) 
account and the maintenance of an “active” account status, a “current” password, and active 
person registration status.  For questions about drug orders, transfers, returns, or accountability, 
call or email PMB any time.  Refer to the PMB’s website for specific policies and guidelines 
related to agent management.   
 
Agent Transfers:   
Bottles MAY NOT be transferred from one patient to another patient or from one protocol to 
another protocol.  All other transfers (e.g., a patient moves from one participating clinical site 
to another participating clinical site, the principal investigator at a given clinical site changes) 
must be approved in advance by the PMB.  To obtain an approval for transfer, investigators 
should complete and submit to the PMB (fax number 240-276-7893) a Transfer Investigational 
Agent Form available on the CTEP home page (http://ctep.cancer.gov).  The patient ID number 
(e.g., "XXXXXXX"') and the patient initials (e.g., "LFM”) should be entered in the "Received 
on NCI Protocol No." and the "Transferred to NCI Protocol No." fields in addition to the 
protocol number (i.e., "A071102"). 
 
Agent Returns:   
Only undispensed clinical supplies should be returned to the PMB.  When it is necessary to 
return study drug (e.g., sealed bottles remaining when a patient permanently discontinues 
protocol treatment, expired bottles recalled by the PMB), investigators should return the study 
drug to the PMB using the NCI Return Drug List available on the CTEP home page 
(http://ctep.cancer.gov) or by calling the PMB at 240-276-6575.  The patient ID number (e.g., 
"XXXXXXX") and the patient initials (e.g., "LFM") should be entered in the "Lot Number" 
field.  Opened bottles with remaining capsules should be documented on the patient-specific 
Oral NCI Investigational Agent Accountability Record (i.e., logged in as “returned by patient” 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
54 
Update #09 
and logged out as “destroyed on site”) and destroyed on-site in accordance with institutional 
policy. 
Agent Accountability:   
The investigator, or a responsible party designated by the investigator, must maintain a careful 
record of the receipt, dispensing and final disposition of all agents received from the PMB using 
the appropriate NCI Investigational Agent (Drug) Accountability Record (DARF) available on 
the CTEP forms page.  Store and maintain separate NCI Investigational Agent Accountability 
Records for each agent, strength, formulation and ordering investigator on this protocol. 
Investigator Brochure Availability:  
The current versions of the IBs for the agents will be accessible to site investigators and research 
staff through the PMB OAOP application.  Access to OAOP requires the establishment of a 
CTEP IAM account and the maintenance of an “active” account status, and a “current” password 
and active person registration status.  Questions about IB access may be directed to the PMB IB 
Coordinator via email. 
Useful Links and Contacts 
• 
CTEP Forms, Templates, Documents:  http://ctep.cancer.gov/forms/  
• 
NCI CTEP Investigator Registration:  RCRHelpDesk@nih.gov  
• 
PMB 
Online 
Agent 
Order 
Processing 
(OAOP) 
application: 
https://eapps-
ctep.nci.nih.gov/OAOP/pages/login.jspx   
• 
CTEP Identity and Access Management (IAM) account: https://ctepcore.nci.nih.gov/iam/   
• 
CTEP Associate Registration and IAM account help:  ctepreghelp@ctep.nci.nih.gov   
• 
IB Coordinator:  IBCoordinator@mail.nih.gov   
• 
PMB email:  PMBAfterHours@mail.nih.gov  
• 
PMB phone and hours of service: (240) 276-6575 Monday through Friday between 8:30 
am and 4:30 pm (ET) 
 
ADMINISTRATION 
Administer veliparib orally without regard to meals.   
 
DISPOSAL 
Patients should return drug on day 1 of each cycle for cycle 2 and beyond. Drug destruction is per 
institutional standard. 
 
 
DRUG INTERACTIONS 
Clinical studies evaluating the metabolism of veliparib have not been conducted.  However, results 
from the in vitro analysis reveal that his agent is metabolized by multiple isoenzymes – CYP1A1, 
2D6, 2C19, and 3A4.  Veliparib is neither a potent inhibitor nor a potent inducer of the CYP450 
isoenzymes.  Use caution when concomitantly administering medications that are substrates, 
inhibitors, or inducers of CYP1A1, 2D6, 2C19 and 3A4.   
 
Veliparib clears primarily in the urine as intact parent drug along with metabolites suggesting that 
renal function plays an important role in the drug clearance and its metabolites. Use caution when 
concomitantly administer with oxaliplatin, carboplatin, cisplatin, and topotecan in patients with 
pre-existing renal impairment. 
 
PHARMACOKINETICS 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
55 
Update #09 
Absorption: The absorption of veliparib after oral dosing was relatively rapid, with average 
time to maximum observed plasma concentration (Tmax) ranging from 1 to 2 hours across dose 
levels. The maximum observed plasma concentration (Cmax) and the area under the plasma 
concentration curve from time zero to infinity (AUC∞) of veliparib were approximately dose-
proportional across the dose range studied, with minimal accumulation following BID dosing.  
Available data, while not definitive, shows an absence of significant food effect. 
Distribution:  The apparent volume of distribution (V/D) of veliparib was large, and oral 
clearance was rapid. 
Metabolism: Results from in vitro analysis reveal that this agent is metabolized by multiple 
isoenzymes – CYP1A1, 2D6, 2C19 and 3A4. Veliparib has one major metabolite in plasma, M8, 
a lactam derivative of the parent drug.  The cellular PARP-inhibitory activity of M8 is 18-fold 
lower than veliparib. 
Excretion: The average terminal half-life (t½) of veliparib ranged from 4 to 5 hours across dose 
levels.  Recovery of the dose as parent drug in the urine over 24 hours after dosing averaged 
78% (N = 6).  Following multiple oral doses given twice daily, total recovery of the dose in the 
urine (as both parent drug and M8 metabolite) over 12 hours averaged 86% (N = 34). Veliparib 
is primarily cleared in the urine as intact parent drug along with metabolites, suggesting that 
renal function plays an important role in the clearance of veliparib and its metabolites. 
Coadministration of veliparib with oxaliplatin, carboplatin, cisplatin, and topotecan should be 
used with caution in patients with pre-existing renal impairment since the primary elimination 
route of all of these drugs is renal. 
 
ADVERSE EVENTS 
Refer to the CAEPR. 
 
NURSING GUIDELINES: 
• 
Cytopenias are common. Monitor CBC and instruct patients to report any signs or 
symptoms of infection, bruising or bleeding to the study team. 
• 
Gastrointestinal side effects (nausea, vomiting, and diarrhea) have been seen. Treat 
symptomatically and monitor for effectiveness. 
• 
Patients may experience loss of appetite and subsequent weight loss. Instruct patients to 
eat frequent small meals and monitor their weight. 
• 
Maculo-papular rash can occur. Sun exposure may exacerbate this rash. Instruct patient 
to avoid prolonged sun exposure and to report any rash to the study team. 
• 
Fatigue is common. Patients should be taught about an energy conserving lifestyle. 
11.0 MEASUREMENT OF EFFECT  
Tumor response and regrowth can frequently be difficult to measure directly. Serial MRI/CT scans 
along with neurological exams will provide a guide for the effectiveness of therapy and the time-
course of the disease. It is important to note that this particular study is likely to result in a 
higher 
than 
normal 
incidence 
of 
treatment-related 
contrast 
enhancement, 
or 
“pseudoprogression,” due to the nature of the tumor phenotype (i.e. MGMT promoter 
hypermethylation) and the treatments involved.  
 
Time interval to progression will be measured from registration until deterioration is documented by 
the individual investigator using the guidelines in Section 11.4. The patient should use the same 
diagnostic imaging modality (MRI or CT) throughout the study. Ideally, patients should also be 
evaluated on the same physical imaging device throughout the length of the study to ensure the most 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
56 
Update #09 
accurate assessments of tumor response. (Note: The CT evaluation option should ONLY be used for 
patients unable to undergo MR imaging because of non-compatible devices).  
Overall survival will be measured from registration to death. Progression-free survival will be 
measured from registration until the first occurrence of progression or death. The quality of survival 
will be measured by performance status.  
The primary measure of response will be by serial measures of the product of the two largest cross-
sectional diameters (bidirectional product) using the RANO criteria (59).  
11.1 
Schedule of Evaluations: 
For the purposes of this study, patients should be reevaluated every 8 weeks while on therapy 
and then at a minimum every 3 months for years 1-3 and every 6 months for years 4 and 5 after 
completion of therapy, or until confirmed progression. For the definition of Progressive Disease, 
please see Section 11.4.3.2. For patients with suspected progression on imaging, a confirmatory 
scan is required that should be performed 4+/-2 weeks after the ‘initial scan’ with suspected 
progression. If the confirmatory scan confirms progression (confirmed progression), then the 
date of progression should be noted as that of the ‘initial scan’. 
11.2 
Definitions of Measurable and Non-Measurable Disease  
11.2.1 Measurable Disease 
We will define Measurable and Non-Measurable disease according to the updated RANO 
criteria (59).  In short, measurable disease requires bidimensional contrast enhancing lesions 
with clearly defined margins on MRI (or CT scan) with two perpendicular diameters of at 
least 10mm, visible on two or more axial slices that are at most 5 mm in thickness (0-mm 
skip).   
11.2.2 Non-Measurable Disease 
We will define non-measurable disease as either unidimensionally measurable lesions, 
masses with indistinct margins, or lesions with maximal perpendicular diameters less than 
10mm.  
11.3 
Guidelines for Evaluation of Measurable Disease 
11.3.1 Measurement Methods:   
• 
All measurements should be recorded in metric notation (i.e., decimal fractions of 
centimeters) using a ruler or calipers. We will measure all lesions in millimeters using 
standard ruler tools in the PACS system.   
• 
The same method of assessment and the same technique must be used to characterize 
each identified and reported lesion at baseline and during follow-up.  
11.3.2 Acceptable Modalities for Measurable Disease: 
• 
Conventional MRI and CT: CT scan imaging is only acceptable if patients are 
medically unable to undergo MR evaluation. This guideline has defined measurability 
of lesions on MRI or CT scan based on the assumption that MRI or CT slice thickness 
is 5 mm or less. If MRI or CT scans have slice thickness greater than 5 mm, the 
minimum size for a measurable lesion should be twice the slice thickness. 
As with MRI, if a CT scan is performed, the technical specifications of the scanning 
sequences used should be optimized for the evaluation of the brain tumors.  Ideally, the 
same type of scanner should be used and the image acquisition protocol should be 
followed as closely as possible to prior scans.   

 
 
Alliance A071102 
 
Version date: 01/22/2021  
57 
Update #09 
11.4 
Measurement of Treatment/Intervention Effect 
11.4.1 Target Lesions  
• 
Measurable lesions (as defined in Section 11.2.1) up to a maximum of 5 lesions, should 
be identified as “Target Lesions” and recorded and measured at baseline.   
Note: If fewer than 5 target lesions are identified (as there often will be), there is no 
reason to perform additional studies beyond those specified in the protocol to discover 
new lesions.   
• 
Target lesions should be selected on the basis of their size, be representative of all 
involved sites of disease, and should lend themselves to reproducible and repeated 
measurements.   
• 
Baseline Sum of Largest Bi-Dimensional Measurement (Baseline BDM): The sum 
of product of the largest bi-dimensional measurements for all target lesions will be 
calculated and reported as the baseline sum of bi-dimensional measurement. The 
baseline sum of the largest bi-dimensional measurement will be used as reference to 
further characterize any objective tumor response in the measurable dimension of the 
disease.   
• 
Post-Baseline Sum of Bi-Dimensional Measurement (Post-Baseline BDM):  The 
sum of product of the largest bi-dimensional measurements for all target lesions will be 
calculated and reported as the post-baseline sum of bi-dimensional measurements (Post-
Baseline BDM).  If the radiologist is able to provide an actual measure on the target 
lesion, that should be recorded.  If the target lesion is believed to be present and is faintly 
seen but too small to measure, a default value of 0.5 cm2 should be assigned.  If it is the 
opinion of the radiologist that the target lesion has likely disappeared, the measurement 
should be recorded as 0 cm2. 
• 
The minimum sum of the largest bi-directional measurements (Minimum BDM) is the 
minimum of the BDM of the baseline and post-baseline BDMs. 
11.4.2 Non-Target Lesions  
Non-measurable sites of disease (Section 11.2.2) are classified as non- target lesions and 
should also be recorded at baseline.   
11.4.3 Response Criteria 
11.4.3.1 Radiographic response should be determined in comparison to the tumor 
measurements obtained at pre-treatment baseline (post-radiation scan obtained prior 
to trial registration) for determination of response, and the smallest tumor 
measurement at either pre-treatment baseline or following initiation of therapy for 
determining progression.  
Because the current treatment is likely to result in a higher than normal incidence of 
treatment-related contrast enhancement (“pseudoprogression”), patients should 
continue therapy with close observation (e.g. 4 to 8 week intervals) if there is a 
suspicion of pseudoprogression. If subsequent imaging studies and/or clinical 
observations demonstrate that progression in fact has occurred, the date of confirmed 
progression should be noted as the scan at which the potential progression was first 
identified. We will define complete response, partial response, progressive disease, 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
58 
Update #09 
and stable disease based on updated RANO criteria (59).  We will consider all 
measurable disease as target lesions. 
11.4.3.2 Evaluation of Target Lesions 
• 
Pseudoprogression (PsP): All of the following must be true: 
a. Progression of contrast enhancing lesions and or T2/FLAIR is restricted to 
the initial radiation therapy volume. 
b. There are no new enhancing lesions outside of the initial radiation therapy 
volume. 
c. Patients are stable or improved clinically. 
d. PsP may be diagnosed at any time during therapy (beyond the typical 12 week 
window defined by RANO). 
• 
Complete Response (CR): All of the following must be true: 
a. Disappearance of all enhancing measurable and non-measurable disease 
(sustained for at least 4 weeks). 
b. No new enhancing lesions. 
c. Stable or improved non-enhancing (T2/FLAIR) lesions 
d.  Patients must be off corticosteroids (or on physiologic replacement doses 
only). 
e. Stable or improved clinically 
 
NOTE:  Patients with non-measurable disease only cannot have CR; the best response 
possible is stable disease. 
• 
Partial Response (PR): Requires all of the following: 
a. > 50% decrease in sum of products of perpendicular diameters of all 
measurable enhancing lesions (sustained for at least 4 weeks) compared with 
baseline. 
b. No progression of non-measurable disease 
c. No new lesions 
d. Stable or improved non-enhancing (T2/FLAIR) lesions on same or lower 
dose of corticosteroids compared with baseline scan  
e. Steroid dose should be same or lower compared with baseline scan. 
f. 
Stable or improved clinically 
 
NOTE:  Patients with non-measurable disease only cannot have PR; the best response 
possible is stable disease. 
• 
Progression (PD): Defined by any of the following: 
a. > 25% increase in sum of products of perpendicular diameters of enhancing 
lesions, compared with the smallest tumor measurement obtained either at 
baseline (if no decrease) or best response (on stable or increasing steroid 
dose).  
b. Significant increase in T2/FLAIR nonenhancing lesion on stable or increasing 
doses of corticosteroids compared with baseline scan or best response after 
therapy initiation (stable doses of steroids include patient not on steroids) not 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
59 
Update #09 
caused by comorbid events (e.g., radiation therapy, demyelination, ischemic 
injury, infection, seizures, post-operative change).  
c. Any new lesion 
d. Clear clinical deterioration not attributable to other causes apart from tumor 
(e.g., seizures, medication adverse effect, therapy complication, stroke, 
infection) or change in corticosteroid dose 
e. Failure to return for evaluation as a result of death or deteriorating condition 
f. 
Clear progression of nonmeasurable disease 
• 
Stable Disease (SD): Requires all of the following: 
a. Does not qualify for complete response, partial response, or progression. 
b. Stable non-enhancing (T2/FLAIR) lesions on same or lower dose of 
corticosteroids compared with baseline scan.  
c. In the event that corticosteroid dose was increased (for new symptoms/signs) 
without confirmation of disease progression on neuroimaging, and 
subsequent follow-up imaging shows that the steroid increase was required 
because of disease progression, the last scan considered to show stable 
disease will be the scan obtained when the corticosteroid dose was equivalent 
to the baseline dose. 
11.4.4 Overall Objective Status 
The overall objective status for an evaluation is determined by combining the patient’s status 
on target lesions, and new disease as defined in the following tables:  
NOTE:  Patients with possible PsP should initially be given the Objective Status of 
Preliminary Progression.  Once PsP or Progression is confirmed, the Objective Status can 
be changed accordingly. 
For Patients with Measurable Disease  
Target Lesions  
 
New  
Sites of Disease 
Overall Objective 
Status 
CR 
No 
CR 
PR 
No 
PR 
SD 
No 
SD 
Not all Evaluated 
No 
Not Evaluated 
(NE) 
PD 
Yes or No 
Confirmed PD 
CR/PR/SD/PD/Not all 
Evaluated 
Yes 
Confirmed PD 
 
 
 
Possible PsP 
 
Preliminary PD 
PsP 
No 
PsP 
11.4.5 Symptomatic Deterioration: Patients with global deterioration of health status requiring 
discontinuation of treatment without objective evidence of disease progression at that time, 
and not either related to study treatment or other medical conditions, should be reported as 
PD due to “symptomatic deterioration.”  Every effort should be made to document the 
objective progression even after discontinuation of treatment due to symptomatic 
deterioration. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
60 
Update #09 
11.5 
Definitions of analysis variables 
Formal definitions of variables used in analyses can be found in the Statistical Considerations 
section of the protocol. 
12.0 END OF TREATMENT/INTERVENTION  
12.1 
Duration of Treatment  
12.1.1 CR, PR, or SD: Patients who are in CR, PR or SD will continue on therapy for a total of 6 
cycles.  Patients with possible pseudoprogression (preliminary progression) also should 
remain on therapy. After treatment is discontinued, patients will be followed per the study 
calendar in Section 5.0. 
12.1.2 Disease Progression:  
Patients who develop PD while receiving therapy will go to the survival and disease follow 
up phase.  
True progression versus pseudoprogression:  Given the high incidence of 
pseudoprogression (20-30% of patients) following standard radiotherapy with 
concurrent/adjuvant temozolomide, the development of enhancement following therapy 
cannot be assumed to represent tumor progression.  Differentiation between true progression 
and post-treatment effects (i.e., pseudoprogression, radiation necrosis) is difficult based on 
conventional MRI alone, as these entities appear identically with contrast enhancement, 
mass effect, and abnormal T2/FLAIR signal.    The updated RANO criteria have attempted 
to address this issue (59).  In short, tumor progression can only be determined within the 
first 12 weeks of completing chemo-radiation therapy if the majority of the enhancement is 
outside of the radiation field (80% isodose line) or if radiographic changes within the 
radiation field are associated with clinical deterioration, requirement for escalating steroid 
doses, or pathologic confirmation of tumor progression; otherwise, the diagnosis of 
pseudoprogression should be made. There may be a higher than normal rate of 
pseudoprogression on this study, and pseudoprogression may occur later than normally 
observed when using a TMZ-sensitizing strategy. Moreover, the ‘intensity’ of pseudo-
progression in a given patient may be higher for individual patients. Therefore, for this 
trial, pseudoprogression may be defined at any time during treatment on this study 
and stable steroid doses are not required to make a presumed diagnosis of pseudo-
progression as long as patients remain clinically stable. Patients with probable 
pseudoprogression should continue on therapy until true progression is confirmed or they 
complete adjuvant therapy.   
12.1.3 Discontinuation of study agent: Patients who go off protocol treatment for reasons other 
than PD will go to post treatment follow up, then to the survival and disease status follow 
up per Section 5.0. Patients that refuse post treatment follow up will also go to survival and 
disease status follow up phase. 
12.1.4 Non-protocol therapy: Continuation of TMZ beyond Cycle 6 is discouraged. Patients who 
choose to continue TMZ beyond 6 cycles should NOT be removed from the study. Patients 
who begin non-protocol treatment should continue clinical and survival follow-up as 
outlined in Section 5.0. Information regarding the treatment should be reported in Rave. 
12.2 
Managing ineligible and canceled patients and major protocol violations 
Data must be submitted per Section 5.0 for patients deemed ineligible or canceled. See also the 
Forms Packet for full details of data submission requirements. If a patient is deemed ineligible, 
they may be replaced. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
61 
Update #09 
12.2.1 Definitions 
Cancelled Patient: A study participant who is registered to the trial but never receives 
study treatment. 
Ineligible Patient: A study participant who is registered to the trial but does not meet all 
of the eligibility criteria at time of registration. 
Clinical Follow-up: The follow-up period where the study participant is no longer 
receiving treatment, but is still following the study calendar for tests, exams, and 
correlative endpoints (e.g., specimen collection, quality of life, disease assessments as 
required by the study). 
Survival Only Follow-up: The follow-up period where the study participant is monitored 
for long-term endpoints, is no longer receiving study treatment, and is not required to 
follow the study calendar for tests, exams, and correlative endpoints (e.g., specimen 
collection, quality of life, disease assessments as required by the study). In this follow-up 
period, there is a schedule in which case report forms should be submitted, but the 
physician visits are based on the standard of care. 
12.2.2 Follow-up Requirements 
Patients who are deemed ineligible may continue protocol treatment provided the treating 
physician, study chair, and Executive Officer agree there are no safety concerns. If the 
patient continues protocol treatment, all scans, tests, data submission will continue as if the 
patient were eligible. Notification of the local IRB may be necessary per local IRB policies. 
12.3 
Extraordinary Medical Circumstances 
If, at any time the constraints of this protocol are detrimental to the patient's health and/or the 
patient no longer wishes to continue protocol therapy, protocol therapy shall be discontinued. In 
this event: 
• 
Document the reason(s) for discontinuation of therapy on data forms. 
• 
Follow the patient for protocol endpoints as required by the Study Calendar. 
13.0 STATISTICAL CONSIDERATIONS  
13.1 
Endpoints 
13.1.1 Primary Endpoint 
 
The primary endpoint is overall survival, which is defined as the date from study registration 
to the date of death due to any cause. A dynamic allocation procedure with a 1:1 
randomization will be used to allocate an equal number of patients to two arms. This 
procedure will balance the marginal distributions of the stratification factors among arms. 
The stratification factors that will be used are: age (≤ 70 vs. >70), performance score (ECOG 
0-1 vs. 2), and extent of resection (gross total resection vs. subtotal resection or biopsy). 
13.1.2 Secondary Endpoints 
• 
Progression-free survival:  is defined as the date from study registration to the date 
of first observation of disease progression or death due to any cause (whichever 
comes first).  
• 
Objective tumor response: is defined as CR or PR as specified in the RANO 
criteria in Section 11. Pseudoprogression is defined in Section 11.4.3.2. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
62 
Update #09 
• 
Treatment-related Adverse Events: As per CTEP Active Version of the CTCAE, 
the phrase “treatment-related adverse event” is defined as an adverse event that is 
classified as either “possibly,” “probably,” or “definitely related” to study treatment.   
13.2 
Sample Size Derivation 
The phase III portion of the study has OS as an endpoint with one interim futility analysis (to be 
done at the completion of the Phase II portion). Based on the RTOG 0525 study, the median 
overall survival (OS) for patients with MGMT promoter methylation assessed by the standard 
qMS-PCR assay planned in this study is about 21.2 months with standard therapy of RT/TMZ 
followed by adjuvant TMZ.  In the phase II portion of the study, we plan to enroll a total of 293 
patients (73% of total patients needed for phase III comparison) in 4.1 years (49 months) and 
will do an interim futility analysis for OS (to be done by an independent statistician) if the phase 
II study was positive (based on PFS). The interim futility analysis will be based on the number 
of deaths observed at the time the phase II PFS data are mature. We will compare the OS curves 
and resume the accrual and move on to phase III portion using a futility boundary that accounts 
for the amount of study information (portion of total deaths) on hand at the time of the phase II 
final analysis. The table below contains example boundaries as a function of the proportion of 
deaths (amount of information) observed. The independent statistician will determine the 
proportion of deaths (amount of information) and use the appropriate futility boundary that 
spends a beta amount of no more than 0.001. These are Lan-DeMets futility boundaries with OF 
parameter. 
Amount of  
information 
Number of  
deaths 
Do not continue if  
p-value ≥ 
Do not continue if  
HR ≥  
10% 
30 
1.00 
4.59 
15% 
45 
1.00 
2.43 
20% 
60 
0.99 
1.77 
25% 
76 
0.95 
1.45 
30% 
91 
0.88 
1.28 
35% 
106 
0.82 
1.17 
40% 
121 
0.69 
1.09 
45% 
136 
0.59 
1.04 
50% 
151 
0.48 
0.99 
Once the study moves on to the phase III portion, we plan to accrue another 107 patients (for a 
total sample size of 293+107=400 in phase III) in 1.5 years (18 months) with a minimum follow 
up of 2 years to get a total of 302 death events. This design with one interim analysis for futility 
will yield 90% power to detect a hazard ratio of 0.71 (median OS of 21.2 vs. 29.7 months) using 
a one-sided log-rank test with a type I error rate of 0.05. The final analysis of the phase III trial 
will occur when 302 deaths have been observed (expected to be approximately 3.5 years after 
phase III portion opens) and we will conclude the combination therapy TMZ/ABT888 extends 
the OS significantly if the observed OS HR is 0.82 or smaller (an observed increase in median 
OS from 21.2 to 25.6 months). 
13.3 
Analysis plans  
13.3.1 Phase II Analysis 
The phase II trial has PFS as the primary endpoint and will have one interim analysis for 
futility (accrual will not stop for this interim analysis) using a Lan-DeMets boundary. A 
total sample size of 293 for the phase II trial will yield 90% power to detect a HR of 0.67 
(equivalent to the median PFS of 8.7 vs. 13.0 months) using a one-sided log-rank test with 
a type I error rate of 0.2 and one interim analysis for futility. The interim analysis for the 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
63 
Update #09 
phase II will occur after 79 PFS events have been observed. We will recommend the trial be 
stopped for futility if the observed HR (comparing control to experimental arm) is greater 
than 0.97 at the interim analysis. At the end of the phase II trial we will perform an analysis 
when 121 PFS events have been observed. We will recommend not proceeding with the 
phase III trial if the observed HR is 0.86 or greater. 
13.3.2 OS Interim Analysis at End of Phase II 
Accrual will be suspended at the end of the phase II portion of the trial (once 293 patients 
have been accrued), and the interim OS analysis will be done based on the number of OS 
events observed when there are 121 PFS events. At this point, an independent statistician 
(one not associated with this trial) will perform an interim analysis of the OS data. The 
independent statistician will determine how much information there is in the data (i.e. the 
proportion of the 302 deaths for the final analysis) and set the OS futility boundary 
accordingly. The independent statistician will recommend that the trial be closed to accrual 
due to futility if the HR (comparing control to experimental) crosses the futility boundary 
determined based on the amount of OS information available. This recommendation would 
imply that accrual to the phase III trial be halted. If HR for OS does not cross the futility 
boundary, the trial will be reopened to complete accrual for the Phase III portion. The 
independent statistician will not share the results of the OS analysis with the study team. 
13.3.3 Analysis Plans for Primary, Secondary, and Exploratory Endpoints 
• 
Overall survival:  is defined as the date from study registration to death due to any 
cause. Efficacy analysis will be based on the intent-to-treat principle. The primary 
analysis of overall survival will occur after 302 deaths have been observed. The 
primary analysis will be a re-randomization test. To perform the test, 50,000 
simulations will be performed in which patients will be randomized according to 
the dynamic allocation procedures used in the original randomization. The order 
that the patients are entered into each simulated trial will be randomized. The p-
value will be computed as the number of instances the simulated test-statistic (from 
a stratified logrank test) is the same or more extreme than the observed test statistic 
from the trial data divided by 50,000 .  Patients who are lost to follow-up will be 
censored at the date of their last follow-up. Patients still alive at the time of analysis 
will be censored. In addition as a secondary analysis, the distribution of OS for each 
arm will be estimated using the Kaplan-Meier method and compared with a 
stratified logrank test.  Stratified Cox proportional hazard models will be used to 
estimate the hazard ratio for the treatment effect. 
Note: 50,000 simulations will yield a standard deviation of 0.001 of the resulting p-
value if the observed p-value is 0.05, and a standard deviation of 0.0007 if the 
observed standard deviation is 0.025. 
 
• 
Interaction with Optune: A Cox proportional hazards model will be used to 
evaluate whether there is a potential interaction between the treatment arm and the 
Optune device. If an interaction is detected, separate analyses of treatment effect 
(using Cox models as described above) will be done for patients treated with the 
Optune device and patients who were not treated with the Optune device. 
• 
Progression Free Survival: The distribution of PFS for each arm will be estimated 
using the Kaplan-Meier method, and be compared using Cox proportional hazard 
models with all stratification factors adjusted.   

 
 
Alliance A071102 
 
Version date: 01/22/2021  
64 
Update #09 
• 
Objective tumor response: an objective tumor response will be evaluated for each 
patient and the tumor response rate will be summarized for each arm and compared 
using the Chi-square test.  
• 
Adverse Events: The overall adverse event rates for grade 3 or higher adverse 
events will be summarized and be compared using Chi-Square or Fisher’s Exact 
tests between treatment arms. The maximum grade for each type of treatment-
related adverse event will be recorded for each patient, and frequency tables for 
each arm will be reviewed to determine patterns.  In addition, we will review all 
adverse event data that is graded as 3, 4, or 5 and classified as either “unrelated” or 
“unlikely to be related” to study treatment in the event of an actual relationship 
developing.  Adverse events and treatment-related adverse events will be evaluated 
using all patients who have received any study treatment as well as summarizing 
those who have been included in the efficacy analyses.  Treatment-related adverse 
events will be tabulated for each arm. 
• 
Fatigue/Uniscale Assessment: The fatigue/uniscale tool will be used as a measure 
of QOL for patients because fatigue has been identified as a particular concern for 
GBM patients. Potential differences in fatigue levels of patients treated on the two 
different arms will be evaluated. Changes in this measure will be evaluated over the 
course of treatment for both arms and will be compared using a two-sample t-test at 
each timepoint. We will also compute a normalized area under the curve (AUC) for 
the values of each patient over time and compare the mean AUCs for patients on 
the two arms. This aim is more exploratory than confirmatory. Results will be used 
to inform future trials. 
• 
Exploratory Endpoints: Binary or categorical exploratory endpoints will be 
compared using Chi-Square or Fisher’s Exact tests between treatment arms, and 
continuous exploratory endpoints will be analyzed using change-from-baseline 
measures and compared using t-tests between treatment arms. 
• 
The concordance between site-determined MGMT methylation status and central 
laboratory determination of MGMT status will be analyzed using the Chi-Square 
test of proportions and 95% confidence intervals for the proportion of tests in 
disagreement with the local site. 
13.3.4 Accrual and Study Duration 
The study will be opened to all sites within The Alliance for Clinical Trials in Oncology 
(the Alliance) and to other cooperative groups through the CTSU mechanism. All patients 
enrolled must have tumor MGMT hypermethylation determined by the study central 
laboratory. We anticipate 338 GBM patients per year will be registered for pathology central 
review and central MGMT testing. In the RTOG 0525 experience, 71% of patients registered 
for screening were ultimately randomized to therapy, and 30% of patients with MGMT 
testing were found to have MGMT promoter hypermethylation. Thus, we expect the accrual 
rate will be about 72 evaluable methylated (338*71%*30%) patients per year from 
screening.  
A minimum of 208 and a maximum of 322 eligible patients, including an extra 10% each to 
accommodate losses due to cancellations, ineligibility, or major protocol violations, will be 
entered into the phase II trial. Similarly, a maximum 118 eligible patients will be entered 
into the phase III.  The study duration will be a minimum of 2.7 years (32 months) and a 
maximum of 4.6 years for the phase II, and an additional 3.5 years for the phase III portion. 
Therefore, the entire study may take between 2.7 years and 8.1 years. Based on the 
assumptions described above, the Phase II portion of the trial will require a maximum of 
1512 patients to be screened at the study central laboratory for MGMT methylation.  For the 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
65 
Update #09 
Phase III portion of the trial, a maximum of 554 patients will be screened at the study central 
laboratory for MGMT methylation.  
13.4 
Monitoring the Study 
13.4.1 Adverse Event Stopping Rule 
For the experimental arm, if 3 out of the first 20 or if at any time after the first 20 patients 
are enrolled 15% or more patients on the experimental arm develop Grade 4 or 5 non-
hematologic adverse events felt to be at least possibly related to treatment, the study team 
will review the data to determine the proper course of action. These actions may include 
further AE monitoring, suspension of accrual, dose modification, and closure of the trial. 
Accrual to the trial will continue until official notification is received from The Alliance. 
We will review grade 4 and 5 adverse events deemed “unrelated” or “unlikely to be related”, 
to verify their attribution and to monitor the emergence of a previously unrecognized 
treatment-related adverse event. CTCAE v4.0 will be used to determine grading.  
13.4.2 Adverse Event Stopping Rule (Optune) 
If there are 3 patients out of 20 treated concomitantly with the Optune device or if at any 
time 15% or more patients concomitantly treated with the Optune device develop Grade 4 
or 5 non-hematologic adverse events felt to be at least possibly related to treatment, the 
study team will review the data to determine the proper course of action. These actions may 
include further AE monitoring and disallowing further concomitant treatment with the 
Optune device. Accrual to the trial may continue while the decision is being made. We will 
review grade 4 and 5 adverse events deemed “unrelated” or “unlikely to be related”, to verify 
their attribution and to monitor the emergence of a previously unrecognized treatment-
related adverse event.  
13.4.3 Accrual Monitoring Stopping Rule 
Accrual to the Phase-III portion of the study will be monitored closely. The study team will 
evaluate accrual within the 5th to 6th quarter from Phase-III activation. If accrual is less 
than 50% of what was projected, working together with the Alliance Data Safety Monitoring 
Board, we will plan modifications including the potential for closure. 
13.5 
Study Reporting 
13.5.1 Alliance Data Safety Monitoring Board (DSMB) 
Both the Phase-II and Phase-III portions of this study will be monitored by the Alliance Data 
Safety Monitoring Board (DSMB), an NCI-approved functioning body. Reports containing 
efficacy, adverse event, accrual, and administrative information will be provided to the 
DSMB every six months as per NCI guidelines. 
13.5.2 Clinical Data Update System (CDUS) 
This study will be monitored by the Clinical Data Update System (CDUS) version 2.0. An 
abbreviated report containing cumulative CDUS data will be submitted quarterly to CTEP 
by electronic means. Reporting time points are: January 31, April 30, July 31, and October 
31.  
13.6 
Descriptive Factors  
13.6.1 Location of Lesions 
Frontal vs. temporal vs. parietal vs. occipital vs. crosses boundaries 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
66 
Update #09 
13.6.2 Other Tumor Sites 
Thalamus vs. basal ganglia vs. hypothalamus vs. brain stem vs. other. 
13.6.3 Side of Lesion 
Right vs. left vs. midline vs. bilateral. 
13.6.4 Baseline Imaging Assessment – CT vs. MRI 
13.6.5 Maximum Diameter  
Maximal diameter in centimeters on a preoperative scan of: 
1. Contrast enhancement. 
2. Abnormal T2 signal on MRI (specify) or low attenuation on CT. 
13.6.6 Extent of Resection 
 
Extent of resection (by treating physician’s opinion): Biopsy vs. subtotal vs. gross total. 
13.6.7 Family History of Brain Tumor  
Yes vs. no. 
 
If yes, check all that apply 
 
_____Father 
 
_____Mother 
 
_____Brother or sister 
 
_____Child 
 
_____Other (list :____________________________________________) 
13.6.8 Corticosteroid Therapy at Study Entry 
  
Yes vs. no. 
13.6.9 Anticonvulsant Use 
Yes vs. no. 
13.6.10 Radiation Therapy 
RT Dose 
60 Gy in 30 fractions vs. 59.4 Gy in 33 fractions 
 
RT to T2 abnormality  
Yes vs. no 
 
Dose to T2 abnormality 
<50 Gy vs. >=50 Gy 
 
Number of fractions to treat T2 abnormality 
<30 vs. >=30 
 
CTV expansion of GTV T1 gad 
<=1 cm vs. >1 cm 
 
CTV expansion of GTV T2 abnormality 
<=1 cm vs. >1 cm 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
67 
Update #09 
PTV dose coverage, >= 95% Dose to >90% PTV  
Yes vs. No 
13.7 
Inclusion of Women and Minorities 
This study will be available to all eligible patients regardless of race, gender, or ethnic group.  
There is no information currently available regarding differential agent effects of this regimen 
in subsets defined by race, gender, or ethnicity, and there is no reason to expect such differences 
to exist. Therefore, although the planned analyses will, as always, look for differences in 
treatment effect based on racial and gender groupings, the sample size is not increased in order 
to provide additional power for such subset analyses. A maximum of 1661 patients may be pre-
registered to enroll a total of 440 eligible patients needed for the whole study. 
 
Based on prior studies involving similar disease sites, we expect about 7% of patients will be 
classified as minorities by race and about 40% of patients to be women.  Expected sizes of racial 
by gender subsets are shown in the following table: 
 
 
Accrual Targets 
Ethnic Category 
Sex/Gender 
Females 
Males 
Total 
Hispanic or Latino 
 12 
19  
31 
Not Hispanic or Latino 
 164 
245 
 409 
Ethnic Category: Total of all subjects*  176 
264 
 440 
Racial Category 
American Indian or Alaskan Native 
 5 
7 
 12 
Asian 
 2 
4 
 6 
Black or African American 
 2 
3 
 5 
Native Hawaiian or other Pacific Islander  3 
5 
 8 
White 
 164 
245 
 409 
Racial Category: Total of all subjects*  176 
264  
 440 
 
Ethnic 
Categories: 
Hispanic or Latino – a person of Cuban, Mexican, Puerto Rican, South or Central 
American, or other Spanish culture or origin, regardless of race. The term “Spanish 
origin” can also be used in addition to “Hispanic or Latino.” 
 
Not Hispanic or Latino 
Racial 
Categories: 
 
 
 
 
American Indian or Alaskan Native – a person having origins in any of the original 
peoples of North, Central, or South America, and who maintains tribal affiliations or 
community attachment. 
Asian – a person having origins in any of the original peoples of the Far East, 
Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, 
India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and 
Vietnam. (Note: Individuals from the Philippine Islands have been recorded as Pacific 
Islanders in previous data collection strategies.)  
 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
68 
Update #09 
 
Black or African American – a person having origins in any of the black racial 
groups of Africa. Terms such as “Haitian” or “Negro” can be used in addition to 
“Black or African American.” 
Native Hawaiian or other Pacific Islander – a person having origins in any of the 
original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. 
White – a person having origins in any of the original peoples of Europe, the Middle 
East, or North Africa. 
 
14.0 CORRELATIVE AND COMPANION STUDIES  
The correlative science study must be offered to patients enrolled on A071102. There will be three 
sub-studies (A071102-ST1, A071102-ST2 and A071102-IM) and all patients are encouraged to 
participate.  
14.1 
DNA Extraction from Tissue (A071102-ST1)  
14.1.1 Background 
In the RTOG 0525 clinical study, qMS-PCR determination of MGMT promoter 
hypermethylation was observed in 30% of patients and associated with a median overall 
survival of 21 months as compared to 14 months for patients with hypomethylated 
(unmethylated) tumors. The qMS-PCR MGMT assessment was performed by 
Oncomethylome using a published methodology that is now commercially available by Lab 
Corp. An almost identical method is routinely used in both Dr. Sarkaria’s and Dr. Sulman’s 
laboratories, and in collaboration with Raja Luthra, Erik Sulman will perform this assay as 
a CLIA-certified test suitable for use in this clinical trial.  
As part of a funded RO1, we are evaluating the efficacy of veliparib and TMZ in 18 primary 
GBM xenograft lines using our intracranial therapy evaluation model. These xenograft lines 
also will be characterized by aCGH, gene expression analysis, and exome sequencing to 
identify potential defects in various DNA repair processes involved in recovery from 
replication fork arrest that is induced by persistent O6MG lesions. Following this hypothesis 
generating exercise, molecular studies will be performed to validate potential mechanisms 
of sensitivity and or resistance to veliparib sensitizing effects in combination with TMZ. 
Based on these studies performed in our xenograft model, tumor samples accrued on the 
planned clinical trial as part of the MGMT analysis will be analyzed for these additional 
potential markers for response to combination therapy. Since the preliminary studies in our 
animal models are not complete, we are unable to define what these specific molecular tests 
will be at this time. Once these studies mature, then the clinical protocol will be amended to 
include specific analyses that are guided by these pre-clinical studies. However, in 
anticipation of these studies, we will collect a pre-treatment blood sample from each patient 
consenting to A071102-ST2 and archive normal genomic DNA for future studies. 
14.1.2 Objectives 
We would like to identify additional biomarkers that predict for response to the combination 
of veliparib and TMZ. Based on ongoing pre-clinical studies, we anticipate evaluating 
molecular alterations in DNA repair processes in exploratory studies that could be 
confirmed in subsequent clinical trials. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
69 
Update #09 
14.1.3 Methods 
The specific nature of the future molecular studies focused on mechanisms of sensitivity to 
combination treatment with veliparib and TMZ have yet to be determined. This protocol 
section will be amended when the plan for these studies is finalized.  
DNA will be extracted from patient tumor blocks as required for MGMT promoter 
methylation analysis. For most specimens, the amount of DNA extracted will be in excess 
of that required for MGMT methylation analysis. This unused DNA will be returned from 
Dr. Sulman’s laboratory to the Alliance Biorepository at Mayo Clinic and will be archived 
for all patients who undergo screening for MGMT status.   
We anticipate evaluating the mutation status in various DNA repair genes in the tumor DNA. 
Because there are rare germline single nucleotide polymorphisms in many of the DNA repair 
genes of potential interest, we will collect and isolate germline DNA from all patient that 
register for the therapeutic study. The DNA extraction will be performed by the Mayo 
Biospecimens Accessioning and Processing laboratory and then archived in the Alliance 
Biorepository at Mayo Clinic. Collection of this DNA is critically important to facilitate the 
planned analysis of somatic DNA repair gene mutations. Any future use of banked 
specimens will require review and approval according to the policies of the NCTN. 
14.2 
DNA Extraction from Blood (A071102-ST2) 
14.2.1 Background 
We hypothesize that subtle defects in DNA repair capacity may be important modulators of 
the TMZ-sensitizing effects of veliparib. This hypothesis currently is being studied in 
multiple pre-clinical animal models that were used to generate the preliminary data 
supporting this clinical trial. From initial RNAseq and whole exome-seq studies performed 
in our laboratory, we anticipate that single nucleotide variants (SNVs) or small 
insertion/deletion (INDEL) in the somatic tumor DNA can be linked to these defects in DNA 
repair associated with TMZ-sensitizing effects. Because any given tumor typically has 
numerous SNV or INDELs in the somatic DNA, a comparison of these sequence variants 
against germ-line DNA is an essential first step in determining whether a specific SNV or 
INDEL is functionally significant. Therefore, we will collect blood from all patients enrolled 
on this study and extract DNA from these samples to support the planned correlative studies 
directed at understanding somatic DNA variations associated with a sensitizing effect of 
veliparib. 
14.2.2 Objectives 
Isolate and archive germ-line DNA from all patients to support functional analysis of 
somatic mutations in tumor DNA. 
14.2.3 Methods 
DNA extraction from whole blood will be performed in the Biospecimen Accessioning and 
Processing (BAP) core laboratory at Mayo Clinic. Blood samples received in BAP will be 
processed to extract DNA using the AutoGenFlex STAR purification instrument along with 
the Qiagen FlexiGene DNA AGF3000 kit. The FlexiGene DNA AGF3000 kit is designed 
for automated purification of total DNA (i.e. genomic and mitochondrial DNA) from human 
whole blood using the AutoGenFlex STAR workstation. FlexiGene technology provides 
high-quality DNA that is free of protein, nucleases, and other contaminants or inhibitors. 
Typically, DNA extraction typically yields 100-150 ug of DNA. Once the DNA is extracted 
the sample will have its optical density (OD) measured to ensure the quality of the 
extraction. The sample then will be transferred to the Alliance Biorepository at Mayo Clinic 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
70 
Update #09 
for archiving and storage. Any future use of banked specimens will require review and 
approval according to the policies of the NCTN. 
14.3 
Analysis of advanced MR imaging (A071102-IM) 
14.3.1 Background 
The Response Assessment in Neuro-Oncology (RANO) criteria have established criteria for 
assessing tumor progression vs. treatment effects by recommending that enhancing lesions 
on CE-MRI be followed over time to distinguish growing recurrent tumor from regressing 
post-treatment radiation effects (PTRE), including pseudoprogression (PsP) and radiation 
necrosis (59).  Despite this recent advance in response criterion, driven by both awareness 
of PTRE/PsP and pseudoresponse in anti-angiogenic therapies, significant limitations 
remain. For example, comprehensive serial imaging generally delays both diagnosis and 
management by several months due to the time required to observe adequate tumoral or 
PTRE/PsP-related evolution. This results in clinical inefficiency that is compounded, in 
some cases, when PTRE/PsP continues to grow or remains stable. The requirement for serial 
imaging to retrospectively determine PTRE/PsP from tumor progression also adds 
significant costs to clinical trials. Additionally, CE-MRI poorly estimates the histologic 
admixture between tumor and PTRE/PsP, which almost universally follows standard 
multimodal therapies. Contrast enhancement alone can represent a combination of viable 
tumor, persisting PTRE/PsP, or a combination of both, making it difficult to diagnose the 
precise composition as well as changes in tumor behavior and kinetics. The relative quantity 
of tumor, as determined by histopathology, has been shown to correlate with both treatment 
response and OS, and offers more prognostic information than simply reporting the presence 
of tumor (60-64); however, surgical biopsies introduce additional medical risks, morbidities, 
and costs as well as limited information regarding the heterogeneity of tumor response.  
These issues highlight the critical need to improve the imaging-based clinical trial 
assessment of tumor progression.  
Imaging for all patients enrolled on the study will be collected prospectively by the IROC. 
There are two purposes for this imaging banking. First, a secondary endpoint for this trial is 
progression free survival. Given the potential difficulties in differentiating tumor 
progression from PTRE/PsP, we plan to archive all images obtained during and immediately 
following therapy to facilitate future retrospective central radiology review of images. This 
is especially relevant since the rate of PTRE/PsP may be higher in MGMT methylated 
tumors and treatment with a TMZ-sensitizing agent may increase further the rate of 
PTRE/PsP. Thus, prospective collection and banking of images will ensure our ability to 
robustly address questions regarding differences in PTRE/PsP and time to tumor progression 
for each in the 2 treatment groups. Second, for institutions that elect to participate in the 
advanced MR imaging study, dynamic susceptibility contrast (DSC) and diffusion weighted 
imaging (DWI) will be performed at each imaging time point and submitted to the IROC 
along with the standard imaging studies. These advanced MR series will be analyzed as 
described below. 
14.3.2 Objectives 
• 
Hypothesis #1: Metrics on DSC will provide earlier and more accurate 
assessment of tumor progression (vs. PTRE/PsP) compared with RANO criteria 
assessment and will correlate more strongly with OS. 
 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
71 
Update #09 
• 
Hypothesis #2: Probabilistic functional diffusion map (fDM) parameters will 
enable earlier and more accurate differentiation of PTRE/PsP from tumor 
progression compared with RANO criteria assessment.  
 
• 
Hypothesis #3: Combining pMRI and ADC metrics will improve distinction of 
PTRE/PsP from tumor progression compared with traditional evaluations of 
tumor progression (i.e. RANO/Macdonald criteria). 
14.3.3 Methods 
Standardized dynamic susceptibility contrast (DSC) and diffusion weighted imaging (DWI) 
will be performed at each imaging time point as detailed in Appendix III. These advanced 
MR imaging series will be analyzed retrospectively using quantitative analyses to address 3 
specific hypotheses listed above.  
We expect approximately 60% of patients to participate in DSC-MRI and >80% of patients 
to participate in DW-MRI. Although these numbers are partially dependent on the imaging 
capabilities of the particular sites chosen for the study, we anticipate the majority of patients 
to have DW-MRI (as this is routinely used in clinical neuroimaging protocols) and fewer 
patients to have DSC-MRI because it is more technically challenging. As a reference, in 
ACRIN-6677 which did not have standardized DW-MRI acquisition protocols, 100% of 
patients had DW-MRI data collected, for which 68% of the DW-MRI data was usable. We 
expect this percentage to be higher in the current study because of better image acquisition 
standardization. 

Alliance A071102 
Version date: 01/22/2021 
72 
Update #09 
14.3.4 Image Analysis 
We will compare the diagnosis of tumor progression, timing of diagnosis (in months after 
therapy), and correlations with OS as determined by the various aforementioned imaging 
methods (i.e., RANO criteria, multiple pMRI metrics). Ultimately, these studies will provide 
an understanding of how reliably a standardized DSC pMRI sequence can be used in a large 
prospective clinical trial to differentiate treatment effects from tumor progression. 
Moreover, by directly comparing several post-processing methods in this large cohort of 
patients, we will define whether there is an optimal method for evaluating pMRI data in the 
context of newly diagnosed GBM patients. 
We will identify the sensitivity and specificity of Prob-fDMs calculated from pre- and post-
treatment within the pre- or post-treatment contrast enhancing lesions to correctly identify  
PTRE/PsP from true tumor progression in patients who have progressed via RANO by 6 
months post-treatment using receiver-operator characteristic (ROC) analysis. We will 
determine whether Prob-fDM changes at the time of RANO-determined PD can provide 
differentiation between PTRE/PsP and tumor progression. We will also determine whether 
early changes in Prob-fDMs can predict OS. This will be a retrospective analysis on the 
imaging data. Therefore, true progression vs. pseudoprogression will be determined by 
serial imaging and use of a confirmatory scan. For example, if a patient has early progression 
on MRI, the current study will require an additional MRI scan to confirm progressive 
disease. If this confirmatory scan does not show disease progression, this patient will be 
categorized as having pseudoprogression 
We will co-register the ADC and rCBV maps, as well as conventional imaging types (T2 
and Pre/Post T1s) using the T1-Post contrast image as the template. We will then create a 
5-dimensional plot of intensities.  We will look for differences in the clusters between 
patients that progress versus those with treatment effects. The number of subjects in each 
category will be determined by the subjects enrolled and the effectiveness of therapy. In 
addition, we will manually evaluate threshold values for rCBV/ADC based on the 
hypothesis that true progression will be reflected by high rCBV and low ADC (due to 
cellularity), and thus the highest ratio. We will perform a sensitivity analysis to determine 
the optimal threshold for the population of subjects available to us. From this analysis, we 
will define whether analysis of pMRI and DWI can be optimally combined to provide a 
clearly superior predictor of ultimate tumor progression compared to either measure alone. 
14.3.5 Statistical Design 
The primary goal of this imaging analysis is to evaluate whether DWI and/or DSC imaging 
can be used to more reliably differentiate pseudoprogression from true progression in 
patients treated either with TMZ + placebo or TMZ + veliparib. Thus, for the purposes of 
this analysis, patients exhibiting progression or pseudoprogression on either arm will be 
combined for this analysis. Predicting how many patients will have true progression vs. 
pseudo progression is difficult since a study like this has not been performed (e.g. MGMT 
methylated + new drug). Based on data from the AVAglio trial (Chinot, NEJM, 2014), the 
placebo arm suggests 216/463 (46.7%) of patients had progressed by 6 months, for which 
43/463 (9.3%) had pseudoprogression, or 43/216 (20%) of early progressors. Extrapolating 
these results to the current study of 400 patients, we might anticipate 187 patients will have 
progressed via RANO by 6 months post-treatment. If we assume the same rate of 
pseudoprogression across both arms, and assume this is equal to the rate of 
pseudoprogression in the placebo arm in the AVAglio trial (~20%), this will result in 
approximately 37 patients across both arms with confirmed pseudoprogression 
(37/187).Using ROC analysis with 150 true progressors versus 37 psuedoprogressors, a two-

 
 
Alliance A071102 
 
Version date: 01/22/2021  
73 
Update #09 
sided test will have at least 74% power at the 5% significance level to detect an effect size 
of 0.10 increase in the area under the ROC curve between RANO and DSC/DWI. This 
power was determined using the R function power.roc.test found in the pROC package. The 
computation for the amount of power is based on the method developed by Obuchowski 
(79). The AUC of the two ROC curves (one based on RANO and the other based on 
DSC/DWI) will be compared with the R function roc.test from the R package pROC. We 
will use the bootstrap method for obtaining the p-value for the comparison. 
 
We will explore the association between imaging metric¹s diagnosis of tumor progression 
and OS.  Specifically, we will classify patients as highly sensitive based upon an OS greater 
than the median in a specific arm. For each imaging metric, we will calculate an ROC curve 
demonstrating its ability to predict highly vs. less sensitive patients. An area under the curve 
(AUC) will be calculated for each imaging metric and compared using the methods proposed 
by DeLong (35). The null hypothesis is two ROC curves are equivalent. Again, these areas 
will be compared using the function roc.test in the R package pROC and we will use the 
bootstrap value. 
 
We will explore the correlation between time to progression (TTP) and OS. First, time to 
progression determined by different imaging metrics will be estimated using Kaplan-Meier 
method and be compared using a bootstrap test because there will be some correlation 
between the curves. Second, for each imaging metrics, association between TTP and OS 
will be evaluated using a landmark analyses (with Cox proportional hazard models) at 
different time points, and time-dependent survival analysis (again using Cox models) where 
progression will be treated as a time-dependent variable. Model fitting statistics obtained 
from each time-dependent survival analysis will be compared to select the best imaging 
metric or metric combinations in predicting OS. 
We will compare DSC-MRI and DW-MRI predictions of OS with that of RANO as c-indices. 
In addition, we plan to compare the time required to achieve a diagnosis by DSC-MRI/DWI-
MRI with that by RANO diagnosis. Typically, RANO criteria require serial exams (over 
several months) to gauge progression/resolution of conventional MRI lesions, while DSC-
MRI/DWI-MRI can provide diagnostic information based on single exam time points. So 
based on these two approaches, we expect that DSC-MRI and DWI-MRI will provide 
quicker diagnoses that are as accurate (if not more accurate) at predicting OS when 
compared to RANO. 
 15.0 GENERAL REGULATORY CONSIDERATIONS AND CREDENTIALING 
15.1 
Institutional credentialing 
Prior to the registration of the first patient, the Imaging and Radiation Oncology Core (IROC) 
must approve institutions to participate in the A071102 imaging study.  
 
A071102 credentialing by the IROC is specific for this study and must be completed regardless 
of previous credentialing for prior CALGB or Alliance studies. There are 2 methods to follow 
for credentialing.  
 
A.      Conditional approval: Review and have site-PI sign the Imaging Site Approval sheet 
obtained from IROC Ohio.  
  
This process allows a participating site to enroll their first patient on A071102 before the site 
gets full approval. Full approval will be granted according to section B below.  

 
 
Alliance A071102 
 
Version date: 01/22/2021  
74 
Update #09 
i) Submit the first registered patient’s post-RT MR imaging data to the core lab upon 
acquisition for QC. This patient must be imaged by MR and not CT. If the patient is 
registered to the parent study only, then submit one set of data per Appendix II. If the patient 
is registered to the advanced imaging sub-study, then submit one set of data per Appendix 
III.  
 
B.      Full approval 
i).       Review and have site-PI sign the Imaging Site Approval sheet obtained from IROC 
Ohio. 
Submit either of the following imaging data sets to IROC Ohio for a quality check:  
a) MR imaging of a local patient with high-grade glioma or brain metastases performed 
according to the Appendix II (if the site will only perform standard MR imaging) or 
Appendix III (if the site plans to offer the advanced MR imaging to patients).  
 
OR 
 
b) Post-RT MR imaging data of the first registered patient. This patient must be imaged by 
MR and not CT. If the patient is registered to the parent study only, then submit one set of 
data per Appendix II. If the patient is registered to the advanced imaging sub-study, then 
submit one set of data per Appendix III. 
 
In either scenario, the submitted images will be reviewed by IROC Ohio, feedback will be 
provided to the sites, and once a suitable imaging set is provided to IROC Ohio, full 
credentialing will be granted  
 
For subsequent scans, the IROC confirms data receipt within 24 hours, performs quality check 
of the images with identifying any non-compliant exams that have protocol deviations, and 
notifies sites of the quality check report within 72 hours upon data receipt.  

Alliance A071102 
Version date: 01/22/2021 
75 
Update #09 
16.0 REFERENCES 
1. 
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus 
concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine. 
2005;352:987-96. 
2. 
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing 
and benefit from temozolomide in glioblastoma. New England Journal of Medicine. 2005;352:997-
1003. 
3. 
Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, et al. Potentiation of 
temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine 
diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res. 
2000;6:2860-7. 
4. 
Leuraud P, Taillandier L, Medioni J, Aguirre-Cruz L, Criniere E, Marie Y, et al. Distinct Responses 
of Xenografted Gliomas to Different Alkylating Agents Are Related to Histology and Genetic 
Alterations. Cancer Res. 2004;64:4648-53. 
5. 
Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The Role of Base Excision Repair 
in the Sensitivity and Resistance to Temozolomide-Mediated Cell Death. Cancer Res. 2005;65:6394-
400. 
6. 
Barvaux VA, Lorigan P, Ranson M, Gillum AM, McElhinney RS, McMurry TBH, et al. Sensitization 
of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 
antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase. Mol Cancer Ther. 
2004;3:1215-20. 
7. 
Wedge SR, Newlands ES. O6-benzylguanine enhances the sensitivity of a glioma xenograft with low 
O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br J Cancer. 
1996;73:1049-52. 
8. 
Hirose Y, Kreklau EL, Erickson LC, Berger MS, Pieper RO. Delayed repletion of O6-methylguanine-
DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from 
temozolomide-induced cytotoxicity. J Neurosurg. 2003;98:591-8. 
9. 
Jean-Claude BJ, Mustafa A, Watson AJ, Damian Z, Vasilescu D, Chan TH, et al. Tetrazepinones are 
equally cytotoxic to Mer+ and Mer- human tumor cell lines. J Pharmacol Exp Ther. 1999;288:484-9. 
10. Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, et al. O-6-methylguanine DNA 
methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J 
Neurochem. 2006;96:766-76. 
11. Liu L, Gerson SL. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base 
excision repair pathway. Current Opinion in Investigational Drugs. 2004;5:623-7. 
12. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nature 
Reviews Drug Discovery. 2005;4:421-40. 
13. Boulton S, Pemberton LC, Porteous JK, Curtin NJ, Griffin RJ, Golding BT, et al. Potentiation of 
temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) 
polymerase inhibitors. Br J Cancer. 1995;72:849-56. 
14. Yan L, Bulgar A, Miao Y, Mahajan V, Donze JR, Gerson SL, et al. Combined treatment with 
temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting 
topoisomerase IIalpha. Clin Cancer Res. 2007;13:1532-9. 
15. Luo M, Kelley MR, Luo M, Kelley MR. Inhibition of the human apurinic/apyrimidinic endonuclease 
(APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with 
lucanthone. Anticancer Res. 2004;24:2127-34. 
16. Liu L, Yan L, Donze JR, Gerson SL, Liu L, Yan L, et al. Blockage of abasic site repair enhances 
antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts. Molecular 
Cancer Therapeutics. 2003;2:1061-6. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
76 
Update #09 
17. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and 
cancer.[erratum appears in Nat Rev Mol Cell Biol. 2008 Dec;9(12). doi: 10.1038/nrm2514]. Nature 
Reviews Molecular Cell Biology. 2008;9:759-69. 
18. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nature Reviews Molecular 
Cell Biology. 2008;9:616-27. 
19. Liu N, Lamerdin JE, Tebbs RS, Schild D, Tucker JD, Shen MR, et al. XRCC2 and XRCC3, new 
human Rad51-family members, promote chromosome stability and protect against DNA cross-links 
and other damages. Mol Cell. 1998;1:783-93. 
20. Takata M, Sasaki MS, Tachiiri S, Fukushima T, Sonoda E, Schild D, et al. Chromosome Instability 
and Defective Recombinational Repair in Knockout Mutants of the Five Rad51 Paralogs. Mol Cell 
Biol. 2001;21:2858-66. 
21. Takata M, Sasaki MS, Sonoda E, Fukushima T, Morrison C, Albala JS, et al. The Rad51 paralog 
Rad51B promotes homologous recombinational repair. Mol Cell Biol. 2000;20:6476-82. 
22. Smiraldo PG, Gruver AM, Osborn JC, Pittman DL. Extensive chromosomal instability in Rad51d-
deficient mouse cells. Cancer Res. 2005;65:2089-96. 
23. Saintigny Y, Delacote F, Vares G, Petitot F, Lambert S, Averbeck D, et al. Characterization of 
homologous recombination induced by replication inhibition in mammalian cells. EMBO J. 
2001;20:3861-70. 
24. Lundin C, Schultz N, Arnaudeau C, Mohindra A, Hansen LT, Helleday T. RAD51 is involved in repair 
of damage associated with DNA replication in mammalian cells. J Mol Biol. 2003;328:521-35. 
25. Tsaryk R, Fabian K, Thacker J, Kaina B. Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and 
the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide. Cancer Lett. 
2006;239:305-13. 
26. Wang ZM, Chen ZP, Xu ZY, Christodoulopoulos G, Bello V, Mohr G, et al. In vitro evidence for 
homologous recombinational repair in resistance to melphalan. J Natl Cancer Inst. 2001;93:1473-8. 
27. Roos WP, Nikolova T, Quiros S, Naumann SC, Kiedron O, Zdzienicka MZ, et al. Brca2/Xrcc2 
dependent HR, but not NHEJ, is required for protection against O6-methylguanine triggered apoptosis, 
DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair. 2009;8:72-86. 
28. Smith LM, Willmore E, Austin CA, Curtin NJ. The novel poly(ADP-Ribose) polymerase inhibitor, 
AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand 
breaks. Clin Cancer Res. 2005;11:8449-57. 
29. Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res. 
2005;52:25-33. 
30. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, et al. Anticancer 
chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor 
AG14361. J Natl Cancer Inst. 2004;96:56-67. 
31. Schultz N, Lopez E, Saleh-Gohari N, Helleday T. Poly(ADP-ribose) polymerase (PARP-1) has a 
controlling role in homologous recombination. Nucleic Acids Res. 2003;31:4959-64. 
32. Helleday T, Bryant HE, Schultz N. Poly(ADP-ribose) polymerase (PARP-1) in homologous 
recombination and as a target for cancer therapy. Cell Cycle. 2005;4:1176-8. 
33. Yang Y-G, Cortes U, Patnaik S, Jasin M, Wang Z-Q. Ablation of PARP-1 does not interfere with the 
repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks. 
Oncogene. 2004;23:3872-82. 
34. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of 
DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase 
inhibition. Cancer Res. 2006;66:8109-15. 
35. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-
deficient tumours with inhibitors of poly(ADP-ribose) polymerase.[erratum appears in Nature. 2007 
May 17;447(7142):346]. Nature. 2005;434:913-7. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
77 
Update #09 
36. McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A, et al. BRCA2-deficient CAPAN-
1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. 
Cancer Biology & Therapy. 2005;4:934-6. 
37. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AOH, Zander SAL, et al. High 
sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in 
combination with platinum drugs. Proc Natl Acad Sci U S A. 2008;105:17079-84. 
38. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) 
polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123-34. 
39. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, et al. Efficacy of BSI-201, a 
poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin 
(G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase 
II trial. J Clin Oncol (Meeting Abstracts). 2009;27:3-. 
40. Isakoff SJ, Overmoyer B, Tung NM, Gelman RS, Giranda VL, Bernhard KM, et al. A phase II trial of 
the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 
(Meeting Abstracts). 2010;28:1019-. 
41. Ratnam K, Low JA. Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in 
Oncology. Clin Cancer Res. 2007;13:1383-8. 
42. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA 
repair defect in BRCA mutant cells as a therapeutic strategy. 2005;434:917-21. 
43. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PWB, et al. Selective Inhibition of 
BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin. Clin Cancer Res. 
2008;14:3916-25. 
44. Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, et al. Effective 
sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in 
glioblastoma xenograft lines. Mol Cancer Ther. 2009;8:407-14. 
45. Pishvaian MJ, Slack R, Witkiewicz A, He AR, Hwang JJ, Hankin A, et al. A phase II study of the 
PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal 
cancer. ASCO Meeting Abstracts. 2011;29:3502. 
46. Giannini C, Sarkaria J, Saito A, Uhm J, Galanis E, Carlson B, et al. Patient  Tumor EGFR and 
PDGFRA Gene Amplifications Retained  in an Invasive Intracranial Xenograft Model of GBM. 
Neuro-Oncology. 2005;7:164-76. 
47. Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, et al. Radiosensitizing 
Effects of Temozolomide Observed in vivo only in a Subset of O6-Methylguanine-DNA 
Methyltransferase Methylated Glioblastoma Multiforme Xenografts. Int J Radiat Oncol Biol Phys. 
2009;75:212-9. 
48. Sarkaria JN, Carlson BL, Schroeder MA, Grogan P, Brown PD, Giannini C, et al. Use of an orthotopic 
xenograft model for assessing the effect of epidermal growth factor receptor amplification on 
glioblastoma radiation response. Clin Cancer Res. 2006;12:2264-71. 
49. Allen C, Paraskevakou G, Iankov I, Giannini C, Schroeder M, Sarkaria J, et al. Interleukin-13 
displaying retargeted oncolytic measles virus strains have significant activity against gliomas with 
improved specificity. Molecular Therapy: the Journal of the American Society of Gene Therapy. 
2008;16:1556-64. 
50. Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, et al. Identification of 
molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through 
use of an intracranial xenograft test panel. Mol Cancer Ther. 2007;6:1167-74. 
51. Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M, et al. Combination of 
measles virus virotherapy and radiation therapy has synergistic activity in the treatment of 
glioblastoma multiforme. Clin Cancer Res. 2007;13:7155-65. 
52. Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, et al. PTEN Loss Does Not 
Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel. 
Clin Cancer Res. 2008;14:3993-4001. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
78 
Update #09 
53. Yu C, Friday BB, Yang L, Atadja P, Wigle D, Sarkaria J, et al. Mitochondrial Bax translocation 
partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome 
inhibitors in glioma cells. Neuro-oncol. 2008;10:309-19. 
54. Yu CR, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, et al. Cytotoxic synergy between the 
multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of 
apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Molecular Cancer Therapeutics. 
2006;5:2378-87. 
55. Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, et al. Induction of 
MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-
oncol. 2009;11:281-91. 
56. Dinca EB, Lu KV, Sarkaria JN, Pieper RO, Prados MD, Haas-Kogan DA, et al. p53 Small-molecule 
inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. 
Cancer Res. 2008;68:10034-9. 
57. Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, et al. Bioluminescence 
monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide 
therapy. J Neurosurg. 2007;107:610-6. 
58. Kitange G, Carlson B, Mladek A, Decker P, Schroeder M, Wu W, et al. Evaluation of MGMT 
promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma 
xenograft model. J Neurooncol. 2009;92:23-31. 
59. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated 
response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working 
group. J Clin Oncol. 2010;28:1963-72. 
60. Perry A, Schmidt R. Cancer therapy-associated CNS neuropathology: an update and review of the 
literature. Acta Neuropathol (Berl). 2006;111:197-212. 
61. Forsyth P, PJ K, TL C, BW S, EG S, Dinapoli R, et al. Radiation necrosis or glioma recurrence: is 
computer-assisted stereotactic biopsy useful? J Neurosurg. 1995;3:436-44. 
62. Tihan T, Barletta J, Parney I, Lamborn K, Sneed PK, Chang S. Prognostic value of detecting recurrent 
glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology 
evaluation alter treatment decisions? Hum Pathol. 2006;37:272-82. 
63. Hu LS, Eschbacher JM, Heiserman JE, Dueck AC, Shapiro WR, Liu S, et al. Reevaluating the imaging 
definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, 
pseudoprogression, and radiation necrosis to predict survival. Neuro-oncology. 2012;14:919-30. 
64. Kim J-H, Bae Kim Y, Han JH, Cho K-G, Kim S-H, Sheen SS, et al. Pathologic diagnosis of recurrent 
glioblastoma: morphologic, immunohistochemical, and molecular analysis of 20 paired cases. Am J 
Surg Pathol. 2012;36:620-8.     
65. Tan, A. D., P. J. Novotny, et al. (2008). "A patient-level meta-analytic investigation of the prognostic 
significance of baseline quality of life (QOL) for overall survival (OS) among 3,704 patients 
participating in 24 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center 
(MC) oncology clinical trials." J Clin Oncol 26 
66.  Sloan JA, Liu H, Sargent DJ, Satele D, Schaefer PL, Halyard MY, Grothey A, Garces YI, Brown PD, 
Loprinzi CL, Buckner JC.  A patient-level pooled analysis of the prognostic significance of baseline 
fatigue for overall survival (OS) among 3,915 patients participating in 43 North Central Cancer 
Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials.  J Clin 
Oncol 2009; 27(507s) 
67. Stuplich M, Hadizadeh DR, Kuchelmeister K, Scorzin  J, Filss C, Langen K-J, et al. Late and 
Prolonged Pseudoprogression in Glioblastoma After Treatment With Lomustine and Temozolomide. 
J Clin Oncol. 2012;30:e180-e3. 
68. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE. Early necrosis following 
concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol. 2007;82:81-3. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
79 
Update #09 
69. Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H. Pseudoprogression after radiotherapy 
with concurrent temozolomide for high-grade glioma: clinical observations and working 
recommendations. Surg Neurol. 2009;72:423-8. 
70. Hygino da Cruz LC, Jr., Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG. 
Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment 
glioma. Ajnr: American Journal of Neuroradiology. 2011;32:1978-85. 
71. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, et al. MGMT promoter 
methylation status can predict the incidence and outcome of pseudoprogression after concomitant 
radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26:2192-7. 
72. Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, 
S. B., and Herman, J. G. (2000a). Inactivation of the DNA-repair gene MGMT and the clinical 
response of gliomas to alkylating agents. N Engl J Med 343, 1350-1354. 
73. Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., and Herman, J. G. (1999). Inactivation of 
the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a 
common event in primary human neoplasia. Cancer Res 59, 793-797. 
74.  Esteller, M., Toyota, M., Sanchez-Cespedes, M., Capella, G., Peinado, M. A., Watkins, D. N., Issa, J. 
P., Sidransky, D., Baylin, S. B., and Herman, J. G. (2000b). Inactivation of the DNA repair gene O6-
methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A 
mutations in K-ras in colorectal tumorigenesis. Cancer Research 60, 2368-2371. 
75. Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., 
Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014). A randomized trial of bevacizumab for 
newly diagnosed glioblastoma. N Engl J Med 370, 699-708. 
76.  Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., 
Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013). Dose-Dense Temozolomide for Newly 
Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. J Clin Oncol 31, 4085-4091. 
77.  Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller, M., Kros, J. M., 
Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005). MGMT gene silencing and benefit from 
temozolomide in glioblastoma. N Engl J Med 352, 997-1003. 
78.  Vlassenbroeck, I., Califice, S., Diserens, A. C., Migliavacca, E., Straub, J., Di Stefano, I., Moreau, F., 
Hamou, M. F., Renard, I., Delorenzi, M., et al. (2008). Validation of real-time methylation-specific 
PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. 
J Mol Diagn 10, 332-337. 
79. Nancy A. Obuchowski, Donna K. McClish (1997). “Sample size determination for diagnostic accurary 
studies involving binormal ROC curve indices”. Statistics in Medicine, 16, 1529–1542. DOI: 
10.1002/(SICI)1097-0258(19970715)16:13<1529::AID-SIM565>3.0.CO;2-H. 
 
 
 
 
 
 

Alliance A071102 
Version date: 01/22/2021 
80 
Update #09 
APPENDIX I: DEFINITION OF STANDARD RT/TMZ 
 
Patients are only eligible for this trial if they have completed conventional standard of care treatment for 
WHO Grade IV gliomas and adequately recovered from treatment related toxicities (CTCAE v4.0 grade 3 
or less lymphopenia and grade 2 or less for all other toxicities). The patient must have undergone MRI 
based treatment planning (CT with contrast-based planning only if patient unable to undergo MRI). At a 
minimum, the contrast enhancing lesion (and/or surgical cavity) defined on a T1-weighted image (gross 
tumor volume; GTV) must be targeted with a minimum of a 1 cm dosimetric margin expansion to define a 
planning target volume (PTV). This volume must have been treated to a prescribed dose of 59.4 Gy in 33 
fractions or 60 Gy in 30 fractions. Treatment with larger volumes to the contrast enhancing region is 
acceptable. Treatment or no treatment of the T2/FLAIR abnormality is acceptable. Because this is optional, 
dosimetric expansion and dose-fractionation for the T2/FLAIR volume are not specified here. The 
prescribed dose to the T2/FLAIR volume may not exceed 60 Gy. Radiation therapy must be completed 
within an overall treatment time of less than 52 calendar days. 
  
Prescribed treatment with concomitant temozolomide must be consistent with the FDA package insert. The 
dose must be 75 mg/m2 daily for the 6 to 6.5 weeks of radiation therapy. If the patient missed more than 1 
week of temozolomide dosing during radiotherapy, then they are not eligible for the trial. Veliparib can 
accentuate thrombocytopenia induced by temozolomide. Therefore, if patients had a platelet < 75,000/mm3 
during concomitant temozolomide therapy during radiation, they are not eligible for this trial.  
NOTE: CBC should be monitored during chemoradiation and lowest platelet count must be submitted at 
registration.

Alliance A071102 
Version date: 01/22/2021 
81 
Update #09 
APPENDIX II: REQUIRED CONSENSUS MRI ACQUISITION PARAMETERS  
For sites that do NOT have advanced imaging available: (FDA/NBTS/NCI Standardized MRI Protocol). 
See section 6.3.  
 
The MRI acquisition protocols defined in the following table have been defined by an international 
consensus panel. These parameters have been reviewed and adopted by the National Cancer Institute (NCI) 
and the Federal Drug Administration (FDA), and these acquisition parameters are required for all national 
and FDA drug-registration trials. The specific acquisition parameters, the sequence of imaging acquisition, 
and the plane of imaging are all required as explicitly stated in these protocols. Additionally, individual 
patients must be consistently imaged at the same field strength as their baseline post-RT registration scan. 
 
3T Protocol: 
 
 
Ax FLAIR 
Ax DWI 
3D T1 Pre 
Contrast Injection a 
Ax T2 
3D T1 Postb 
Sequence 
TSEc – 
(turbo dark 
fluid) 
EPIf 
MPRAGEd,e 
TSEc 
MPRAGEd,e 
 
 
 
 
 
 
Plane 
Axial 
Axial 
Axial/Sagittal 
Axial 
Axial/Sagittal 
Mode 
2D 
2D 
3D 
2D 
3D 
TR [ms] 
>6000 
>5000 
2100g 
>2500 
2100g 
TE [ms] 
100-140 
Min 
Min 
80-120 
Min 
TI [ms] 
2500 
 
1100h 
 
1100h 
Flip Angle 
90/160 
90/180 
10-15 
90/160 
10-15 
Frequency 
256 
128 
256 
256 
256 
Phase 
256 
128 
256 
256 
256 
NEX 
1 
1 
1 
1 
1 
Frequency 
Direction 
A/P 
R/L 
A/P 
A/P 
A/P 
FOV 
240mm 
240mm 
256mm (for 1mm 
isotropic)i 
240mm 
256mm (for 
1mm isotropic)i 
Slice 
Thickness 
3mm 
3mm 
1mmi 
3mm 
1mmi 
Gap/Spacing 
0 
0 
0 
0 
0 
Diffusion 
Options 
 
b = 0, 500, 
and 1000 
s/mm2 
 
 
 
Parallel 
Imaging 
Up to 2x 
Up to 2x 
Up to 2x 
Up to 2x 
Up to 2x 
Scan Time 
(Approx) 
4-5 min 
3-5 min 
5-8 min 
3-5 min 
5-8 min 
 
a 0.1 mmol/kg or up to 20cc (single, full dose) of MR contrast. 
b Post-contrast 3D axial T1-weighted images should be collected with identical parameters to pre-contrast 
3D axial T1-weighted images 
c TSE = turbo spin echo (Siemens & Philips) is equivalent to FSE (fast spin echo; GE, Hitachi, Toshiba) 
d MPRAGE = magnetization prepared rapid gradient-echo (Siemens & Hitachi) is equivalent to the 
inversion recovery SPGR (IR-SPGR or Fast SPGR with inversion activated; GE), 3D turbo field echo (TFE; 
Philips), or 3D fast field echo (3D Fast FE; Toshiba). 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
82 
Update #09 
e A 3D acquisition without inversion preparation will result in different contrast compared with MPRAGE 
or another IR-prepped 3D T1-weighted sequences and therefore should be avoided. 
f In the event of significant patient motion, a radial acquisition scheme may be used (e.g. BLADE [Siemens], 
PROPELLER [GE], MultiVane [Philips], RADAR [Hitachi], or JET [Toshiba]); however, this acquisition 
scheme is can cause significant differences in ADC quantification and therefore should be used only if EPI 
is not an option. 
g For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TR = 5-15ms for 
similar contrast. 
h For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TI = 400-450ms for 
similar contrast. 
i FOV and matrix size should be chosen to keep resolution at 1mm isotropic voxel size. Note that all voxel 
measurements should be equal in x, y, and z dimensions.  
 
 
Acronyms: 
Ax = Axial; ADC = apparent diffusion coefficient. FLAIR = fluid attenuated inversion recovery; DWI = 
diffusion-weighted imaging; 3D = three dimensional; TSE = turbo spin echo; EPI = echo planar imaging; 
MPRAGE = magnetization prepared rapid gradient-echo; A/P = anterior to posterior; R/L = right to left; 
NEX = number of excitations or averages; FOV = field of view 
 
 
 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
83 
Update #09 
1.5T Protocol: 
 
Ax FLAIR 
Ax DWI 
3D T1 Pre 
Contrast Injection a 
Ax T2 
3D T1 Postb 
Sequence 
TSEc – 
(turbo dark 
fluid) 
EPIf 
MPRAGEd,e 
TSEc 
MPRAGEd,e 
 
 
 
 
 
 
Plane 
Axial 
Axial 
Sagittal/Axial 
Axial 
Sagittal/Axial 
Mode 
2D 
2D 
3D 
2D 
3D 
TR [ms] 
>6000 
>5000 
2100g 
>3500 
2100g 
TE [ms] 
100-140 
Min 
Min 
100-120 
Min 
TI [ms] 
2200 
 
1100h 
 
1100h 
Flip Angle 
90/160 
90/180 
10-15 
90/180 
10-15 
Frequency 
256 
128 
172 
256 
172 
Phase 
256 
128 
172 
256 
172 
NEX 
1 
1 
1 
1 
1 
Frequency 
Direction 
A/P 
R/L 
A/P 
A/P 
A/P 
FOV 
240mm 
240mm 
256mm 
(for ≤1.5mm 
isotropic)j 
240mm 
256mm 
(for ≤1.5mm 
isotropic)j 
Slice 
Thickness 
4mm 
4mm 
1.5mmj 
4mm 
1.5mmj 
Gap/Spacing 
0 
0 
0 
0 
0 
Diffusion 
Optionsi 
 
b = 0, 500, 
and 1000 
s/mm2 
 
 
 
Parallel 
Imaging 
Yes-If 
Available 
Yes-If 
Available 
Yes-If Available 
Yes-If 
Available 
Yes-If 
Available 
Scan Time 
(Approx) 
4-5 min 
3-5 min 
5-8 min 
3-5 min 
5-8 min 
a 0.1 mmol/kg or up to 20cc (single, full dose) of MR contrast. 
b Post-contrast 3D axial T1-weighted images should be collected with identical parameters to pre-contrast 
2D axial T1-weighted images 
c TSE = turbo spin echo (Siemens & Philips) is equivalent to FSE (fast spin echo; GE, Hitachi, Toshiba) 
d MPRAGE = magnetization prepared rapid gradient-echo (Siemens & Hitachi) is equivalent to the 
inversion recovery SPGR (IR-SPGR or Fast SPGR with inversion activated; GE), 3D turbo field echo (TFE; 
Philips), or 3D fast field echo (3D Fast FE; Toshiba). 
e A 3D acquisition without inversion preparation will result in different contrast compared with MPRAGE 
or another IR-prepped 3D T1-weighted sequences and therefore should be avoided. 
f In the event of significant patient motion, a radial acquisition scheme may be used (e.g. BLADE [Siemens], 
PROPELLER [GE], MultiVane [Philips], RADAR [Hitachi], or JET [Toshiba]); however, this acquisition 
scheme is can cause significant differences in ADC quantification and therefore should be used only if EPI 
is not an option. 
g For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TR = 5-15ms for 
similar contrast. 
h For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TI = 400-450ms for 
similar contrast. 
i Older model MR scanners that are not capable of >2 b-values should use b = 0 and 1000 s/mm2. 
j FOV and matrix size should be chosen to keep resolution less than 1.5mm isotropic voxel size. Note that 
all voxel measurements should be equal in x, y, and z dimensions.  

 
 
Alliance A071102 
 
Version date: 01/22/2021  
84 
Update #09 
 
Acronyms: 
Ax = Axial; ADC = apparent diffusion coefficient. FLAIR = fluid attenuated inversion recovery; DWI = 
diffusion-weighted imaging; 3D = three dimensional; TSE = turbo spin echo; EPI = echo planar imaging; 
MPRAGE = magnetization prepared rapid gradient-echo; A/P = anterior to posterior; R/L = right to left; 
NEX = number of excitations or averages; FOV = field of view 
 
 
 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
85 
Update #09 
APPENDIX III: REQUIRED CONSENSUS MRI ACQUISITION PARAMETERS INCLUDING ADVANCED MRI  
For sites that have the advanced imaging available. See Section 6.3.  
 
The MRI acquisition protocols defined in the following table have been defined by an international 
consensus panel. These parameters have been reviewed and adopted by the National Cancer Institute (NCI) 
and the Federal Drug Administration (FDA), and these acquisition parameters are required for all national 
and FDA drug-registration trials. The specific acquisition parameters, the sequence of imaging acquisition, 
and the plane of imaging are all required as explicitly stated in these protocols. Additionally, individual 
patients must be consistently imaged at the same field strength as their baseline post-RT registration scan. 
 
3T Protocol: 
 
 
Ax T2 
Ax 
FLAIR 
Ax DWI 
3D T1 Pre 
DSC-1a 
DSC-2a 
3D T1 Postb 
Sequence 
TSEc 
TSEc 
EPIf 
MPRAGEd,e 
GE-EPI 
GE-EPI 
MPRAGEd,e 
 
 
 
 
 
 
 
 
Plane 
Axial 
Axial 
Axial 
Axial/Sagitt
al 
Axial 
Axial 
Axial/Sagittal 
Mode 
2D 
2D 
2D 
3D 
2D 
2D 
3D 
TR [ms] 
>2500 
>6000 
>5000 
2100g 
1500 
1500 
2100g 
TE [ms] 
80-120 
100-140 
Min 
Min 
Min 
Min 
Min 
TI [ms] 
 
2500 
 
1100h 
 
 
1100h 
Flip Angle 
90/16
0 
90/160 
90/180 
10-15 
60 
60 
10-15 
Frequency 
256 
256 
128 
256 
128 
128 
256 
Phase 
256 
256 
128 
256 
128 
128 
256 
NEX 
1 
1 
1 
1 
NEX=1 
(120 Reps) 
Inject after 
30sec (~20 
pts) 
NEX=1 
(120 Reps) 
Inject after 
30sec (~20 
pts) 
1 
Frequency 
Direction 
A/P 
A/P 
R/L 
A/P 
A/P 
A/P 
A/P 
FOV 
240m
m 
240mm 
240mm 
256mm (for 
1mm 
isotropic)i 
240 
240 
256mm (for 
1mm 
isotropic)i 
Slice 
Thickness 
3mm 
3mm 
3mm 
1mmi 
5mm 
5mm 
1mmi 
Gap/Spacing 
0 
0 
0 
0 
0 
0 
0 
Diffusion 
Options 
 
 
b = 0, 500, 
and 1000 
s/mm2 
 
 
 
 
Parallel 
Imaging 
Up to 
2x 
Up to 2x 
Up to 2x 
Up to 2x 
 No 
 No 
Up to 2x 
Scan Time 
(Approx) 
3-5 
min 
4-5 min 
3-5 min 
5-8 min 
3 min 
3 min 
5-8 min 
 
a 0.05 mmol/kg (1/2) dose injection at a rate of 3-5cc/sec. This is run a total of 2x (DSC-1 and DSC-2).  
Please maximize slice coverage to include the entire lesion as well as normal brain to the skull vertex.  The 
posterior fossa can be excluded from coverage if there are not enough slices to cover the entire brain. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
86 
Update #09 
b Post-contrast 3D axial T1-weighted images should be collected with equivalent parameters to pre-contrast 
2D axial T1-weighted images 
c TSE = turbo spin echo (Siemens & Philips) is equivalent to FSE (fast spin echo; GE, Hitachi, Toshiba) 
d MPRAGE = magnetization prepared rapid gradient-echo (Siemens & Hitachi) is equivalent to the 
inversion recovery SPGR (IR-SPGR or Fast SPGR with inversion activated; GE), 3D turbo field echo (TFE; 
Philips), or 3D fast field echo (3D Fast FE; Toshiba). 
e A 3D acquisition without inversion preparation will result in different contrast compared with MPRAGE 
or another IR-prepped 3D T1-weighted sequences and therefore should be avoided. 
f In the event of significant patient motion, a radial acquisition scheme may be used (e.g. BLADE [Siemens], 
PROPELLER [GE], MultiVane [Philips], RADAR [Hitachi], or JET [Toshiba]); however, this acquisition 
scheme is can cause significant differences in ADC quantification and therefore should be used only if EPI 
is not an option. 
g For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TR = 5-15ms for 
similar contrast. 
h For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TI = 400-450ms for 
similar contrast. 
i FOV and matrix size should be chosen to keep resolution at 1mm isotropic voxel size. Note that all voxel 
measurements should be equal in x, y, and z dimensions. 
 
Acronyms: 
Ax = Axial; ADC = apparent diffusion coefficient. FLAIR = fluid attenuated inversion recovery; DWI = 
diffusion-weighted imaging; 3D = three dimensional; TSE = turbo spin echo; EPI = echo planar imaging; 
GE-EPI = gradient echo echo planar imaging; MPRAGE = magnetization prepared rapid gradient-echo; 
A/P = anterior to posterior; R/L = right to left; NEX = number of excitations or averages; FOV = field of 
view 
 
 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
87 
Update #09 
1.5T Protocol: 
 
 
Ax 
FLAIR 
Ax DWI 
3D T1 Pre 
Preload (1/4 Dose) Contrast Injection a 
Ax T2 
DSCa 
3D T1 Postb 
Sequence 
TSEc 
EPIf 
MPRAGEd,e 
TSEc 
GE-EPI 
MPRAGEd,e 
 
 
 
 
 
 
 
Plane 
Axial 
Axial 
Sagittal/Axial 
Axial 
Axial 
Sagittal/Axial 
Mode 
2D 
2D 
3D 
2D 
2D 
3D 
TR [ms] 
>6000 
>5000 
2100g 
>3500 
1500 
2100g 
TE [ms] 
100-140 
Min 
Min 
100-120 
Min 
Min 
TI [ms] 
2200 
 
1100h 
 
 
1100h 
Flip Angle 
90/160 
90/180 
10-15 
90/180 
60 
10-15 
Frequency 
256 
128 
172 
256 
128 
172 
Phase 
256 
128 
172 
256 
128 
172 
NEX 
1 
1 
1 
1 
NEX=1 
(120 Reps) 
Inject after 30sec 
(~20 baseline 
points) 
1 
Frequency 
Direction 
A/P 
R/L 
A/P 
A/P 
A/P 
A/P 
FOV 
240mm 
240mm 
256mm 
(for ≤1.5mm 
isotropic)j 
240mm 
240 
256mm 
(for ≤1.5mm 
isotropic)j 
Slice 
Thickness 
4mm 
4mm 
1.5mmj 
4mm 
5mm 
1.5mmj 
Gap/Spacing 
0 
0 
0 
0 
0 
0 
Diffusion 
Optionsi 
 
b = 0, 
500, and 
1000 
s/mm2 
 
 
 
 
Parallel 
Imaging 
Yes-If 
Available 
Yes-If 
Available 
Yes-If 
Available 
Yes-If 
Available 
No 
Yes-If Available 
Scan Time 
(Approx) 
4-5 min 
3-5 min 
5-8 min 
3-5 min 
3 min 
5-8 min 
 
a 0.025 mmol/kg (1/4) dose injection. A 0.075 mmol/kg (3/4) dose injection will then be injected at a rate 
of 3-5cc/sec for DSC.  Please maximize slice coverage to include the entire lesion as well as normal brain 
to the skull vertex.  The posterior fossa can be excluded from coverage if there are not enough slices to 
cover the entire brain. 
b Post-contrast 3D axial T1-weighted images should be collected with identical parameters to pre-contrast 
2D axial T1-weighted images 
c TSE = turbo spin echo (Siemens & Philips) is equivalent to FSE (fast spin echo; GE, Hitachi, Toshiba) 
d MPRAGE = magnetization prepared rapid gradient-echo (Siemens & Hitachi) is equivalent to the 
inversion recovery SPGR (IR-SPGR or Fast SPGR with inversion activated; GE), 3D turbo field echo (TFE; 
Philips), or 3D fast field echo (3D Fast FE; Toshiba). 
e A 3D acquisition without inversion preparation will result in different contrast compared with MPRAGE 
or another IR-prepped 3D T1-weighted sequences and therefore should be avoided. 
f In the event of significant patient motion, a radial acquisition scheme may be used (e.g. BLADE [Siemens], 
PROPELLER [GE], MultiVane [Philips], RADAR [Hitachi], or JET [Toshiba]); however, this acquisition 
scheme is can cause significant differences in ADC quantification and therefore should be used only if EPI 
is not an option. 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
88 
Update #09 
g For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TR = 5-15ms for 
similar contrast. 
h For Siemens and Hitachi scanners. GE, Philips, and Toshiba scanners should use a TI = 400-450ms for 
similar contrast. 
i Older model MR scanners that are not capable of >2 b-values should use b = 0 and 1000 s/mm2. 
j FOV and matrix size should be chosen to keep resolution less than 1.5mm isotropic voxel size. Note that 
all voxel measurements should be equal in x, y, and z dimensions. 
 
Acronyms: 
Ax = Axial; ADC = apparent diffusion coefficient. FLAIR = fluid attenuated inversion recovery; DWI = 
diffusion-weighted imaging; 3D = three dimensional; TSE = turbo spin echo; EPI = echo planar imaging; 
GE-EPI = gradient echo echo planar imaging; 2DFL = two-dimensional FLASH (fast low angle shot) 
gradient recalled echo; MPRAGE = magnetization prepared rapid gradient-echo; A/P = anterior to 
posterior; R/L = right to left; NEX = number of excitations or averages; FOV = field of view 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Alliance A071102 
Version date: 01/22/2021 
89 
Update #09 
APPENDIX IV: FATIGUE/UNISCALE ASSESSMENTS 
 
 
Fatigue/Uniscale Assessments 
 
At patient registration, subsequent therapy visits and post treatment follow-up, this form is to be 
administered by a nurse/CRA/physician, completed by the patient, and recorded on the 
Fatigue/Uniscale Assessments Form (see Forms Packet). 
 
If needed, this appendix can be adapted to use as a source document.  A booklet containing this 
assessment does not exist – please do not order this booklet. 
 
 
 
 
How would you describe: 
 
Your level of fatigue, on the average in the past week including today? 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
No 
Fatigue 
 
 
 
 
 
 
 
 
 
Fatigue 
as bad  
as it can be 
 
Your overall quality of life in the past week including today? 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
As bad as 
it can be 
 
 
 
 
 
 
 
 
 
As good as 
it can be 
 
 
 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
90 
Update #09 
APPENDIX V: PATIENT MEASUREMENT TOOLS 
Mini Mental State Examination (MMSE)  
Introduction  
The Mini-Mental Status Exam could be administered by the physician, a nurse or an assistant trained in the 
administration of such tools. An interpreter may assist in administering the MMSE if needed. The person 
administering the mini-mental status exam needs to be sensitive when the patient shows embarrassment 
about their inability to answer these questions. Patients should be assured by telling them that this is another 
way of telling how the treatment is affecting their brain tumor. It also needs to be made clear to the patient 
that it is very important to get this type of information directly from them. The person administering the 
test needs to understand that either the correct answer is given or not. There should be no partial credit for 
answers short of the mark. 
 
The MMSE begins with a graded assessment of orientation to place and time, for which a maximum of 10 
points is possible. This is followed by testing two aspects of memory. The first is the immediate recall for 
three objects presented orally, followed by a serial sevens task which is interposed to assess attention, 
concentration, and calculation, and also to prevent the individual from rehearsing the three objects 
previously learned. A maximum of 21 points may be obtained on this section of the test. 
 
The final section surveys aphasia and apraxia by testing functions of naming, repetition, understanding a 
three-stage command, reading, writing and copying a drawing. There are a maximum of 9 points which 
may be obtained on this section, for a total possible MMSE score of 30 points. 
 
MMSE Sections  
Detailed instructions are included here. A brief form for recording and scoring MMSE answers follows. 
 
Orientation  
Ask the patient for the date. Then ask for parts omitted (e.g., “Can you also tell me what season it is?”).  
Give one point for each correct response. 
 
Ask in turn, “Can you tell me the name of this hospital? Town? Count? (and so on)”.  Give one point for 
each correct response. 
 
Registration  
Ask the patient if you may test his/her memory. Then name three unrelated objects, clearly and slowly, 
about a second for each. After you have said all three, ask the patient to repeat them. This first repetition 
determines the score. Score one point for each repeated object (0 – 3). If the patient does not repeat all three 
objects, the tester should repeat the objects (up to a maximum of six times) until the patient can say all 
three. In cases where a patient cannot learn all three objects in six trials, recall (see below) cannot be 
meaningfully tested. 
 
When registration if complete, tell the patient, “Try to remember them because I will ask for them in a little 
while”.    
 
 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
91 
Update #09 
Attention and Calculation  
Ask the patient to begin with 100 and count backwards by seven. Stop after five subtractions (93, 86, 79, 
72, 65).  Score the total number of correct answers. If the patient will not perform this task, ask him or her 
to spell the word “WORLD” backwards. The score is the number of letters in correct order (e.g., DLROW 
five, DLORW – three). 
 
Recall    
Ask the patient if he/she can remember the names of the three objects learned in the Registration section.  
Give one point for each correct answer. 
 
Language  
There are six operations in this section. 
 
Naming  
Show the patient a wrist watch and ask him/her what it is.  Repeat for a pencil.  Give one point for each 
correct naming (0 – 2). 
 
Repetition    
Have the patient repeat, “No, ifs, ands, or buts”.  All only one trial.  Given one point for a completely correct 
repetition. 
 
Three-Stage Command  
Place a piece of blank paper in front of the patient and say; “Take this paper in your right hand.  Fold the 
paper in half.  Put the paper on the floor”. Give one point for each correctly performed command. 
 
Reading   
Show the patient the page with the sentence “Close your eyes.” Ask the patient to read it and do what it 
says. Since this is not a memory task, the tester may prompt the reader to “do what it says” after the reader 
reads the sentence. Score one point if the patient actually closes his or her eyes. 
 
Writing   
Give the patient the page with the word sentence and ask him/her to write a sentence for you. Do not dictate 
a sentence; it is to be written spontaneously. The sentence should contain a subject and a verb, and should 
make sense. Ignore minor spelling or minor grammatical errors when scoring. Score one point for a correct 
sentence. 
 
Copying  
Show the patient the page with the intersecting pentagons. Ask the patient to copy it exactly as it is. Give 
one point if all sides are preserved and if the intersecting sides from a four sided figure (i.e., ten sides and 
ten angles). 
 
 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
92 
Update #09 
Special Considerations  
The examination is conducted so as to minimize stress for the patient. Errors are not indicated to the patients 
and, in general, mistakes are not corrected. Refusals are considered to be errors after a minimum of 
encouragement. Individuals with peripheral impairment such as blindness or restriction of the hands due to 
arthritis or other peripheral disorders are scored the number correct out of the possible items they could 
answer given their other non-cognitive impairments. Please note these exceptions on the MMSE and the 
cover sheet. It is important not to allow your administration of this test to be affected by your perception of 
why the patient may have responded incorrectly or not at all. That is, the examination should be conducted 
without the examiner modifying the scoring by assumptions of whether or not the individual was motivated, 
paying attention, or could understand. For the purpose of the exam, the score indicates a failed performance, 
not necessarily a failed performance under all conceivable circumstances. 
 
Spencer MP and Folstein MF. The Mini-Mental State Examination. In: PA Keller and LG Ritt (Eds), 
Innovations in Clinical Practice: A Source Book. Volume 4. Sarasota, FL: Professional Resource Exchange, 
Inc., 1985, 307-308. 
 
 
 
 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
93 
Update #09 
Mini Mental State Examination  
 
 
Date: (mm/dd/yyyy) __ __/__ __/__ __ __ __ 
 
_____/5 What is the: (year) (season) (date) (day) (month)? 
_____/5 Where are we: (state) (county) (town) (building) (floor)? 
_____/3 Learn: “apple, table, penny.”  ______# of trials. 
_____/5 Subtract serial 7’s (100, 93, 86, 79, 72): or spell “WORLD” backwards. 
_____/3 Recall: “apple, table, penny”. 
_____/2 Name: “pencil” and “watch”. 
_____/1 Repeat: “no ifs, ands, or buts”. 
_____/3 “Take this paper in your right hand, fold it in half, and put it on the floor”. 
_____/1 Read and obey: “Close your eyes”. 
_____/1 Write a sentence on the back of this card. 
_____/1 Copy the design on the back of this card. 
 
_____/30 Total (abnormal if <24; if <8th grade, then <21 is considered abnormal) 
 
Close your eyes. 
 
 
 
 

Alliance A071102 
Version date: 01/22/2021 
94 
Update #09 
APPENDIX VI: PATIENT MEDICATION DIARIES 
Appendix VI-A Temozolomide Medication Diary 
 
INSTRUCTIONS TO THE PATIENT: 
1. 
Complete one form for each 4 week-period while you take temozolomide. 
2. 
You will take your dose of temozolomide on days 1-5  
3. 
Record the date, the number of capsules you took, and when you took them. Record doses as soon 
as you take them; do not batch entries together at a later time. 
4. 
If you have any comments or notice any side effects, please record them in the Comments column. 
If you make a mistake while you write, please cross it out with one line, put your initials next to it, 
and then write the corrected information next to your initials.  Example: 10:30 am SB 9:30 am 
5. 
Please return this form to your physician when you go for your next appointment. 
Day 
Date 
Time of daily dose # of capsules taken 
Comments 
For Hospital  
Staff Only  
Total dose (mg) 
1 
 
 
 
 
 
2 
 
 
 
 
 
3 
 
 
 
 
 
4 
 
 
 
 
 
5 
 
 
 
 
 
6 
 
NO MEDICATION ON DAYS 6 THROUGH 28 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
95 
Update #09 
Patient’s Signature                                                                                         Date 
 
 
Physician’s Office will complete this section: 
 
1. Date patient started protocol treatment 
___________________________________________________ 
 
2. Date patient was removed from study 
____________________________________________________ 
 
3. Total number of capsules taken this month (each size) 
_________________________________________ 
 
4. Physician/Nurse/Data Manager’s Signature  
 
_____________________________________________________ 

Alliance A071102 
Version date: 01/22/2021 
96 
Update #09 
Appendix VI-B Veliparib/Placebo Medication Diary 
 
INSTRUCTIONS TO THE PATIENT: 
1. 
Complete one form for each 4 week-period while you take veliparib/placebo 
2. 
You will take your dose of veliparib/placebo twice daily on days 1-7.  
3. 
Record the date, the number of capsules you took, and when you took them. Record doses as soon 
as you take them; do not batch entries together at a later time. 
4. 
If you have any comments or notice any side effects, please record them in the Comments column. 
If you make a mistake while you write, please cross it out with one line, put your initials next to it, 
and then write the corrected information next to your initials.  Example: 10:30 am SB 9:30 am 
5. 
Please return this form to your physician when you go for your next appointment. 
* You can start veliparib/placebo in the evening on day 1. If you do this, you will keep taking it twice 
daily until the morning of day 8. You should fill out day 8 on the form. 
Day 
Date 
Time of dose 
# of capsules taken 
Comments 
For Hospital 
Staff Only  
Total dose 
(mg) 
1 
 
  ______ AM /______PM ______ AM /______PM  
 
2 
 
  ______ AM /______PM ______ AM /______PM  
 
3 
 
  ______ AM /______PM ______ AM /______PM  
 
4 
 
  ______ AM /______PM ______ AM /______PM  
 
5 
 
  ______ AM /______PM ______ AM /______PM  
 
6 
 
  ______ AM /______PM ______ AM /______PM  
 
7 
 
  ______ AM /______PM ______ AM /______PM  
 
8* 
 
  ______ AM  
______ AM 
 
 
9 
 
 
NO MEDICATION ON DAYS 8* THORUGH 28 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
97 
Update #09 
27 
28 
Patient’s Signature                                                                                                     Date 
 
 
Physician’s Office will complete this section: 
 
• 
Date patient started protocol treatment 
___________________________________________________ 
 
2. Date patient was removed from study 
____________________________________________________ 
 
3. Total number of capsules taken this month (each size) 
_________________________________________ 
 
4. Physician/Nurse/Data Manager’s Signature  
 
_____________________________________________________ 
 
 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
98 
Update #09 
APPENDIX VII: MGMT ASSAY DESCRIPTION 
 
Central Laboratory Assessment for Hypermethlyation of the Promoter of the O6-MethylGuanine DNA 
Methyltransferase (MGMT) Gene by Real-Time PCR 
 
The standard method for analysis of MGMT promoter methylation relies on methylation-specific PCR 
(MS-PCR) using bisulfite converted DNA.  The assay was initially reported by Herman et al and is 
performed commercially in the United States by LabCorp (72).  The assay was utilized in the retrospective 
analysis of EORTC 22981 to demonstrate a benefit to MGMT promoter methylation for patients treated 
with concurrent TMZ and RT (77). MGMT promoter methylation has been evaluated in two large, 
multicenter trials prospectively: the RTOG 0525 trial comparing standard dose vs. dose-dense TMZ in the 
adjuvant treatment of newly diagnosed patients with GBM (76) and the RTOG 0825 trial assessing the role 
of bevacizumab for patients with newly diagnosed GBM (75). Both trials stratified patients based on 
MGMT status using the same assay as that planned for the current study.  For RTOG 0525, a total of 833 
patients were randomized and MGMT status was determined to be hypermethylated in 245 tumors (29%), 
unmethylated in 517 tumors (62%).  91% of registered patients had tumors for which MGMT status could 
be determined.  Median survival for methylated patients was significantly longer (22 months) as compared 
to the unmethylated patients (14 months).  Similarly, for RTOG 0825, 621 patients were randomized and 
methylation status determined in 604 cases.  A total of 175 (28%) were methylated and 429 (69%) were 
unmethylated.  Median survival was 23.2 months vs. 14.3 months for the methylated vs. unmethylated 
patients.  Based on these prospective, multicenter cooperative group trials, we anticipate MGMT 
methylation in approximately 30% of cases. 
 
For this clinical trial, the MGMT assay will be performed as initially described by Esteller et al (73) 
and as modified for real time PCR product detection using a modified amplification primer with a capture 
sequence to a standard probe for real time detection in a single-step reaction (78).  This approach is identical 
to that used by Labcorp.  Following central pathology review at the Mayo Clinic, 10 unstained formalin-
fixed, paraffin-embedded (FFPE) tumor sections will be obtained with areas of viable tumor identified.  
Slides will be transferred to the MDACC CLIA MDL via a BioMS shipping manifest for prospective 
analysis of MGMT status. DNA will be prepared using the MasterPure Complete DNA and RNA 
purification kit (Epicentre Biotechnologies, Madison, WI) following deparaffinization using Citrisolve 
(Amity International, Anderson,SC).  Bisulfite conversion of 1 µg of DNA will be performed (Zymo EZ96 
DNA methylation kit, Zymo Research) and the remainder of tumor DNA will be frozen at -20C and kept 
for repeat analyses of MGMT if necessary and for future genomic analyses. 
 
Amplification of bisulfite-modified DNA will encompass the standard enhancer region within the first 
intron of MGMT as previously described (74), generating a 136bp amplicon derived from positions 
131155505-131155619 (RefSeq NM_002412) on chromosome 10.  PCR primer sequences are as published 
(78) and included a tagging sequence in the forward primers for real-time detection with the AmpliFluor 
reagent (Millipore).  Reactions are carried out in 15µl volumes and cycled as follows: 50°C for 2 minutes, 
95°C for 10 minutes, and 45 cycles of 95°C for 15 seconds and 62°C for 1 minute.  The assay detects the 
difference in amplification between methylated and unmethylated cytosine residues within the specific 
primer sequences.  Conversion of unmethylated cytosines to uracil (thymidine) by sodium bisulfite 
treatment leads to a sequence change that can be detected using specifically designed PCR primers.   
 
Amplification will be performed using real-time PCR in an Applied Biosystems 7500 Fast Real-Time 
PCR system. A ∆CT, defined as the difference in the cycle in which the detected amplification curve (on a 
log-linear plot) crosses an empirically determined threshold (set for each batch based within the geometric 
region of amplification) between the MGMT amplicon and the reference ACTB amplicon. Control 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
99 
Update #09 
methylated and unmethylated DNAs will be used with each batch. A ∆CT of greater than 8 cycles (>256 
fold difference) indicates the presence of promoter methylation.  A ∆CT >8 cycles will be coded as 
unmethylated. 
 
All reactions are carried out in triplicate from replicate bisulfite converted DNA preparations.  
Discordant results are repeated (including bisulfite conversion when sufficient DNA is available).  Cases 
in which discordant results persist after repeated assays or for which amplification fails secondary to poor 
quality DNA (or other technical reasons) will be coded as failures/no data. 
 
Assay validation 
 
To validate the assay at MD Anderson using the assay described above, a set of 253 primary GBMs 
were evaluated for MGMT methylation.  Consistent with prior reports, median survival for patients with 
tumor MGMT hyper-methylation was significantly longer (149 weeks) compared to patients with tumor 
MGMT unmethylated status (58 weeks). 
 
Further direct comparison of the assay was performed using samples from RTOG 0525, as this tumors 
had been evaluated by the LabCorp assay.  A total of 184 tumors were re-evaluated and concordance 
between the MD Anderson assay and the LabCorp assay was 97%.  Overall sample failures were 9.2%. 
Sensitivity for MGMT methylation 94% and specificity was 98%.  The positive predictive value for the 
assay was 95.7% and the negative predictive value was 97.5%. 
 
 
 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
100 
Update #09 
APPENDIX VIII: COLLABORATIVE AGREEMENTS LANGUAGE 
 
Protocols that involve agent(s) covered by a collaborative agreement with a biotech/pharma 
company(ies) must incorporate the NCI/ DCTD Collaborative Agreement Language shown below. 
 
 
The agent(s) supplied by CTEP, DCTD, NCI used in this protocol is/are provided to the NCI 
under a Collaborative Agreement (CRADA, CTA, CSA) between the Pharmaceutical 
Company(ies) (hereinafter referred to as “Collaborator(s)”) and the NCI Division of Cancer 
Treatment and Diagnosis.  Therefore, the following obligations/guidelines, in addition to the 
provisions in the “Intellectual Property Option to Collaborator” 
(http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm) contained within 
the terms of award, apply to the use of the Agent(s) in this study: 
 
1.   Agent(s) may not be used for any purpose outside the scope of this protocol, nor can 
Agent(s) be transferred or licensed to any party not participating in the clinical study.  
Collaborator(s) data for Agent(s) are confidential and proprietary to Collaborator(s) and 
shall be maintained as such by the investigators. The protocol documents for studies 
utilizing Agents contain confidential information and should not be shared or distributed 
without the permission of the NCI.  If a copy of this protocol is requested by a patient or 
patient’s family member participating on the study, the individual should sign a 
confidentiality agreement. A suitable model agreement can be downloaded from: 
http://ctep.cancer.gov. 
 
2.   For a clinical protocol where there is an investigational Agent used in combination with 
(an)other Agent(s), each the subject of different Collaborative Agreements, the access to 
and use of data by each Collaborator shall be as follows (data pertaining to such 
combination use shall hereinafter be referred to as "Multi-Party Data”): 
 
a.   NCI will provide all Collaborators with prior written notice regarding the existence 
and nature of any agreements governing their collaboration with NCI, the design of 
the proposed combination protocol, and the existence of any obligations that would 
tend to restrict NCI's participation in the proposed combination protocol. 
 
b.   Each Collaborator shall agree to permit use of the Multi-Party Data from the clinical 
trial by any other Collaborator solely to the extent necessary to allow said other 
Collaborator to develop, obtain regulatory approval or commercialize its own Agent. 
 
c.   Any Collaborator having the right to use the Multi-Party Data from these trials must 
agree in writing prior to the commencement of the trials that it will use the Multi-
Party Data solely for development, regulatory approval, and commercialization of its 
own Agent. 
 
3.   Clinical Trial Data and Results and Raw Data developed under a Collaborative 
Agreement will be made available to Collaborator(s), the NCI, and the FDA, as 
appropriate and unless additional disclosure is required by law or court order as described 
in the IP Option to Collaborator 
(http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm). Additionally, 
all Clinical Data and Results and Raw Data will be collected, used and disclosed 
consistent with all applicable federal statutes and regulations for the protection of human 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
101 
Update #09 
subjects, including, if applicable, the Standards for Privacy of Individually Identifiable 
Health Information set forth in 45 C.F.R. Part 164. 
 
4.   When a Collaborator wishes to initiate a data request, the request should first be sent to 
the NCI, who will then notify the appropriate investigators (Group Chair for Cooperative 
Group studies, or PI for other studies) of Collaborator's wish to contact them. 
 
5.   Any data provided to Collaborator(s) for Phase 3 studies must be in accordance with the 
guidelines and policies of the responsible Data Monitoring Committee (DMC), if there is 
a DMC for this clinical trial. 
 
6.   Any manuscripts reporting the results of this clinical trial must be provided to CTEP by 
the Group office for Cooperative Group studies or by the principal investigator for non-
Cooperative Group studies for immediate delivery to Collaborator(s) for advisory review 
and comment prior to submission for publication.  Collaborator(s) will have 30 days from 
the date of receipt for review.  Collaborator shall have the right to request that publication 
be delayed for up to an additional 30 days in order to ensure that Collaborator’s 
confidential and proprietary data, in addition to Collaborator(s)’s intellectual property 
rights, are protected.  Copies of abstracts must be provided to CTEP for forwarding to 
Collaborator(s) for courtesy review as soon as possible and preferably at least three (3) 
days prior to submission, but in any case, prior to presentation at the meeting or 
publication in the proceedings. Press releases and other media presentations must also be 
forwarded to CTEP prior to release. Copies of any manuscript, abstract and/or press 
release/ media presentation should be sent to: 
 
Email: ncicteppubs@mail.nih.gov  
 
The Regulatory Affairs Branch will then distribute them to Collaborator(s).  No 
publication, manuscript or other form of public disclosure shall contain any of 
Collaborator’s confidential/ proprietary information. 
 

Alliance A071102 
Version date: 01/22/2021 
102 
Update #09 
APPENDIX IX: OPTUNE DIARY  
 
INSTRUCTIONS TO THE PATIENT: 
1. Complete one form for each 4 week-period while you are wearing Optune. 
2. You will wear your Optune daily for at least 18 hours a day. 
3. Record the date, and place a “Yes” or “No” as to whether or not you wore Optune that day. If 
you did wear Optune, then record the length of time (hours and minutes) that you wore the 
device. 
4. If you have any comments or notice any side effects, please record them in the Comments 
column. If you make a mistake while you write, please cross it out with one line, put your initials 
next to it, and then write the corrected information next to your initials.  Example: 10:30 am SB 
9:30 am 
5. Please return this form to your physician when you go for your next appointment. 
 
Day 
Date 
Optune Worn (Y/N) 
Time Worn (HH:MM) 
1 
 
 
 
2 
 
 
 
3 
 
 
 
4 
 
 
 
5 
 
 
 
6 
 
 
 
7 
 
 
 
8 
 
 
 
9 
 
 
 
10 
 
 
 
11 
 
 
 
12 
 
 
 
13 
 
 
 
14 
 
 
 
15 
 
 
 
16 
 
 
 
17 
 
 
 
18 
 
 
 
19 
 
 
 
20 
 
 
 
21 
 
 
 
22 
 
 
 
23 
 
 
 
24 
 
 
 
25 
 
 
 
26 
 
 
 
27 
 
 
 
28 
 
 
 

 
 
Alliance A071102 
 
Version date: 01/22/2021  
103 
Update #09 
Patient’s Signature                                                                                         Date 
 
Physician’s Office will complete this section: 
 
1. Date patient started Optune treatment (for this cycle) 
___________________________________________________ 
 
2. Date patient was removed from study 
____________________________________________________ 
 
3. Total time (HH:MM) Optune was worn this cycle 
_________________________________________ 
 
4. Physician/Nurse/Data Manager’s Signature  
 
_____________________________________________________